Tablets O
, O
Injection O
, O
and O
Oral O
Solution O
One O
study O
in O
six O
subjects O
demonstrated O
that O
the O
combination O
of O
furosemide B-drug
and O
acetylsalicylic B-drug
acid I-drug
temporarily O
reduced O
creatinine O
clearance O
in O
patients O
with O
chronic O
renal O
insufficiency O
. O

Because O
the O
potential O
interaction O
of O
efavirenz B-drug
with O
oral O
contraceptives B-group
has O
not O
been O
fully O
characterized O
, O
a O
reliable O
method O
of O
barrier O
contraception O
should O
be O
used O
in O
addition O
to O
oral O
contraceptives B-group
. O

and O
exert O
direct O
effects O
on O
the O
mechanisms O
of O
insulin O
resistance O
. O

Furthermore O
, O
whenever O
one O
of O
these O
drugs O
is O
withdrawn O
from O
co-therapy O
, O
an O
increased O
dose O
of O
tricyclic B-group
antidepressant I-group
agent I-group
may O
be O
required O
. O

use O
of O
a O
nonhormonal B-group
contraceptive I-group
product I-group
is O
recommended O
. O

Transfer O
from O
the O
intestinal O
lumen O
to O
the O
mucosal O
cells O
at O
low O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
concentration O
( O
0.1 O
mM O
) O
is O
rapid O
, O
while O
transfer O
from O
the O
mucosal O
cells O
to O
the O
body O
occurs O
more O
slowly O
. O

Increased O
metoprolol B-drug
plasma O
levels O
have O
been O
associated O
with O
decreased O
cardioselectivity O
. O

Bacteriostatic B-group
Antibiotics I-group
: O
Chloramphenicol B-drug
, O
erythromycins B-drug
, O
sulfonamides B-group
, O
or O
tetracyclines B-group
may O
interfere O
with O
the O
bactericidal O
effect O
of O
penicillins B-group
. O

It O
is O
possible O
that O
the O
cardiovascular O
action O
of O
other O
calcium B-group
channel I-group
blockers I-group
could O
be O
enhanced O
by O
the O
addition O
of O
Nimotop B-brand
. O

Free O
T4 O
and O
T3 O
concentrations O
are O
unaltered O
. O

uterine O
fibroids O
; O

Co-administration O
of O
tacrolimus B-drug
and O
bosentan B-drug
resulted O
in O
markedly O
increased O
plasma O
concentrations O
of O
bosentan B-drug
in O
animals O
. O

sucralfate B-drug
or O
divalent O
or O
trivalent O
cations O
such O
as O
iron B-drug
; O

Indocyanine B-drug_n
green I-drug_n
as O
an O
index O
of O
hepatic O
drug O
extraction O
has O
been O
tested O
and O
no O
significant O
effects O
have O
been O
found O
. O

Tumors O
of O
more O
malignant O
phenotype O
were O
demonstrated O
only O
in O
genetically O
predisposed O
mice O
( O
C57BL/6N O
X O
C3H/HeN O
F1 O
) O
that O
received O
one O
dose O
of O
carcinogen O
. O

use O
potassium B-drug
supplements O
if O
necessary O
. O

It O
is O
recommended O
that O
plasma O
lithium B-drug
levels O
be O
monitored O
when O
ketoprofen B-drug
is O
coadministered O
with O
lithium B-drug
. O

Tagamet B-brand
, O
apparently O
through O
an O
effect O
on O
certain O
microsomal O
enzyme O
systems O
, O
has O
been O
reported O
to O
reduce O
the O
hepatic O
metabolism O
of O
warfarin-type B-group
anticoagulants I-group
, O
phenytoin B-drug
, O
propranolol B-drug
, O
nifedipine B-drug
, O
chlordiazepoxide B-drug
, O
diazepam B-drug
, O
certain O
tricyclic B-group
antidepressants I-group
, O
lidocaine B-drug
, O
theophylline B-drug
and O
metronidazole B-drug
, O
thereby O
delaying O
elimination O
and O
increasing O
blood O
levels O
of O
these O
drugs O
. O

Drug/Laboratory O
Test O
Interactions O
A O
false-positive O
reaction O
for O
ketones O
in O
the O
urine O
may O
occur O
with O
tests O
using O
nitroprusside B-drug
but O
not O
with O
those O
using O
nitroferricyanide B-drug
. O

Because O
of O
the O
potential O
for O
adverse O
reactions O
from O
the O
drugs O
in O
nursing O
infants O
, O
a O
decision O
must O
be O
made O
whether O
to O
discontinue O
nursing O
or O
discontinue O
PEGASYS B-brand
and O
COPEGUS B-brand
treatment O
. O

Several O
classes O
of O
cardiovascular O
drugs O
are O
also O
discussed O
in O
relationship O
to O
their O
differential O
effects O
on O
the O
management O
and O
progression O
of O
renal O
disease O
. O

Exercise O
that O
produces O
cardiopulmonary O
stimulation O
is O
a O
helpful O
means O
of O
reducing O
drug O
hunger O
and O
anxiety O
during O
recovery O
therapy O
. O

There O
has O
been O
little O
experience O
with O
the O
coadministration O
of O
TAMBOCOR B-brand
and O
either O
disopyramide B-drug
or O
verapamil B-drug
. O

The O
administration O
of O
cefdinir B-drug
may O
result O
in O
a O
false-positive O
reaction O
for O
glucose O
in O
urine O
using O
Clinitest O
, O
Benedict O
s O
solution O
, O
or O
Fehlings O
solution O
. O

Anaesthesia O
and O
the O
epileptic O
pateint O
. O

. O

therefore O
, O
nelfinavir B-drug
should O
be O
administered O
( O
with O
food O
) O
one O
hour O
after O
or O
more O
than O
two O
hours O
before O
didanosine B-drug
. O

Dose O
reduction O
of O
rifabutin B-drug
to O
half O
the O
standard O
dose O
and O
a O
dose O
increase O
of O
CRIXIVAN B-brand
to O
1000 O
mg O
( O
three O
333-mg O
capsules O
) O
every O
8 O
hours O
are O
recommended O
when O
rifabutin B-drug
and O
CRIXIVAN B-brand
are O
coadministered O
. O

Succinylcholine B-drug
may O
cause O
a O
sudden O
extrusion O
of O
potassium O
from O
muscle O
cells O
, O
and O
may O
thereby O
cause O
arrhythmias O
in O
digitalized O
patients O
. O

dextrothyroxine B-drug
; O

Cardiac O
effects O
of O
dopamine B-drug
are O
antagonized O
by O
beta-adrenergic B-group
blocking I-group
agents I-group
, O
such O
as O
propranolol B-drug
and O
metoprolol B-drug
. O

The O
principal O
drugs O
given O
( O
number O
of O
patients O
in O
parentheses O
) O
were O
: O
cardiac B-group
glycosides I-group
( O
115 O
) O
, O
sedatives B-group
and O
hypnotics B-group
( O
103 O
) O
, O
coronary B-group
vasodilators I-group
( O
52 O
) O
, O
oral O
hypoglycemics B-group
( O
45 O
) O
, O
cough O
and O
cold O
preparations O
( O
45 O
) O
, O
NSAIDs B-group
( O
38 O
) O
, O
antihyperlipidemics B-group
( O
29 O
) O
, O
antigout B-group
drugs I-group
( O
24 O
) O
, O
oral O
contraceptives B-group
( O
18 O
) O
, O
bronchodilators B-group
( O
13 O
) O
, O
insulin B-drug
( O
10 O
) O
, O
and O
beta B-group
blockers I-group
( O
10 O
) O
. O

Phenobarbital B-drug
: O
Estimates O
of O
steady-state O
pharmacokinetic O
parameters O
for O
phenobarbital B-drug
or O
gabapentin B-drug
( O
300 O
mg O
TID O
; O

It O
is O
concluded O
that O
chloral B-drug
hydrate I-drug
and O
methaqualone B-drug
may O
be O
administered O
safely O
without O
additional O
caution O
in O
prothrombin O
test O
monitoring O
during O
oral O
anticoagulant B-group
therapy O
. O

Based O
on O
anecdotal O
reports O
, O
there O
may O
be O
an O
interaction O
between O
buprenorphine B-drug
and O
benzodiazepines B-group
. O

Unlike O
nucleolin/C23 O
, O
down-regulation O
of O
nucleophosmin/B23 O
was O
thus O
not O
proliferation-dependent O
but O
caspase-3- O
and O
apoptosis-dependent O
. O

Buforin B-drug_n
II I-drug_n
showed O
moderate O
activity O
, O
which O
increased O
with O
increasing O
concentration O
to O
55.7 O
% O
suppression O
of O
growth O
at O
20 O
microM O
. O

To O
avoid O
this O
interaction O
, O
delavirdine B-drug
or O
indinavir B-drug
should O
be O
given O
1 O
hour O
prior O
to O
dosing O
with O
VIDEX B-brand
. O

Drug O
interactions O
with O
clomiphene B-drug
citrate I-drug
tablets O
USP O
have O
not O
been O
documented O
. O

Drug O
Name O

In O
the O
general O
population O
, O
sildenafil B-drug
is O
considered O
to O
have O
an O
acceptable O
tolerability O
profile O
; O

The O
incidence O
of O
cancer O
increases O
progressively O
with O
age O
. O

Absorption O
of O
tetracycline B-drug
is O
impaired O
by O
bismuth B-drug
subsalicylate I-drug
. O

increased O
factors O
II O
, O
VII O
antigen O
, O
VIII O
antigen O
, O
VIII O
coagulant O
activity O
, O
IX O
, O
X O
, O
XII O
, O
VII-X O
complex O
, O
II-VII-X O
complex O
, O
and O
beta-thromboglobulin O
; O

If O
labetalol B-drug
HCl I-drug
is O
used O
with O
nitroglycerin B-drug
in O
patients O
with O
angina O
pectoris O
, O
additional O
antihypertensive O
effects O
may O
occur O
. O

Oxcarbazepine B-drug
can O
inhibit O
CYP2C19 O
and O
induce O
CYP3A4/5 O
with O
potentially O
important O
effects O
on O
plasma O
concentrations O
of O
other O
drugs O
. O

Thus O
, O
results O
of O
the O
DST O
should O
be O
interpreted O
with O
caution O
in O
these O
patients O
. O

Broad-Spectrum B-group
Antibiotics-Broad-spectrum I-group
antibiotics I-group
may O
sterilize O
the O
bowel O
and O
decrease O
the O
vitamin B-group
K I-group
contribution O
to O
the O
body O
by O
the O
intestinal O
microflora O
. O

The O
effect O
of O
TORADOL B-brand
on O
methotrexate B-drug
clearance O
has O
not O
been O
studied O
. O

Exaggerated O
hypertensive O
responses O
have O
been O
reported O
from O
the O
combined O
use O
of O
beta-adrenergic B-group
antagonists I-group
and O
alpha-adrenergic B-group
stimulants I-group
, O
including O
those O
contained O
in O
proprietary O
cold O
remedies O
and O
vasoconstrictive O
nasal O
drops O
. O

TAMBOCOR B-brand
has O
been O
administered O
to O
patients O
receiving O
digitalis B-group
preparations I-group
or O
beta-adrenergic B-group
blocking I-group
agents I-group
without O
adverse O
effects O
. O

Pharmacological O
treatment O
of O
depression O
: O
the O
role O
of O
paroxetine B-drug
. O

Anticoagulant O
inhibition O
was O
observed O
during O
the O
administration O
of O
phenobarbital B-drug
, O
secobarbital B-drug
and O
glutethimide B-drug
; O

Hypertensive O
crises O
have O
resulted O
when O
sympathomimetic B-group
amines I-group
have O
been O
used O
concomitantly O
within14 O
days O
following O
use O
of O
monoamine B-group
oxidase I-group
inhibitors I-group
. O

Systemic O
exposure O
is O
limited O
, O
as O
fluvastatin B-drug
is O
subject O
to O
first-pass O
metabolism O
, O
and O
the O
plasma O
half-life O
of O
the O
drug O
is O
approximately O
30 O
minutes O
. O

In O
these O
subjects O
( O
R= O
B O
) O
, O
the O
clearance O
of O
diazepam B-drug
was O
reduced O
by O
65 O
% O
and O
that O
of O
N-desmethyldiazepam B-drug_n
to O
a O
level O
that O
was O
too O
low O
to O
measure O
over O
the O
course O
of O
the O
2 O
week O
long O
study O
. O

an O
interval O
of O
at O
least O
4 O
hours O
between O
intake O
of O
these O
agents O
and O
chloroquine B-drug
should O
be O
observed O
. O

Following O
the O
administration O
of O
INAPSINE B-brand
, O
the O
dose O
of O
other O
CNS B-group
depressant I-group
drugs I-group
should O
be O
reduced O
. O

PROLEUKIN B-brand
may O
affect O
central O
nervous O
function O
. O

In O
another O
study O
with O
intravenous O
administration O
of O
midazolam B-drug
, O
Aprepitant B-drug
was O
given O
as O
125 O
mg O
on O
Day O
1 O
and O
80 O
mg/day O
on O
Days O
2 O
and O
3 O
, O
and O
midazolam B-drug
2 O
mg O
IV O
was O
given O
prior O
to O
the O
administration O
of O
the O
3-day O
regimen O
of O
Aprepitant B-drug
and O
on O
Days O
4 O
, O
8 O
, O
and O
15 O
. O

The O
impact O
of O
the O
combined O
chemotherapy O
plus O
HAART O
treatment O
on O
patient O
survival O
needs O
urgently O
to O
be O
evaluated O
in O
prospective O
studies O
. O

In O
clinical O
studies O
, O
caspofungin B-drug
did O
not O
induce O
the O
CYP3A4 O
metabolism O
of O
other O
drugs O
. O

Physostigmine B-drug
pretreatment O
augmented O
the O
depressant O
effect O
of O
alcohol B-drug
on O
the O
early O
components O
P1 O
and O
N1 O
, O
while O
attenuating O
alcohol B-drug
's O
influence O
on O
components O
P2 O
and O
P3 O
. O

Concomitant O
use O
with O
iron B-group
supplements O
may O
result O
in O
the O
reduced O
absorption O
of O
iron B-drug
. O

Skin O
tests O
: O
Corticosteroids B-group
may O
suppress O
reactions O
to O
skin O
tests O
. O

If O
digitalis B-drug
treatment O
is O
continued O
, O
serum O
levels O
should O
be O
closely O
monitored O
and O
patients O
observed O
for O
clinical O
evidence O
of O
toxicity O
. O

Dexamethasone B-drug
is O
a O
moderate O
inducer O
of O
CYP O
3A4 O
. O

Caution O
should O
be O
exercised O
when O
the O
following O
drugs O
are O
administered O
concomitantly O
with O
LODOSYN B-brand
( O
Carbidopa B-drug
) O
given O
with O
levodopa B-drug
or O
carbidopa-levodopa B-drug
combination O
products O
. O

In O
patients O
, O
the O
concomitant O
administration O
of O
digoxin B-drug
with O
dofetilide B-drug
was O
associated O
with O
a O
higher O
occurrence O
of O
torsade O
de O
pointes O
. O

Chlorthalidone B-drug
and O
related O
drugs O
may O
decrease O
arterial O
responsiveness O
to O
norepinephrine B-drug
. O

Anticholinergic B-group
drugs I-group
in O
the O
presence O
of O
increased O
intraocular O
pressure O
may O
be O
hazardous O
when O
taken O
concurrently O
with O
agents O
such O
as O
corti O
costeroids.. O

Although O
there O
may O
be O
decreased O
zalcitabine B-drug
activity O
because O
of O
lessened O
active O
metabolite O
formation O
, O
the O
clinical O
relevance O
of O
these O
in O
vitro O
results O
are O
not O
known O
. O

Phenytoin/Phenobarbital B-drug
: O
The O
coadministration O
of O
phenytoin B-drug
or O
phenobarbital B-drug
will O
not O
affect O
plasma O
concentrations O
of O
vitamin B-group
D I-group
, O
but O
may O
reduce O
endogenous O
plasma O
levels O
of O
calcitriol/ergocalcitriol B-drug
by O
accelerating O
metabolism O
. O

Because O
the O
incidence O
of O
infections O
and O
certain O
malignancies O
is O
higher O
in O
the O
elderly O
population O
, O
in O
general O
, O
caution O
should O
be O
used O
in O
treating O
the O
elderly O
. O

An O
increase O
of O
63 O
% O
in O
the O
mean O
AUC O
and O
increases O
of O
50 O
% O
and O
4 O
% O
, O
respectively O
, O
in O
the O
mean O
T O
max O
and O
mean O
C O
max O
were O
noted O
in O
1 O
study O
of O
6 O
individuals O
. O

- O
Anticoagulants B-group
( O
blood B-group
thinners O
) O
or O

The O
use O
of O
erythromycin B-drug
in O
patients O
concurrently O
taking O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
system O
may O
be O
associated O
with O
elevations O
in O
serum O
levels O
of O
these O
other O
drugs O
. O

Results O
demonstrate O
that O
oxcarbazepine B-drug
and O
its O
pharmacologically O
active O
10-monohydroxy O
metabolite O
( O
MHD B-drug_n
) O
have O
little O
or O
no O
capacity O
to O
function O
as O
inhibitors O
for O
most O
of O
the O
human O
cytochrome O
P450 O
enzymes O
evaluated O
( O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
CYP4A9 O
and O
CYP4A11 O
) O
with O
the O
exception O
of O
CYP2C19 O
and O
CYP3A4/5 O
. O

The O
use O
of O
codeine B-drug
may O
result O
in O
additive O
CNS O
depressant O
effects O
when O
coadministered O
with O
alcohol B-drug
, O
antihistamines B-group
, O
psychotropics B-group
or O
other O
drugs O
that O
produce O
CNS O
depression O
. O

Concomitant O
administration O
of O
Targretin B-brand
capsules O
and O
gemfibrozil B-drug
resulted O
in O
substantial O
increases O
in O
plasma O
concentrations O
of O
bexarotene B-drug
, O
probably O
at O
least O
partially O
related O
to O
cytochrome O
P450 O
3A4 O
inhibition O
by O
gemfibrozil B-drug
. O

It O
is O
recommended O
that O
GABA-positive O
drugs O
be O
included O
into O
a O
complex O
of O
treatment O
measures O
for O
edema O
. O

The O
effects O
of O
coadministered O
drugs O
and O
ethanol B-drug
on O
the O
binding O
of O
therapeutic O
drugs O
to O
human O
serum O
in O
vitro O
was O
investigated O
. O

Oral O
Contraceptives B-group
: O
May O
be O
less O
effective O
and O
increased O
breakthrough O
bleeding O
may O
occur O
. O

rifampin B-drug
; O

Specific O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
ENBREL B-brand
. O

However O
, O
patients O
on O
digoxin B-drug
may O
show O
elevations O
of O
digoxin B-drug
concentrations O
after O
initiation O
of O
therapy O
with O
FLOLAN B-brand
, O
which O
may O
be O
clinically O
significant O
in O
patients O
prone O
to O
digoxin B-drug
toxicity O
. O

A O
number O
of O
substances O
affect O
glucose O
metabolism O
and O
may O
require O
insulin B-drug
dose O
adjustment O
and O
particularly O
close O
monitoring O
. O

While O
no O
clinical O
studies O
have O
been O
conducted O
to O
evaluate O
the O
effect O
of O
grepafloxacin B-drug
on O
the O
metabolism O
of O
C.P.A O
. O

Alternatives O
to O
clarithromycin B-drug
, O
such O
as O
azithromycin B-drug
, O
should O
be O
considered O
. O

Drugs O
that O
raise O
the O
gastrointestinal O
pH O
may O
lead O
to O
an O
earlier O
release O
of O
duloxetine B-drug
. O

indinavir I-drug
concentration O
rifabutin B-drug
concentration O

Coumarin B-group
Anticoagulants I-group
Altered O
coagulation O
parameters O
and/or O
bleeding O
have O
been O
reported O
in O
patients O
taking O
capecitabine B-drug
concomitantly O
with O
coumarin-derivative B-group
anticoagulants I-group
such O
as O
warfarin B-drug
and O
phenprocoumon B-drug
. O

Fluconazole B-drug
, O
and O
the O
5-HT3 B-group
antiemetics I-group
ondansetron B-drug
( O
Zofran B-brand
) O
and O
granisetron B-drug
( O
Kytril B-brand
) O
have O
all O
been O
used O
with O
BUSULFEX B-brand
. O

Though O
individual O
theophylline B-drug
levels O
fluctuated O
, O
there O
were O
no O
clinically O
significant O
symptoms O
of O
drug O
inter-action O
. O

Furthermore O
, O
whenever O
one O
of O
these O
other O
drugs O
is O
withdrawn O
from O
co-therapy O
, O
an O
increased O
dose O
of O
tricyclic B-group
antidepressant I-group
may O
be O
required O
. O

Serum O
potassium O
levels O
should O
be O
monitored O
and O
deficiencies O
corrected O
. O

These O
effects O
were O
not O
observed O
when O
Vardenafil B-drug
20 O
mg O
was O
taken O
24 O
hours O
before O
the O
NTG B-drug
. O

Caution O
should O
be O
exercised O
when O
INDOCIN B-brand
and O
anticoagulants B-group
are O
administered O
concomitantly O
. O

Administration O
of O
quinolones B-group
with O
antacids B-group
containing O
aluminum B-drug
, O
magnesium B-drug
, O
or O
calcium B-drug
, O
with O
sucralfate B-drug
, O
with O
metal O
cations O
such O
as O
iron B-drug
, O
or O
with O
multivitamins B-group
containing O
iron B-drug
or O
zinc B-drug
, O
or O
with O
formulations O
containing O
divalent O
and O
trivalent O
cations O
such O
as O
VIDEX B-brand
( O
didanosine B-drug
) O
chewable/buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
, O
may O
substantially O
interfere O
with O
the O
absorption O
of O
quinolones B-group
, O
resulting O
in O
systemic O
concentrations O
considerably O
lower O
than O
desired O
. O

Steady-state O
serum O
concentrations O
of O
tricyclic B-group
antidepressants I-group
are O
reported O
to O
fluctuate O
significantly O
when O
cimetidine B-drug
is O
either O
added O
or O
deleted O
from O
the O
drug O
regimen O
. O

Concurrent O
therapy O
with O
bumetanide B-drug
is O
thus O
not O
recommended O
. O

Drug O
Laboratory O
Test O
Interactions O
: O
Prolongation O
of O
the O
template O
bleeding O
time O
has O
been O
reported O
during O
continuous O
intravenous O
infusion O
of O
AMICAR B-brand
at O
dosages O
exceeding O
24 O
g/day O
. O

Diazepam B-drug
: O
The O
co-administration O
of O
Fluvoxamine B-drug
Tablets O
and O
diazepam B-drug
is O
generally O
not O
advisable O
. O

Anti-HIV B-group
Protease I-group
Inhibitors I-group

Although O
verapamil B-drug
administered O
at O
either O
dose O
had O
little O
or O
no O
effect O
on O
the O
enhancement O
of O
intestinal O
carcinogenesis O
by O
bombesin B-drug_n
or O
on O
the O
location O
, O
histologic O
type O
, O
depth O
of O
involvement O
, O
labeling O
index O
, O
apoptotic O
index O
or O
tumor O
vascularity O
of O
intestinal O
cancers O
, O
it O
significantly O
decreased O
the O
incidence O
of O
cancer O
metastasis O
. O

The O
following O
are O
examples O
of O
drugs O
known O
to O
inhibit O
the O
metabolism O
of O
other O
related O
benzodiazepines B-group
, O
presumably O
through O
inhibition O
of O
CYP3A O
: O
nefazodone B-drug
, O
fluvoxamine B-drug
, O
cimetidine B-drug
, O
diltiazem B-drug
, O
isoniazide B-drug
, O
and O
some O
macrolide B-group
antibiotics I-group
. O

There O
have O
been O
no O
formal O
drug-interaction O
studies O
performed O
with O
Mylotarg B-brand
. O

Vasoconstrictors B-group
: O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
should O
not O
be O
used O
with O
peripheral B-group
vasoconstrictors I-group
because O
the O
combination O
may O
cause O
synergistic O
elevation O
of O
blood O
pressure O
. O

Valproate B-drug
: O
A O
recent O
case O
study O
has O
shown O
a O
possible O
increase O
in O
the O
plasma O
level O
of O
valproate B-drug
when O
co O
administered O
with O
isoniazid B-drug
. O

This O
did O
not O
result O
in O
any O
statistically O
or O
clinically O
relevant O
changes O
in O
the O
pharmacokinetic O
parameters O
of O
either O
caffeine B-drug
or O
its O
major O
metabolite O
, O
paraxanthine B-drug_n
. O

Leukopenia O
was O
similar O
between O
the O
two O
groups O
, O
but O
colony O
stimulating O
factor O
support O
was O
significantly O
greater O
in O
the O
CHOP-HAART O
group O
than O
in O
the O
control O
group O
( O
92 O
% O
vs. O
66 O
% O
, O
respectively O
; O
P O
= O
0.03 O
) O
. O

The O
possibility O
of O
hypotensive O
effects O
with O
PRINIVIL B-brand
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-group
or O
increasing O
the O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
PRINIVIL B-brand
. O

When O
other O
antiplatelet B-group
agents I-group
or O
anticoagulants B-group
are O
used O
concomitantly O
, O
there O
is O
the O
potential O
for O
FLOLAN B-brand
to O
increase O
the O
risk O
of O
bleeding O
. O

Taking O
a O
rauwolfia B-group
alkaloid I-group
while O
you O
are O
taking O
or O
within O
2 O
weeks O
of O
taking O
MAO B-group
inhibitors I-group
may O
increase O
the O
risk O
of O
central O
nervous O
system O
depression O
or O
may O
cause O
a O
severe O
high O
blood O
pressure O
reaction O
. O

No O
autoinduction O
has O
been O
observed O
with O
Trileptal B-brand
. O

Latent O
diabetes O
mellitus O
may O
become O
manifest O
during O
chlorthalidone B-drug
administration O
. O

Repeated O
oral O
administration O
of O
coumaphos B-drug_n
in O
sheep O
: O
interactions O
of O
coumaphos B-drug_n
with O
bishydroxycoumarin B-drug
, O
trichlorfon B-drug_n
, O
and O
phenobarbital B-drug
sodium I-drug
. O

surgery O
; O

In O
another O
drug O
interaction O
study O
, O
co-administration O
of O
orally O
inhaled O
ciclesonide B-drug
and O
oral O
ketoconazole B-drug
, O
a O
potent O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
, O
increased O
the O
exposure O
( O
AUC O
) O
of O
des-ciclesonide B-drug
by O
approximately O
3.6-fold O
at O
steady O
state O
, O
while O
levels O
of O
ciclesonide B-drug
remained O
unchanged O
. O

rifabutin I-drug
concentration O

The O
percentage O
of O
neurons O
hyperpolarized O
by O
mu- B-group
, O
delta O
( O
1 O
) O
- O
, O
and O
kappa-selective B-group
opioids I-group
was O
significantly O
reduced O
when O
1 O
% O
but O
not O
< O

antacids B-group
after O
meals O
. O

Coadministration O
of O
rifampin B-drug
with O
diltiazem B-drug
lowered O
the O
diltiazem B-drug
plasma O
concentrations O
to O
undetectable O
levels O
. O

Laboratory O
Tests O
: O
The O
combination O
of O
Amprenavir B-drug
and O
low-dose O
ritonavir B-drug
has O
been O
associated O
with O
elevations O
of O
cholesterol O
and O
triglycerides O
, O
SGOT O
( O
AST O
) O
, O
and O
SGPT O
( O
ALT O
) O
in O
some O
patients O
. O

The O
elimination O
half O
life O
of O
midazolam B-drug
and O
triazolam B-drug
also O
increased O
( O
1.5-2.5 O
fold O
) O
during O
coadministration O
with O
diltiazem B-drug
. O

These O
effects O
have O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
by O
the O
NSAID B-group
. O

If O
possible O
, O
anticholinesterase B-group
agents I-group
should O
be O
withdrawn O
at O
least O
24 O
hours O
before O
initiating O
corticosteroid B-group
therapy O
. O

Potential O
for O
Interaction O
with O
Monoamine B-group
Oxidase I-group
Inhibitors I-group

Therefore O
, O
the O
combination O
of O
ketoprofen B-drug
and O
probenecid B-drug
is O
not O
recommended O
. O

Eprosartan B-drug
doses O
of O
up O
to O
300 O
mg O
b.i.d O
. O
have O
been O
safely O
used O
concomitantly O
with O
sustained-release O
calcium B-group
channel I-group
blockers I-group
( O
sustained-release O
nifedipine B-drug
) O
with O
no O
clinically O
significant O
adverse O
interactions O
. O

there O
was O
no O
effect O
on O
the O
3 O
major O
metabolites O
( O
5-DFUR B-drug_n
, O
5-FU B-drug_n
and O
FBAL B-drug_n
) O
. O

Concomitant O
use O
of O
ELLENCE B-brand
with O
other O
cardioactive O
compounds O
that O
could O
cause O
heart O
failure O
( O
e.g. O
, O
calcium B-group
channel I-group
blockers I-group
) O
, O
requires O
close O
monitoring O
of O
cardiac O
function O
throughout O
treatment O
. O

Clearance O
of O
hydrodolasetron B-drug_n
decreased O
by O
about O
27 O
% O
when O
dolasetron B-drug
mesylate I-drug
was O
administered O
intravenously O
concomitantly O
with O
atenolol B-drug
. O

The O
blockade O
of O
the O
spinal O
endorphinergic O
system O
by O
intrathecal O
naloxone B-drug
on O
the O
production O
of O
tail-flick O
inhibition O
induced O
by O
intraventricular O
beta-endorphin B-drug_n
and O
morphine B-drug
was O
then O
studied O
. O

The O
time O
to O
onset O
of O
maximum O
block O
following O
NIMBEX B-brand
is O
approximately O
2 O
minutes O
faster O
with O
prior O
administration O
of O
succinylcholine B-drug
. O

There O
is O
no O
significant O
change O
in O
platelet O
count O
, O
prothrombin O
time O
, O
partial O
thromboplastin O
time O
, O
or O
thrombin O
time O
. O

Serum O
transaminase O
levels O
should O
be O
obtained O
before O
starting O
treatment O
with O
Plenaxis B-brand
and O
periodically O
during O
treatment O
. O

Benzthiazide B-drug
may O
interact O
with O
alcohol B-drug
, O
blood B-group
thinners O
, O
decongestant B-group
drugs I-group
( O
allergy O
, O
cold O
, O
and O
sinus O
medicines O
) O
, O
diabetic O
drugs O
, O
lithium B-drug
, O
norepinephrine B-drug
, O
NSAIDs B-group
like O
Aleve B-brand
or O
Ibuprofen B-drug
, O
and O
high O
blood O
pressure O
medications O
. O

Concomitant O
use O
of O
prostaglandin O
synthase O
inhibiting O
drugs O
, O
eg O
, O
indomethacin B-drug
, O
may O
decrease O
the O
hypotensive O
effects O
of O
beta B-group
blockers I-group
. O

Therefore O
when O
central B-group
nervous I-group
system I-group
depressants I-group
are O
administered O
concomitantly O
with O
hydroxyzine B-drug
their O
dosage O
should O
be O
reduced O
. O

- O
The O
persistence O
of O
clinical O
and O
laboratory O
evidence O
of O
hypothyroidism O
in O
spite O
of O
adequate O
dosage O
replacement O
indicates O
either O
poor O
patient O
compliance O
, O
poor O
absorption O
, O
excessive O
fecal O
loss O
, O
or O
inactivity O
of O
the O
preparation O
. O

. O

Diclofenac B-drug
: O
Administration O
of O
morning O
and O
lunch O
doses O
of O
Starlix B-brand
120 O
mg O
in O
combination O
with O
a O
single O
75-mg O
dose O
of O
diclofenac B-drug
in O
healthy O
volunteers O
resulted O
in O
no O
significant O
changes O
to O
the O
pharmacokinetics O
of O
either O
agent O
. O

Loratadine B-drug
( O
10 O
mg O
once O
daily O
) O
has O
been O
coadministered O
with O
therapeutic O
doses O
of O
erythromycin B-drug
, O
cimetidine B-drug
, O
and O
ketoconazole B-drug
in O
controlled O
clinical O
pharmacology O
studies O
in O
adult O
volunteers O
. O

No O
data O
on O
the O
level O
of O
circulating O
catecholamines O
after O
ALPHAGAN B-brand
P I-brand
administration O
are O
available O
. O

Amitriptyline B-drug
in O
combination O
with O
clonidine B-drug
enhances O
the O
manifestation O
of O
corneal O
lesions O
in O
rats O
Epidural O
Injection O
Clonidine B-drug
may O
potentiate O
the O
CNS-depressive O
effect O
of O
alcohol B-drug
, O
barbiturates B-group
or O
other O
sedating B-group
drugs I-group
. O

Other O
substances O
, O
including O
herbal O
preparations O
: O
St. O
John O
s O
Wort O
( O
Hypericum O
perforatum O
) O
induces O
CYP3A4 O
. O

In O
normal O
volunteers O
receiving O
indomethacin B-drug
, O
the O
administration O
of O
diflunisal B-drug
decreased O
the O
renal O
clearance O
and O
significantly O
increased O
the O
plasma O
levels O
of O
indomethacin B-drug
. O

Valproate B-drug
: O
Felbatol B-brand
causes O
an O
increase O
in O
steady-state O
valproate B-drug
concentrations O
. O

APRD00513_IN O
, O
txt O

These O
agents O
should O
not O
be O
taken O
within O
the O
two O
hour O
period O
before O
or O
within O
the O
two-hour O
period O
after O
nalidixic B-drug
acid I-drug
administration O
. O

Intrathecal O
injection O
of O
naloxone B-drug
at O
doses O
of O
0.4 O
to O
40 O
micrograms O
caused O
a O
dose-related O
blockade O
of O
the O
inhibition O
of O
the O
tail-flick O
response O
induced O
by O
intraventricular O
injection O
of O
beta-endorphin B-drug_n
, O
and O
a O
high O
dose O
of O
naloxone B-drug
( O
40 O
micrograms O
) O
completely O
blocked O
the O
tail-flick O
inhibition O
induced O
by O
intraventricular O
beta-endorphin B-drug_n
( O
16 O
micrograms O
) O
. O

In O
one O
survey O
, O
2.3 O
% O
of O
patients O
taking O
labetalol B-drug
HCl I-drug
in O
combination O
with O
tricyclic B-group
antidepressants I-group
experienced O
tremor O
, O
as O
compared O
to O
0.7 O
% O
reported O
to O
occur O
with O
labetalol B-drug
HCl I-drug
alone O
. O

When O
sympathomimetic B-group
drugs I-group
are O
given O
to O
patients O
receiving O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
hypertensive O
reactions O
, O
including O
hypertensive O
crises O
, O
may O
occur O
. O

Resins B-group
: O
Since O
bile B-group
acid I-group
sequestrants I-group
may O
bind O
other O
drugs O
given O
concurrently O
, O
patients O
should O
take O
TRICOR B-brand
at O
least O
1 O
hour O
before O
or O
4-6 O
hours O
after O
a O
bile B-group
acid I-group
binding I-group
resin I-group
to O
avoid O
impeding O
its O
absorption O
. O

No O
drug O
interaction O
studies O
have O
been O
performed O
. O

In O
common O
with O
other O
broad-spectrum B-group
antibiotics I-group
, O
AUGMENTIN B-brand
XR I-brand
may O
reduce O
the O
efficacy O
of O
oral O
contraceptives B-group

Antimycobacterial B-group
Agents I-group

Valdecoxib B-drug
steady O
state O
plasma O
concentrations O
( O
40 O
mg O
BID O
) O
were O
not O
affected O
significantly O
with O
multiple O
doses O
of O
omeprazole B-drug
( O
40 O
mg O
QD O
) O
. O

lopinavir I-drug
concentration O

3 O
. O

Warfarin B-drug
and O
Anticoagulants B-group
: O
Increased O
prothrombin O
time O
, O
with O
or O
without O
clinical O
bleeding O
, O
has O
been O
reported O
when O
cefixime B-drug
is O
administered O
concomitantly O
. O

Drugs O
that O
Lower O
Seizure O
Threshold O
: O
Concurrent O
administration O
of O
WELLBUTRIN B-brand
and O
agents O
( O
e.g. O
, O
antipsychotics B-group
, O
other O
antidepressants B-group
, O
theophylline B-drug
, O
systemic O
steroids B-group
, O
etc O
. O
) O
that O
lower O
seizure O
threshold O
should O
be O
undertaken O
only O
with O
extreme O
caution O
. O

Drug O
Name O

A O
single O
0.5 O
mg O
oral O
dose O
of O
digoxin B-drug
elixir O
was O
administered O
on O
the O
7th O
day O
of O
each O
11-day O
period O
. O

HCTZ B-drug
50 O
mg O
QD O
or O
HCTZ/triamterene B-drug
50/100 O
mg O
QD O
was O
co-administered O
with O
TIKOSYN B-brand
( O
500 O
mcg O
BID O
) O
for O
5 O
days O
( O
following O
2 O
days O
of O
diuretic B-group
use O
at O
half O
dose O
) O
. O

Results O
from O
existing O
clinical O
trials O
suggest O
no O
significant O
interactions O
between O
COPAXONE B-brand
and O
other O
therapies O
commonly O
used O
in O
MS O
patients O
, O
including O
the O
concurrent O
use O
of O
corticosteroids B-group
for O
up O
to O
28 O
days O
. O

Antacids B-group
may O
interfere O
with O
the O
absorption O
of O
LEVSIN B-brand
. O

The O
zidovudine B-drug
study O
dosed O
subjects O
with O
1200 O
mg/day O
of O
azithromycin B-drug
( O
n O
= O
7 O
) O
( O
later O
changed O
to O
600 O
mg/day O
[ O
n O
= O
5 O
] O
) O
for O
Days O
8 O
to O
21 O
of O
a O
21-day O
course O
of O
100 O
mg O
, O
five O
times/day O
of O
zidovudine B-drug
. O

Sulindac B-drug
: O
The O
concomitant O
administration O
of O
diflunisal B-drug
and O
sulindac B-drug
in O
normal O
volunteers O
resulted O
in O
lowering O
of O
the O
plasma O
levels O
of O
the O
active O
sulindac O
sulfide O
metabolite O
by O
approximately O
one-third O
. O

Thus O
, O
concomitant O
administration O
of O
enoxacin B-drug
and O
bismuth B-drug
subsalicylate I-drug
should O
be O
avoided O
. O

CRIXIVAN B-brand
may O
not O
be O
effective O
due O
to O
decreased O
indinavir B-drug
concentrations O
in O
patients O
taking O
these O
agents O
concomitantly O
. O

Nifedipine B-drug
: O
Vardenafil B-drug
20 O
mg O
, O
when O
co-administered O
with O
slow-release O
nifedipine B-drug
30 O
mg O
or O
60 O
mg O
once O
daily O
, O
did O
not O
affect O
the O
relative O
bioavailability O
( O
AUC O
) O
or O
maximum O
concentration O
( O
Cmax O
) O
of O
nifedipine B-drug
, O
a O
drug O
that O
is O
metabolized O
via O
CYP3A4 O
. O

Isoflurane B-drug
, O
enflurane B-drug
, O
and O
halothane B-drug
decrease O
the O
ED50 O
of O
NUROMAX B-brand
by O
30 O
% O
to O
45 O
% O
. O

Since O
photic O
evoked O
potential O
components O
are O
representations O
of O
neural O
pathways O
which O
are O
activated O
during O
photic O
stimulation O
, O
study O
of O
the O
effects O
of O
alcohol B-drug
on O
these O
components O
may O
help O
to O
trace O
pathways O
which O
are O
affected O
by O
alcohol B-drug
. O

While O
all O
the O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
e.g. O
, O
fluoxetine B-drug
, O
seriraline O
, O
and O
paroxetine B-drug
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O

In O
this O
study O
, O
we O
investigated O
the O
mechanism O
( O
s O
) O
of O
resveratrol-induced B-drug_n
vasorelaxation O
in O
resistance O
mesenteric O
arteries O
from O
male O
lean O
and O
dietary-induced O
obese O
rats O
. O

Coadministration O
of O
VIDEX B-brand
with O
drugs O
that O
are O
known O
to O
cause O
pancreatitis O
may O
increase O
the O
risk O
of O
this O
toxicity O
( O
see O
WARNINGS O
) O
and O
should O
be O
done O
with O
extreme O
caution O
, O
only O
if O
other O
alternatives O
are O
not O
available O
, O
and O
only O
if O
clearly O
indicated O
. O

When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
glipizide B-drug
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

The O
in O
vitro O
interaction O
between O
nevirapine B-drug
and O
the O
antithrombotic B-group
agent I-group
warfarin B-drug
is O
complex O
. O

In O
addition O
, O
neuromuscular O
blocking O
action O
is O
enhanced O
by O
general O
anesthetics B-group
, O
local O
anesthetics B-group
like O
lidocaine B-drug
, O
procaine B-drug
, O
beta-blockers B-group
, O
metaclopramide B-drug
, O
lithium B-drug
carbonate I-drug
, O
and O
terbutaline B-drug
. O

The O
optimal O
dose O
of O
indinavir B-drug
, O
when O
given O
in O
combination O
with O
efavirenz B-drug
, O
is O
not O
known O
. O

Example O
inducers O
include O
aminoglutethimide B-drug
, O
carbamazepine B-drug
, O
nafcillin B-drug
, O
nevirapine B-drug
, O
phenobarbital B-drug
, O
phenytoin B-drug
, O
and O
rifamycins B-group
. O

Cobalt B-drug
excretion O
was O
enhanced O
by O
supplementary O
cobalt B-drug
; O

This O
effect O
is O
small O
with O
occasional O
doses O
of O
antacids B-group
, O
but O
may O
be O
clinically O
significant O
when O
antacids B-group
are O
used O
on O
a O
continuous O
schedule O
. O

Toxicologic O
and O
toxicokinetic O
studies O
in O
rats O
did O
not O
demonstrate O
any O
alterations O
in O
the O
clearance O
or O
toxicologic O
profile O
of O
either O
methotrexate B-drug
or O
Kineret B-brand
when O
the O
two O
agents O
were O
administered O
together O
. O

Whether O
this O
interaction O
also O
occurs O
with O
the O
intravenous O
, O
topical O
, O
or O
vaginal O
preparations O
of O
miconazole B-drug
is O
not O
known O
. O

Concomitant O
administration O
of O
Aprepitant B-drug
with O
strong O
CYP3A4 O
inhibitors O
should O
be O
approached O
cautiously O
. O

Dosage O
adjustment O
may O
be O
warranted O
when O
levobupivacaine B-drug
is O
concurrently O
administered O
with O
CYP3A4 O
inhibitors O
and O
CYP1A2 O
inhibitors O
as O
systemic O
levobupivacaine B-drug
levels O
may O
rise O
resulting O
in O
toxicity O
. O

Microdosed O
minipill O
progestin B-drug
preparations O
are O
not O
recommended O
for O
use O
with O
Soriatane B-drug
. O

An O
in O
vivo O
interaction O
study O
in O
humans O
demonstrated O
that O
a O
single O
1mg O
dose O
of O
anagrelide B-drug
administered O
concomitantly O
with O
a O
single O
900 O
mg O
dose O
of O
aspirin B-brand
was O
generally O
well O
tolerated O
. O

N=50 O
) O
Cmax O
and O
AUC O
values O
in O
a O
dose-dependent O
manner O
relative O
to O
administration O
of O
hydrocodone B-drug
alone O
; O

INDOCIN B-brand
can O
reduce O
the O
antihypertensive O
effects O
of O
captopril B-drug
and O
losartan B-drug
. O

The O
general O
public O
feels O
that O
cocaine B-drug
is O
not O
particularly O
dangerous O
because O
it O
does O
not O
produce O
a O
well O
defined O
physical O
dependency O
and O
abstinence O
syndrome O
. O

It O
should O
also O
be O
avoided O
in O
patients O
with O
blood O
, O
liver O
or O
kidney O
diseases O
, O
recent O
radiation O
treatment O
, O
or O
uncontrolled O
diabetes O
. O

A O
decrease O
of O
the O
dosage O
may O
be O
necessary O
when O
patient O
becomes O
euthyroid O
. O

dihydropyridine B-group
calcium I-group
channel I-group
blockers I-group
concentration O

The O
clinical O
relevance O
of O
the O
potential O
effect O
of O
grepafloxacin B-drug
on O
the O
metabolism O
of O
C.P.A O
. O
substrates O
is O
not O
known O
. O

Acute O
hydrocortisone B-drug
administration O
does O
not O
affect O
subjective O
responses O
to O
d-amphetamine B-drug
in O
humans O
. O

Acetaminophen B-drug
: O
May O
increase O
plasma O
concentration O
of O
synthetic B-group
estrogens I-group
, O
possibly O
by O
inhibiting O
conjugation O
. O

Concomitant O
Crohn O
s O
disease O
medications O
were O
antibiotics B-group
, O
antivirals B-group
, O
corticosteroids B-group
, O
6-MP/AZA B-drug
and O
aminosalicylates O
. O

Serum O
concentrations O
of O
drugs O
metabolized O
by O
the O
cytochrome O
P450 O
system O
should O
be O
monitored O
closely O
in O
patients O
concurrently O
receiving O
erythromycin B-drug
. O

Interaction O
between O
oxytocin B-drug
and O
antidiuretic O
hormone O
and O
its O
effect O
on O
the O
milk O
secretion O
by O
alveoli O
of O
the O
mammary O
gland O
of O
lactating O
rats O
. O

The O
following O
eight O
target O
drug/added O
drug O
combinations O
were O
studied O
: O
acetaminophen/phenobarbital B-drug
. O

The O
antifungal B-group
drug I-group
, O
miconazole B-drug
nitrate I-drug
, O
inhibits O
the O
growth O
of O
several O
species O
of O
Candida O
. O

No O
dosage O
adjustment O
is O
required O
for O
Fluvoxamine B-drug
Tablets O
. O

Fluoroquinolones B-drug
, O
macrolide B-drug
antibiotics I-drug
, O
and O
azoles O
are O
known O
to O
cause O
QTc O
prolongation O
. O

Concomitant O
use O
with O
other O
calcium-containing B-drug
medicines O
( O
including O
antacids B-group
) O
may O
cause O
too O
much O
calcium B-drug
in O
the O
blood O
or O
urine O
, O
which O
may O
increase O
the O
chance O
of O
side O
effects O
. O

These O
individuals O
may O
develop O
higher O
than O
expected O
plasma O
concentrations O
of O
clozapine B-drug
when O
given O
usual O
doses O
. O

Other O
reported O
interactions O
with O
amiodarone B-drug
: O
Fentanyl B-drug
( O
CYP3A4 B-drug
substrate O
) O
in O
combination O
with O
amiodarone B-drug
may O
cause O
hypotension O
, O
bradycardia O
, O
and O
decreased O
cardiac O
output O
. O

Finally O
, O
it O
is O
notable O
that O
xanthine-derived O
adenosine O
antagonists O
tested O
here O
commonly O
showed O
anxiogenic O
effects O
in O
the O
light/dark O
test O
in O
mice O
. O

Theophylline B-drug
: O
The O
pharmacokinetics O
of O
theophylline B-drug
( O
aminophylline B-drug
5.8 O
mg/kg O
infused O
over O
20 O
minutes O
) O
were O
unchanged O
following O
a O
single O
oral O
dose O
of O
albendazole B-drug
( O
400 O
mg O
) O
in O
6 O
healthy O
subjects O
. O

Drug/Laboratory O
Tests O
Interactions O
Because O
false O
positive O
readings O
were O
reported O
with O
the O
Ames O
N-Multistix O
SG O
dipstick O
test O
for O
urinary O
protein O
when O
gabapentin B-drug
was O
added O
to O
other O
antiepileptic B-group
drugs I-group
, O
the O
more O
specific O
sulfosalicylic O
acid O
precipitation O
procedure O
is O
recommended O
to O
determine O
the O
presence O
of O
urine O
protein O

Thus O
, O
certain O
factors O
, O
such O
as O
reinforcing O
drug O
effects O
, O
conditioning O
processes O
, O
automatic O
behavior O
, O
and O
stress O
, O
may O
influence O
the O
development O
of O
dependence O
on O
both O
drugs O
. O

. O

This O
risk O
is O
present O
whether O
the O
drugs O
are O
administered O
as O
oral O
, O
parenteral O
, O
or O
topical O
formulations O
. O

Successful O
prophylaxis O
of O
manic-depressive O
disorder O
requires O
more O
than O
the O
prescription O
of O
lithium B-drug
carbonate I-drug
. O

Dependent O
measures O
included O
self-reported O
mood O
and O
subjective O
effects O
( O
Addiction O
Research O
Center O
inventory O
, O
the O
profile O
of O
mood O
states O
, O
and O
a O
series O
of O
visual O
analogue O
scales O
) O
, O
vital O
signs O
, O
salivary O
cortisol O
, O
and O
psychomotor O
performance O
. O

When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
or O
other O
suitable O
coagulation O
tests O
should O
be O
monitored O
closely O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
Cyanokit B-brand
. O

vitamin B-drug
C I-drug
; O

Meclofenamate B-drug
sodium I-drug
does O
not O
affect O
serum O
salicylate B-group
levels O
. O

The O
use O
of O
NSAIDs B-group
in O
patients O
who O
are O
receiving O
ACE B-group
inhibitors I-group
may O
potentiate O
renal O
disease O
states O
. O

Therapeutic O
drug O
monitoring O
can O
avoid O
iatrogenic O
alterations O
caused O
by O
99mTc-methylene B-drug
diphosphonate I-drug
( O
MDP O
) O
-gentamicin B-drug
interaction O
. O

Consequently O
, O
prothrombin O
time O
should O
be O
reassessed O
periodically O
in O
patients O
receiving O
both O
drugs O
. O

Rifampin B-drug
has O
been O
reported O
to O
increase O
the O
warfarin B-drug
requirements O
in O
human O
subjects O
ingesting O
these O
agents O
simultaneously O
. O

This O
appears O
to O
be O
the O
only O
clinically O
relevant O
interaction O
of O
this O
kind O
with O
Mefloquine B-drug
, O
although O
theoretically O
, O
coadministration O
of O
other O
drugs O
known O
to O
alter O
cardiac O
conduction O
( O
eg O
, O
anti-arrhythmic B-drug
or O
beta-adrenergic B-group
blocking I-group
agents I-group
, O
calcium B-group
channel I-group
blockers I-group
, O
antihistamines B-group
or O
H1-blocking B-group
agents I-group
, O
tricyclic B-group
antidepressants I-group
and O
phenothiazines B-group
) O
might O
also O
contribute O
to O
a O
prolongation O
of O
the O
QTc O
interval O
. O

The O
effect O
was O
present O
for O
at O
least O
7 O
days O
after O
the O
last O
dose O
of O
bupropion B-drug
. O

Barbiturates B-group
, O
carbamazepine B-drug
, O
and O
phenytoin B-drug
decrease O
the O
half-life O
of O
doxycycline B-drug
. O

If O
nifedipine B-drug
therapy O
is O
initiated O
in O
a O
patient O
currently O
receiving O
cimetidine B-drug
, O
cautious O
titration O
is O
advised O
. O

During O
concomitant O
therapy O
of O
Ponstel B-brand
with O
furosemide B-drug
, O
the O
patient O
should O
be O
observed O
closely O
for O
signs O
of O
renal O
failure O
, O
as O
well O
as O
to O
assure O
diuretic O
efficacy O
. O

However O
, O
appropriate O
monitoring O
of O
blood O
glucose O
should O
be O
performed O
when O
initiating O
EXTRANEAL B-brand
in O
diabetic O
patients O
and O
insulin B-drug
dosage O
should O
be O
adjusted O
if O
needed O
. O

Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8-fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-group
) O
. O

An O
alternative O
non-CYP3A4 O
substrate O
hypnotic B-group
agent I-group
may O
be O
considered O
in O
patients O
taking O
CYP3A4 O
inducers O
such O
as O
rifampin B-drug
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
and O
phenobarbital B-drug
. O

Antidiabetic B-group
Agents I-group
: O
Disturbances O
of O
blood O
glucose O
, O
including O
hyperglycemia O
and O
hypoglycemia O
, O
have O
been O
reported O
in O
patients O
treated O
concomitantly O
with O
quinolones B-group
and O
an O
antidiabetic B-group
agent I-group
. O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
sodium B-drug_n
carboxymethylcellulose I-drug_n
( O
NaCMC B-drug_n
) O
and O
carboxymethylcellulose-cysteine B-drug_n
( O
CMC-Cys B-drug_n
) O
conjugates O
on O
the O
intestinal O
permeation O
of O
sodium B-drug
fluorescein I-drug
( O
NaFlu B-drug
) O
and O
model O
peptide O
drugs O
, O
bacitracin B-drug
and O
insulin B-drug
. O

Uricosuric B-group
Agents I-group
: O
Aspirin B-brand
may O
decrease O
the O
effects O
of O
probenecid B-drug
, O
sulfinpyrazone B-drug
, O
and O
phenylbutazone B-drug
. O

The O
effects O
of O
fulvestrant B-drug
on O
the O
fertility O
of O
female O
rats O
appear O
to O
be O
consistent O
with O
its O
anti-estrogenic O
activity O
. O

The O
availability O
of O
potent O
non-nucleoside B-group
reverse I-group
transcriptase I-group
inhibitor I-group
( O
NNRTI B-group
) O
-based O
regimens O
for O
antiretroviral B-group
therapy O
and O
concerns O
regarding O
protease B-group
inhibitor I-group
( O
PI B-group
) O
-related O
metabolic O
disturbances O
have O
led O
to O
significant O
shifts O
in O
treatment O
practices O
in O
HIV O
infection O
. O

- O
Antidiabetic B-group
drugs I-group
: O
( O
Oral O
agents O
and O
insulin B-drug
) O
Dosage O
adjustment O
of O
the O
antidiabetic B-group
drug I-group
may O
be O
required O

Ketoconazole B-drug
: O
Ketoconazole B-drug
has O
been O
reported O
to O
decrease O
the O
metabolism O
of O
certain O
corticosteroids B-group
by O
up O
to O
60 O
% O
, O
leading O
to O
increased O
risk O
of O
corticosteroid B-group
side O
effects O
. O

a O
See O
Tables O
1 O
and O
2 O
. O

NSAIDs B-group
should O
be O
used O
with O
caution O
in O
patients O
taking O
cyclosporine B-drug
, O
and O
renal O
function O
should O
be O
carefully O
monitored O
. O

Electrophilic O
agents O
-- O
a O
class O
of O
chemicals O
that O
includes O
most O
genotoxic O
compounds O
-- O
can O
be O
inactivated O
by O
reaction O
with O
glutathione O
or O
other O
SH-bearing O
molecules O
. O

Theophylline B-drug
: O
In O
three O
pharmacokinetic O
studies O
including O
46 O
normal O
, O
healthy O
subjects O
, O
theophylline B-drug
clearance O
and O
concentration O
were O
not O
significantly O
altered O
by O
the O
addition O
of O
lomefloxacin B-drug
. O

Concurrent O
therapy O
with O
ORENCIA B-brand
and O
TNF B-group
antagonists I-group
is O
not O
recommended O
. O

Cimetidine B-drug
: O
Cimetidine B-drug
can O
inhibit O
the O
metabolism O
of O
chloroquine B-drug
, O
increasing O
its O
plasma O
level O
. O

the O
time O
to O
reach O
maximum O
concentration O
was O
delayed O
approximately O
30 O
minutes O
. O

It O
is O
also O
shown O
that O
after O
14 O
days O
of O
daily O
administration O
of O
chlordiazepoxide B-drug
, O
withdrawal O
of O
the O
drug O
not O
only O
re-results O
in O
almost O
complete O
loss O
of O
bar-press O
response O
in O
the O
E-strain O
subjects O
but O
also O
results O
in O
a O
temporary O
decrease O
in O
the O
acquired O
behavioral O
response O
of O
the O
stable O
A-strain O
subjects O
. O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
CELEBREX B-brand
concomitantly O
with O
ACE-inhibitors B-group
. O

Lithium B-drug
: O
Lithium B-drug
toxicity O
has O
been O
reported O
in O
patients O
receiving O
lithium B-drug
concomitantly O
with O
drugs O
which O
cause O
elimination O
of O
sodium O
, O
including O
ACE B-group
inhibitors I-group
. O

Reciprocal O
interactions O
may O
occur O
with O
concomitant O
use O
of O
Antizol B-brand
and O
drugs O
that O
increase O
or O
inhibit O
the O
cytochrome O
P450 O
system O
( O
e.g. O
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
cimetidine B-drug
, O
ketoconazole B-drug
) O
, O
though O
this O
has O
not O
been O
studied O

Ranitidine B-drug
also O
has O
no O
effect O
on O
eprosartan B-drug
pharmacokinetics O
. O

multivitamins B-group
containing O
zinc B-drug
; O

The O
benzodiazepines B-group
are O
a O
family O
of O
anxiolytic B-group
and O
hypnotic B-group
drugs I-group
. O

Warfarin B-drug
: O
The O
effects O
of O
aliskiren B-drug
on O
warfarin B-drug
pharmacokinetics O
have O
not O
been O
evaluated O
in O
a O
well-controlled O
clinical O
trial O
. O

Phenobarbital B-drug
: O
It O
appears O
that O
phenobarbital B-drug
may O
reduce O
plasma O
felbamate B-drug
concentrations O
. O

False-negative O
results O
in O
the O
dexamethasone O
suppression O
test O
( O
DST O
) O
in O
patients O
being O
treated O
with O
INDOCIN B-brand
have O
been O
reported O
. O

The O
EC50 O
values O
for O
isoproterenol B-drug
, O
which O
is O
not O
a O
substrate O
for O
norepinephrine B-drug
uptake-1 O
, O
were O
reduced O
in O
myocardium O
in O
functional O
classes O
II O
to O
III O
and O
IV O
compared O
with O
those O
in O
nonfailing O
myocardium O
. O

HIV B-group
Protease I-group
Inhibitors I-group
: O
The O
effect O
of O
amprenavir B-drug
on O
total O
drug O
concentrations O
of O
other O
HIV B-group
protease I-group
inhibitors I-group
in O
subjects O
receiving O
both O
agents O
was O
evaluated O
using O
comparisons O
to O
historical O
data O
. O

A O
false-positive O
direct O
Coombs O
test O
has O
been O
reported O
during O
treatment O
with O
other O
cephalosporin B-group
antibiotics I-group
; O

Another O
study O
showed O
that O
alosetron B-drug
had O
no O
clinically O
significant O
effect O
on O
plasma O
concentrations O
of O
the O
oral O
contraceptive B-group
agents I-group
ethinyl B-drug
estradiol I-drug
and O
levonorgestrel B-drug
( O
CYP3A4 O
substrates O
) O
. O

Cytadren B-brand
accelerates O
the O
metabolism O
of O
dexamethasone B-drug
; O

CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
acute O
ergot O
toxicity O
characterized O
by O
peripheral O
vasospasm O
and O
ischemia O
of O
the O
extremities O
and O
other O
tissues O
. O

Anticholinergics B-group
: O
Concurrent O
administration O
of O
certain O
anticholinergic B-group
compounds I-group
, O
such O
as O
belladonna B-group
alkaloids I-group
and O
dicyclomine B-drug
, O
would O
be O
expected O
to O
compromise O
the O
beneficial O
effects O
of O
cisapride B-drug
. O

Use O
of O
a O
nonhormonal B-group
contraceptive I-group
product I-group
is O
recommended O
. O

Phenytoin B-drug
: O
Isoniazid B-drug
may O
increase O
serum O
levels O
of O
phenytoin B-drug
. O

Non-nucleoside B-group
reverse I-group
transcriptase I-group
inhibitors I-group
( O
NNRTIs B-group
) O
: O
Nevirapine B-drug
may O
decrease O
plasma O
levels O
of O
combination B-group
hormonal I-group
contraceptives I-group
; O

PEGASYS B-brand
contains O
benzyl B-drug_n
alcohol I-drug_n
. O

because O
of O
this O
, O
the O
dosage O
of O
flecainide B-drug
should O
be O
adjusted O
when O
these O
drugs B-drug
are O
administered O
concomitantly O
. O

The O
possibility O
of O
hypotensive O
effects O
with O
Lotensin B-brand
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-group
or O
increasing O
the O
salt O
intake O
prior O
to O
initiation O
of O
treatment O
with O
Lotensin B-brand
. O

these O
drugs O
were O
not O
tested O
to O
determine O
the O
effect O
of O
administration O
one O
hour O
before O
colestipol B-drug
hydrochloride I-drug
. O

Patients O
receiving O
beta-adrenergic B-group
blocking I-group
agents I-group
along O
with O
either O
oral O
or O
intravenous O
calcium B-group
antagonists I-group
should O
be O
monitored O
for O
possible O
atrioventricular O
conduction O
disturbances O
, O
left O
ventricular O
failure O
and O
hypotension O
. O

Nitrofurantoin B-drug
interferes O
with O
the O
therapeutic O
action O
of O
nalidixic B-drug
acid I-drug
. O

In O
vitro O
, O
at O
total O
drug O
concentrations O
27-fold O
higher O
than O
peak O
plasma O
concentrations O
observed O
with O
the O
1-mg O
dosage O
, O
alosetron B-drug
inhibited O
CYP O
enzymes O
1A2 O
( O
60 O
% O
) O
and O
2E1 O
( O
50 O
% O
) O
. O

Activity O
of O
buforin B-drug_n
II I-drug_n
alone O
and O
in O
combination O
with O
azithromycin B-drug
and O
minocycline B-drug
against O
Cryptosporidium O
parvum O
in O
cell O
culture O
. O

In O
patients O
using O
cardiac B-group
glycosides I-group
( O
digoxin B-drug
and O
others O
) O
, O
plasma O
levels O
of O
calcium O
, O
potassium O
and O
magnesium O
must O
be O
carefully O
monitored O
. O

This O
study O
indicates O
that O
: O
( O
a O
) O
the O
maximal O
effects O
of O
resveratrol B-drug_n
on O
resistance O
arteries O
from O
lean O
and O
dietary-obese O
rats O
are O
not O
effected O
by O
endothelial O
dysfunction O
, O
and O
( O
b O
) O
the O
effects O
of O
resveratrol B-drug_n
in O
lean O
animals O
( O
where O
endothelial O
function O
is O
not O
impaired O
) O
, O
but O
not O
in O
dietary-obese O
rats O
, O
are O
mediated O
via O
NO O
. O

In O
period O
B O
, O
the O
volunteers O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O

However O
, O
there O
are O
several O
instances O
in O
the O
animal O
literature O
showing O
that O
hippocampal O
lesions O
actually O
produced O
enhanced O
learning O
and O
memory O
function O
. O

This O
secretory O
diarrhea O
model O
is O
suitable O
for O
evaluating O
the O
antidiarrheal O
activity O
of O
drugs O
. O

In O
addition O
, O
there O
have O
been O
cases O
reported O
in O
which O
concomitant O
use O
of O
amphotericin B-drug
B I-drug
and O
hydrocortisone B-drug
was O
followed O
by O
cardiac O
enlargement O
and O
congestive O
heart O
failure O
. O

Cyclosporine B-drug
: O
Increased O
activity O
of O
both O
cyclosporine B-drug
and O
corticosteroids B-group
may O
occur O
when O
the O
two O
are O
used O
concurrently O
. O

Phenytoin/Phenobarbital B-drug
: O
The O
coadministration O
of O
phenytoin B-drug
or O
phenobarbital B-drug
will O
not O
affect O
plasma O
concentrations O
of O
vitamin B-group
D I-group
, O
but O
may O
reduce O
endogenous O
plasma O
levels O
of O
calcitriol/ergocalcitriol B-drug
by O
accelerating O
metabolism O
. O

Clinical O
studies O
in O
healthy O
volunteers O
show O
that O
the O
pharmacokinetics O
of O
CANCIDAS B-brand
are O
not O
altered O
by O
itraconazole B-drug
, O
amphotericin B-drug
B I-drug
, O
mycophenolate B-drug
, O
nelfinavir B-drug
, O
or O
tacrolimus B-drug
. O

The O
implications O
of O
these O
results O
are O
discussed O
, O
especially O
with O
respect O
to O
observations O
which O
indicate O
that O
homocysteine O
may O
be O
a O
precipitating O
factor O
in O
the O
development O
of O
thrombosis O
. O

Calcium B-drug
Supplements O
: O
Uncontrolled O
intake O
of O
additional O
calcium-containing B-drug
preparations O
should O
be O
avoided O
. O

Available O
data O
are O
neither O
sufficient O
to O
rule O
out O
possible O
increases O
in O
serum O
digoxin B-drug
with O
concomitant O
treatment O
in O
some O
patients O
, O
nor O
other O
possible O
interactions O
, O
particularly O
in O
patients O
with O
cardiac O
conduction O
abnormalities O
( O
Also O
see O
WARNINGS O
Congestive O
Heart O
Failure O
) O
. O

6 O
. O

In O
clinical O
studies O
propofol B-drug
had O
no O
effect O
on O
the O
duration O
of O
action O
or O
dosing O
requirements O
for O
NIMBEX B-brand
. O

The O
pharmacodynamic O
consequences O
of O
concomitant O
use O
of O
losartan B-drug
and O
inhibitors O
of O
P450 O
2C9 O
have O
not O
been O
examined O
. O

this O
was O
seen O
in O
studies O
with O
estazolam B-drug
. O

In O
some O
cases O
the O
onset O
of O
the O
injection O
site O
reaction O
either O
occurred O
during O
a O
prolonged O
infusion O
or O
was O
delayed O
by O
a O
week O
to O
ten O
days O
. O

Free O
T3 O
resin O
uptake O
is O
decreased O
, O
reflecting O
the O
elevated O
TBG O
; O

Anticonvulsants B-group
: O
In O
a O
pharmacokinetic O
study O
, O
maximum O
plasma O
concentrations O
of O
felodipine B-drug
were O
considerably O
lower O
in O
epileptic O
patients O
on O
long-term O
anticonvulsant B-group
therapy O
( O
eg O
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
or O
phenobarbital B-drug
) O
than O
in O
healthy O
volunteers O
. O

The O
injection O
should O
be O
made O
immediately O
after O
mixing O
. O

Patients O
using O
cardiovascular O
drugs O
concurrently O
with O
IOPIDINE B-brand
0.5 O
% O
Ophthalmic O
Solution O
should O
have O
pulse O
and O
blood O
pressures O
frequently O
monitored O
. O

Because O
of O
the O
potential O
for O
ARAVA B-brand
levels O
to O
continue O
to O
increase O
with O
multiple O
dosing O
, O
caution O
should O
be O
used O
if O
patients O
are O
to O
be O
receiving O
both O
ARAVA B-brand
and O
rifampin B-drug
. O

Frequent O
vital O
sign O
monitoring O
, O
particularly O
during O
the O
first O
hour O
of O
TAXOL B-brand
infusion O
, O
is O
recommended O
. O

tricyclic B-group
antidepressants I-group
( O
such O
as O
amitriptyline B-drug
) O
; O

Numerous O
drug O
interactions O
are O
possible O
with O
some O
anticonvulsant B-group
agents I-group
, O
such O
as O
phenobarbitone B-drug
and O
phenytoin B-drug
, O
which O
affect O
hepatic O
microsomal O
enzyme O
systems O
. O

Therefore O
, O
cyclosporine B-drug
serum O
levels O
should O
be O
monitored O
and O
appropriate O
cyclosporine B-drug
dosage O
adjustments O
made O
when O
these O
drugs O
are O
used O
concomitantly O
. O

Amprenavir B-drug
decreased O
the O
results O
of O
the O
ERMBT O
by O
83 O
% O
. O

There O
was O
no O
effect O
on O
the O
pharmacokinetics O
of O
representative O
drugs O
metabolized O
by O
CYP O
2C9 O
, O
CYP O
2C19 O
, O
CYP O
2D6 O
or O
CYP O
3A4 O
. O

Systemic B-group
Corticosteroids I-group
: O
Systemic B-group
corticosteroids I-group
are O
known O
to O
cause O
osteoporosis O
. O

The O
influence O
of O
midazolam B-drug
and O
diazepam B-drug
on O
antinociceptive O
effect O
of O
morphine B-drug
( O
10 O
mg/kg O
) O
, O
metamizol B-drug
( O
500 O
mg/kg O
) O
and O
indomethacin B-drug
( O
10 O
mg/kg O
) O
was O
investigated O
in O
a O
mouse O
model O
using O
the O
tail-flick O
and O
hot-plate O
tests O
. O

Drug/Laboratory O
Test O
Interactions O
: O
There O
have O
been O
no O
chemical O
or O
laboratory O
test O
interactions O
with O
ceftibuten B-drug
noted O
to O
date O
. O

incomplete O
data O
for O
efavirenz B-drug
. O

Preliminary O
clinical O
data O
suggest O
that O
the O
incidence O
of O
nephrolithiasis O
is O
higher O
in O
patients O
receiving O
indinavir B-drug
in O
combination O
with O
ritonavir B-drug
than O
those O
receiving O
CRIXIVAN B-brand
800 O
mg O
q8h O
. O

Propranolol B-drug
: O
In O
normal O
volunteers O
, O
there O
was O
no O
clinically O
significant O
pharmacokinetic O
or O
pharmacodynamic O
interaction O
with O
concomitant O
administration O
of O
single O
doses O
of O
lovastatin B-drug
and O
propranolol B-drug
. O

cases O
, O
occurred O
between O
the O
5th O
and O
the O
11th O
day O
of O
treatment O
. O

Arginine B-drug
, O
in O
the O
presence O
of O
glucose B-drug
and O
theophylline B-drug
, O
caused O
excessive O
glucagon O
release O
but O
nearly O
normal O
insulin O
release O
in O
the O
diabetics O
. O

A O
routine O
dosage O
adjustment O
of O
zaleplon B-drug
is O
not O
considered O
necessary O
. O

Sirolimus B-drug
: O
mammalian O
target O
of O
rapamycin B-drug
inhibitor O
to O
prevent O
kidney O
rejection O
. O

Serum O
theophylline B-drug
concentrations O
increase O
when O
grepafloxacin B-drug
is O
initiated O
in O
a O
patient O
maintained O
on O
theophylline B-drug
. O

Amprenavir B-drug
is O
an O
inhibitor O
of O
cytochrome O
P450 O
C.P.A O
. O
metabolism O
and O
therefore O
should O
not O
be O
administered O
concurrently O
with O
medications O
with O
narrow O
therapeutic O
windows O
that O
are O
substrates O
of O
CYP3A4 O
. O

Colestipol B-drug
: O
Plasma O
concentrations O
of O
atorvastatin B-drug
decreased O
approximately O
25 O
% O
when O
colestipol B-drug
and O
atorvastatin B-drug
were O
coadministered O
. O

Although O
the O
clinical O
significance O
is O
not O
known O
, O
it O
is O
not O
recommended O
that O
cefditoren B-drug
pivoxil I-drug
be O
taken O
concomitantly O
with O
antacids B-group
. O

Maprotiline B-drug
: O
Risk O
of O
cardiac O
arrhythmias O
may O
increase O
. O

Effects O
of O
Aliskiren B-drug
on O
Other O
Drugs O
Aliskiren B-drug
does O
not O
inhibit O
the O
CYP450 O
isoenzymes O
( O
CYP1A2 O
, O
2C8 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
, O
and O
CYP O
3A O
) O
or O
induce O
CYP O
3A4 O
. O

Clinical O
interaction O
studies O
with O
cimetidine B-drug
and O
warfarin B-drug
indicated O
that O
the O
coadministration O
of O
Femara B-brand
with O
these O
drugs O
does O
not O
result O
in O
clinically- O
significant O
drug O
interactions O
. O

This O
may O
lead O
to O
reduced O
clearance O
of O
caffeine B-drug
and O
a O
prolongation O
of O
its O
serum O
half-life O
. O

Ganciclovir B-drug
: O
The O
pharmacokinetics O
of O
foscarnet B-drug
and O
ganciclovir B-drug
were O
not O
altered O
in O
13 O
patients O
receiving O
either O
concomitant O
therapy O
or O
daily O
alternating O
therapy O
for O
maintenance O
of O
CMV O
disease O
. O

Drug/Laboratory O
Tests O
Interactions O
No O
clinically O
relevant O
changes O
in O
the O
results O
of O
clinical O
laboratory O
tests O
have O
been O
observed O
. O

Pretreatment O
with O
atropine B-drug
likewise O
further O
reduced O
the O
amplitudes O
of O
components O
P1 O
and O
N1 O
, O
and O
produced O
a O
similar O
effect O
on O
component O
N3 O
. O

naproxen B-drug
; O

Pharmacodynamic-related O
Interactions O
: O
The O
mechanism O
of O
Clozapine B-drug
induced O
agranulocytosis O
is O
unknown O
; O

Consequently O
, O
the O
effect O
of O
iron B-drug
on O
the O
retention O
of O
cobalt B-drug
was O
lower O
than O
on O
absorption O
. O

Dextromethorphan B-drug
is O
a O
substrate O
for O
both O
CYP2D6 B-drug
and O
CYP3A4 B-drug
. O

The O
AUC O
and O
Cmax O
of O
metoprolol B-drug
, O
however O
, O
were O
increased O
approximately O
31 O
and O
38 O
% O
, O
respectively O
. O

Patients O
receiving O
antihistamines B-group
should O
be O
advised O
against O
the O
concurrent O
use O
of O
other O
CNS B-group
depressant I-group
drugs I-group
. O

Fourteen O
days O
later O
, O
all O
animals O
were O
challenged O
with O
a O
single O
hypnotic O
dose O
of O
ethanol B-drug
( O
3.5 O
g/kg O
IP O
) O
. O

Quinidine B-drug
at O
648 O
mg O
bid O
decreased O
the O
bioavailability O
( O
AUC O
) O
of O
nisoldipine B-drug
by O
26 O
% O
, O
but O
not O
the O
peak O
concentration O
. O

Dopamine B-group
D2 I-group
receptor I-group
antagonists I-group
( O
e.g. O
, O
phenothiazines B-group
, O
butyrophenones B-group
, O
risperidone B-drug
) O
and O
isoniazid B-drug
may O
reduce O
the O
therapeutic O
effects O
of O
levodopa B-drug
. O

or O
=0.2 O
% O
biocytin O
was O
included O
in O
the O
recording O
pipette O
, O
compared O
with O
neurons O
recorded O
without O
biocytin O
. O

Whenever O
increased O
thioether O
excretion O
is O
observed O
, O
it O
is O
likely O
to O
be O
due O
to O
exposure O
to O
one O
or O
more O
suspect O
compounds O
. O

Two O
studies O
were O
conducted O
in O
HIV-infected O
subjects O
to O
assess O
the O
potential O
for O
azithromycin B-drug
to O
interact O
with O
zidovudine B-drug
and O
dideoxyinosine B-drug
. O

Comparative O
analysis O
of O
the O
effects O
of O
stimulation O
and O
inhibition O
of O
cholino- O
and O
adrenoreceptors O
on O
this O
inhibitory O
action O
of O
angiotensins B-drug_n
suggested O
the O
mediation O
of O
angiotensin B-drug_n
influence O
through O
the O
modulation O
of O
cholinergic O
reactions O
of O
parietal O
cells O
in O
the O
stomach O
. O

Cimetidine B-drug
reduces O
the O
clearance O
of O
ALFENTA B-brand
. O

Drugs O
that O
cause O
significant O
sustained O
elevation O
in O
gastric O
pH O
( O
histamine B-group
H2-receptor I-group
antagonists I-group
such O
as O
ranitidine B-drug
or O
cimetidine B-drug
) O
may O
reduce O
plasma O
concentrations O
of O
IRESSA B-brand
and O
therefore O
potentially O
may O
reduce O
efficacy O
. O

Therefore O
, O
linezolid B-drug
has O
the O
potential O
for O
interaction O
with O
adrenergic B-group
and O
serotonergic B-group
agents I-group
. O

Phencyclidine B-drug_n
( O
PCP B-drug_n
) O
produces O
psychotomimetic O
effects O
in O
humans O
that O
resemble O
schizophrenia O
symptoms O
. O

Simvastatin B-drug
and O
Other O
Statins B-group
: O
Co-administration O
of O
bosentan B-drug
decreased O
the O
plasma O
concentrations O
of O
simvastatin B-drug
( O
a O
CYP3A4 O
substrate O
) O
, O
and O
its O
active O
-hydroxy O
acid O
metabolite O
, O
by O
approximately O
50 O
% O
. O

After O
prolonged O
administration O
of O
neuroleptics B-group
the O
displacing O
effect O
of O
cerulein B-drug_n
, O
an O
analog O
of O
cholecystokinin O
octapeptide O
, O
was O
replaced O
by O
the O
stimulant O
action O
on O
3H-spiroperidol B-drug_n
binding O
. O

therefore O
, O
administration O
of O
EQUETROTM B-brand
to O
a O
patient O
taking O
another O
drug O
that O
is O
highly O
protein O
bound O
should O
not O
cause O
increased O
free O
concentrations O
of O
the O
other O
drug O
. O

Medication O
such O
as O
digitalis B-group
may O
also O
influence O
serum O
electrolytes O
. O

Antidiabetic B-group
drug I-group
requirements O
( O
i.e. O
, O
insulin B-drug
) O
may O
be O
altered O
. O

Drug/Laboratory O
Test O
Interactions O
As O
a O
result O
of O
the O
presence O
of O
nitrofurantoin B-drug
, O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
. O

Urinary B-group
acidifying I-group
agents I-group
( O
ammonium B-drug
chloride I-drug
, O
sodium B-drug
acid I-drug
phosphate I-drug
, O
etc O
. O
) O
increase O
the O
concentration O
of O
the O
ionized O
species O
of O
the O
amphetamine B-drug
molecule O
, O
thereby O
increasing O
urinary O
excretion O
. O

Responses O
to O
arginine B-drug
of O
the O
perfused O
pancreas O
of O
the O
genetically O
diabetic O
Chinese O
hamster O
. O

A O
two-way O
interaction O
between O
the O
hydantoin B-group
antiepileptic I-group
, O
phenytoin B-drug
, O
and O
the O
coumarin B-group
anticoagulants O
has O
been O
suggested O
. O

Amprenavir B-drug
plus O
rifampin B-drug
was O
well O
tolerated O
. O

Therefore O
, O
if O
concomitant O
use O
of O
these O
agents O
is O
indicated O
because O
of O
demonstrated O
hypokalemia O
, O
they O
should O
be O
used O
with O
caution O
and O
with O
frequent O
monitoring O
of O
serum O
potassium O
. O

Lithium B-drug
: O
Increased O
serum O
lithium B-drug
levels O
and O
symptoms O
of O
lithium B-drug
toxicity O
have O
been O
reported O
in O
patients O
receiving O
concomitant O
lithium B-drug
and O
ACE B-group
inhibitor I-group
therapy O
. O

Patients O
who O
have O
developed O
severe O
hypersensitivity O
reactions O
should O
not O
be O
rechallenged O
with O
TAXOL B-brand
. O

and O
, O
rarely O
, O
enuresis O
, O
urinary O
retention O
, O
dysuria O
, O
impotence O
, O
inability O
to O
ejaculate O
, O
nocturia O
, O
hematuria O
. O

A O
single O
dose O
of O
liquid O
antacid B-group
did O
not O
affect O
the O
C O
max O
or O
AUC O
of O
ceftibuten B-drug
; O

An O
evaluation O
of O
prothrombin O
time O
and O
an O
adjustment O
of O
anticoagulant B-group
dosage O
are O
recommended O

For O
this O
reason O
, O
the O
dose O
of O
the O
anticoagulant B-drug
should O
be O
reduced O
by O
30 O
- O
50 O
% O
at O
the O
start O
of O
treatment O
with O
Bezalip B-brand
or O
Bezalip B-brand
retard O
and O
then O
titrated O
according O
to O
the O
blood O
clotting O
parameters O

ibuprofen B-drug
; O

The O
appropriate O
dose O
for O
nelfinavir B-drug
incombination O
with O
nevirapine B-drug
, O
with O
respectto O
safety O
and O
efficacy O
, O
has O
not O
been O
established O
. O

Concomitant O
administration O
of O
fenofibrate B-drug
( O
equivalent O
to O
145mg O
TRICOR B-brand
) O
with O
pravastatin B-drug
( O
40 O
mg O
) O
once O
daily O
for O
10 O
days O
has O
been O
shown O
to O
increase O
the O
mean O
Cmax O
and O
AUC O
values O
for O
pravastatin B-drug
by O
36 O
% O
( O
range O
from O
69 O
% O
decrease O
to O
321 O
% O
increase O
) O
and O
28 O
% O
( O
range O
from O
54 O
% O
decrease O
to O
128 O
% O
increase O
) O
, O
respectively O
, O
and O
for O
3 O
-hydroxy-iso-pravastatin O
by O
55 O
% O
( O
range O
from O
32 O
% O
decrease O
to O
314 O
% O
increase O
) O
and O
39 O
% O
( O
range O
from O
24 O
% O
decrease O
to O
261 O
% O
increase O
) O
, O
respectively O
in O
23 O
healthy O
adults O
. O

Data O
from O
several O
studies O
, O
ie O
, O
TIMI-II O
, O
ISIS-2 O
, O
currently O
do O
not O
suggest O
any O
clinical O
interaction O
between O
aspirin B-brand
and O
beta B-group
blockers I-group
in O
the O
acute O
myocardial O
infarction O
setting O
. O

chlordiazepoxide B-drug
; O

Treatment O
with O
daily O
doses O
of O
2 O
mg O
of O
coumaphos/kg B-drug_n
for O
6 O
days O
did O
not O
modify O
the O
anticholinesterase O
effect O
of O
a O
2nd O
series O
of O
treatments O
given O
6 O
weeks O
later O
. O

Effects O
of O
Vardenafil B-drug
on O
other O
drugs O

Doxorubicin B-drug
: O
Doxorubicin B-drug
caused O
a O
decrease O
in O
zalcitabine B-drug
phosphorylation O
( O
50 O
% O
inhibition O
of O
total O
phosphate O
formation O
) O
in O
U937/Molt O
4 O
cells O
. O

it O
is O
possible O
that O
larger O
theophylline B-drug
doses O
could O
have O
a O
greater O
effect O
. O

Progestin-only O
oral O
contraception O
: O
a O
comprehensive O
review O
. O

Although O
the O
magnitude O
of O
changes O
in O
diazepam B-drug
plasma O
exposure O
when O
coadministered O
with O
valdecoxib B-drug
were O
not O
sufficient O
to O
warrant O
dosage O
adjustments O
, O
patients O
may O
experience O
enhanced O
sedative O
side O
effects O
caused O
by O
increased O
exposure O
of O
diazepam B-drug
under O
this O
circumstance O
. O

cardiovascular O
effects O
can O
be O
potentiated O
. O

However O
, O
interactions O
may O
be O
expected O
, O
and O
UROXATRAL B-brand
should O
NOT O
be O
used O
in O
combination O
with O
other O
alpha-blockers B-group
. O

The O
addition O
of O
540 O
mg/kg/day O
of O
cromolyn B-drug
sodium I-drug
( O
approximately O
340 O
times O
the O
maximum O
recommended O
daily O
inhalation O
dose O
in O
adults O
on O
a O
mg/m2 O
basis O
) O
to O
2.7 O
mg/kg/day O
of O
isoproterenol B-drug
( O
approximately O
7 O
times O
the O
maximum O
recommended O
daily O
inhalation O
dose O
in O
adults O
on O
a O
mg/m2 O
basis O
) O
appears O
to O
have O
increased O
the O
incidence O
of O
both O
resorptions O
and O
malformations O
. O

Agents O
with O
Decreased O
Levels O
in O
the O
Presence O
of O
Carbamazepine B-drug
due O
to O
Induction O
of O
Cytochrome O
P450 O
Enzymes O
Carbamazepine B-drug
is O
known O
to O
induce O
CYP1A2 O
and O
CYP3A4 O
. O

Drug/Laboratory O
Test O
Interactions O
As O
with O
other O
penicillins B-drug
, O
the O
administration O
of O
PIPRACIL B-brand
may O
result O
in O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
using O
a O
copper-reduction O
method O
. O

The O
total O
drug O
exposure O
for O
the O
plasma O
was O
approximately O
twofold O
at O
the O
higher O
cisplatin B-drug
dose O
. O

The O
patient O
should O
be O
informed O
that O
the O
response O
to O
alcohol B-drug
may O
be O
exaggerated O
. O

Drug O
Interaction O
with O
Fluoxetine B-drug
: O
A O
multiple-dose O
study O
was O
conducted O
to O
assess O
the O
effect O
of O
fluoxetine B-drug
20 O
mg O
BID O
on O
the O
pharmacokinetics O
of O
estazolam B-drug
2 O
mg O
QHS O
after O
seven O
days O
. O

Reductions O
in O
serum O
endogenous O
vitamin O
D O
concentrations O
have O
been O
observed O
following O
the O
administration O
of O
300 O
mg/day O
to O
1200 O
mg/day O
ketoconazole B-drug
for O
a O
week O
to O
healthy O
men O
. O

+45 O
% O
+39 O
% O
+43 O
% O
+72 O
% O

Geocillin B-brand
( O
carbenicillin B-drug
indanyl I-drug
sodium I-drug
) O
blood O
levels O
may O
be O
increased O
and O
prolonged O
by O
concurrent O
administration O
of O
probenecid B-drug
. O

It O
may O
increase O
excretion O
of O
barbiturates B-group
, O
lithium B-drug
, O
and O
ASA B-drug
and O
may O
also O
increase O
the O
toxicity O
of O
salicylates B-group
. O

Do O
not O
mix O
TORADOL B-brand
and O
morphine B-drug
in O
the O
same O
syringe O
. O

The O
steady-state O
Cmin O
increased O
to O
21 O
5 O
micrograms/mL O
when O
1200 O
mg/day O
of O
felbamate B-drug
was O
coadministered O
. O

Isoflurane B-drug
or O
enflurane B-drug
administered O
with O
nitrous B-drug
oxide/oxygen I-drug
to O
achieve O
1.25 O
MAC O
[ O
Minimum O
Alveolar O
Concentration O
] O
may O
prolong O
the O
clinically O
effective O
duration O
of O
action O
of O
initial O
and O
maintenance O
doses O
of O
NIMBEX B-brand
and O
decrease O
the O
required O
infusion O
rate O
of O
NIMBEX B-brand
. O

It O
is O
, O
therefore O
, O
advisable O
to O
monitor O
digoxin B-drug
concentrations O
in O
patients O
receiving O
ketoconazole B-drug
. O

- O
Vitamin B-group
K I-group
( O
e.g. O
, O
AquaMEPHYTON B-brand
, O
Synkayvite B-brand
) O
Use O
of O
sulfapyridine B-drug
with O
these O
medicines O
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
blood O

No O
information O
provided O

Patients O
receiving O
the O
two O
drugs O
concomitantly O
should O
be O
carefully O
monitored O
. O

Notably O
, O
systemic O
exposure O
( O
AUC0-12 O
) O
of O
dapsone B-drug_n
hydroxylamine I-drug_n
( O
DHA B-drug_n
) O
was O
more O
than O
doubled O
in O
the O
presence O
of O
TMP/SMX B-drug
. O

If O
the O
two O
drugs O
are O
coadministered O
, O
the O
beta B-group
blocker I-group
should O
be O
withdrawn O
several O
days O
before O
the O
gradual O
withdrawal O
of O
clonidine B-drug
. O

Therefore O
concomitant O
administration O
of O
ketoconazole B-drug
tablets O
with O
cisapride B-drug
is O
contraindicated O
. O

benign O
breast O
disease O
; O

Colchicine B-drug
is O
inhibited O
by O
acidifying B-group
agents I-group
. O

Co-administration O
with O
efavirenz B-drug
or O
fluconazole B-drug
had O
a O
modest O
effect O
on O
the O
pharmacokinetics O
of O
azithromycin B-drug
. O

Oral O
Hypoglycemic B-group
Agents I-group
: O
In O
pharmacokinetic O
studies O
of O
MEVACOR B-brand
in O
hypercholesterolemic O
noninsulin O
dependent O
diabetic O
patients O
, O
there O
was O
no O
drug O
interaction O
with O
glipizide B-drug
or O
with O
chlorpropamide B-drug

Comparison O
of O
cisplatin B-drug
pharmacokinetics O
in O
patients O
treated O
with O
202.5 O
mg/m2 O
plus O
thiosulfate B-drug
to O
those O
in O
patients O
treated O
with O
100 O
mg/m2 O
without O
thiosulfate B-drug
indicated O
that O
there O
were O
no O
changes O
in O
the O
elimination O
rate O
constant O
, O
volume O
of O
distribution O
, O
or O
total O
body O
clearance O
of O
cisplatin B-drug
. O

Dosage O
adjustment O
may O
be O
required O
if O
cyclosporine B-drug
, O
tacrolimus B-drug
, O
or O
methylprednisolone B-drug
are O
given O
concomitantly O
with O
NIZORAL B-brand
Tablets O
. O

No O
depressant O
effect O
on O
blood O
levels O
in O
humans O
was O
noted O
when O
colestipol B-drug
hydrochloride I-drug
was O
administered O
with O
any O
of O
the O
following O
drugs O
: O
aspirin B-brand
, O
clindamycin B-brand
, O
clofibrate B-drug
, O
methyldopa B-drug
, O
nicotinic B-drug
acid I-drug
( O
niacin B-drug
) O
, O
tolbutamide B-drug
, O
phenytoin B-drug
or O
warfarin B-drug
. O

- O
phenytoin B-drug
( O
Dilantin B-brand
) O
; O

Withdrawal O
from O
cocaine B-drug
dependence O
usually O
involves O
depression O
, O
anxiety O
and O
lethargy O
. O

Therapeutic O
drug O
monitoring O
( O
TDM O
) O
of O
gentamicin B-drug
therapy O
, O
and O
bone O
scintigraphy O
employing O
99mTc-MDP B-drug
as O
the O
radiopharmaceutical B-group
was O
carried O
out O
in O
22 O
patients O
. O

Refer O
to O
the O
package O
insert O
for O
lithium B-drug
preparations O
before O
use O
of O
such O
preparations O
with O
chlorothiazide B-drug

Drug O
Interaction O
with O
Erythromycin B-drug
and O
Ketoconazole B-drug
Fexofenadine I-drug
has O
been O
shown O
to O
exhibit O
minimal O
( O
ca O
. O
5 O
% O
) O
metabolism O
. O

Because O
eprosartan B-drug
is O
not O
metabolized O
by O
the O
cytochrome O
P450 O
system O
, O
inhibitors O
of O
CYP450 O
enzyme O
would O
not O
be O
expected O
to O
affect O
its O
metabolism O
, O
and O
ketoconazole B-drug
and O
fluconazole B-drug
, O
potent O
inhibitors O
of O
CYP3A O
and O
2C9 O
, O
respectively O
, O
have O
been O
shown O
to O
have O
no O
effect O
on O
eprosartan B-drug
pharmacokinetics O
. O

The O
concomitant O
intake O
of O
alcohol B-drug
and O
Acamprosate B-drug
does O
not O
affect O
the O
pharmacokinetics O
of O
either O
alcohol B-drug
or O
acamprosate B-drug
. O

The O
following O
specific O
interactions O
have O
been O
reported O
: O
Itraconazole O
Co-administration O
of O
another O
extended O
release O
formulation O
of O
felodipine B-drug
with O
itraconazole B-drug
resulted O
in O
approximately O
8-fold O
increase O
in O
the O
AUC O
, O
more O
than O
6- O
fold O
increase O
in O
the O
Cmax O
, O
and O
2-fold O
prolongation O
in O
the O
half- O
life O
of O
felodipine B-drug
. O

Erythromycin B-drug
has O
been O
reported O
to O
significantly O
alter O
the O
metabolism O
of O
nonsedating O
antihistamines B-group
terfenadine B-drug
and O
astemizole B-drug
when O
taken O
concomitantly O
. O

Mixtures O
of O
cadmium O
and O
zinc B-drug
had O
a O
synergistic O
effect O
compared O
with O
single O
metal O
toxicity O
but O
only O
at O
50000 O
microg/l O
. O

ALLEGRA B-brand
should O
not O
be O
taken O
closely O
in O
time O
with O
aluminum B-drug
and O
magnesium B-drug
containing O
antacids B-group
. O

No O
interaction O
was O
noted O
with O
the O
MAO-B B-group
inhibitor I-group
selegiline B-drug
in O
two O
multiple-dose O
interaction O
studies O
when O
entacapone B-drug
was O
coadministered O
with O
a O
levodopa/dopa B-drug
decarboxylase B-group
inhibitor I-group
( O
n=29 O
) O
. O

There O
is O
the O
risk O
of O
convulsions O
occurring O
in O
susceptible O
patients O
following O
the O
use O
of O
the O
new O
anaesthetic B-group
agents I-group
which O
are O
capable O
of O
inducing O
CNS O
excitability O
. O

RESULTS O
: O
Hydrocortisone B-drug
elevated O
salivary O
cortisol O
levels O
, O
produced O
modest O
dysphoria O
, O
and O
reduced O
subjects O
' O
reports O
of O
wanting O
more O
drug O
. O

Clarithromycin I-drug
14OH- O
clarithromycin O

Caution O
should O
be O
exercised O
during O
the O
administration O
of O
adrenaline B-drug
to O
patients O
anaesthetised O
with O
FLUOTHANE B-brand
as O
arrhythmias O
may O
be O
precipitated O
. O

Probenecid B-drug
: O
The O
oral O
combination O
of O
probenecid B-drug
before O
intramuscular O
injection O
of O
PIPRACIL B-brand
produces O
an O
increase O
in O
piperacillin B-drug
peak O
serum O
level O
of O
about O
30 O
% O
. O

A O
review O
. O

The O
effects O
of O
medicinal O
products O
with O
similar O
properties O
such O
as O
inotropes O
milrinone B-drug
, O
enoximone B-drug
, O
amrinone B-drug
, O
olprinone B-drug_n
and O
cilostazol B-drug
may O
be O
exacerbated O
by O
anagrelide B-drug
. O

Our O
data O
suggest O
that O
TAM B-drug_n
significantly O
potentiates O
the O
reduction O
in O
cell O
number O
induced O
by O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
alone O
. O

Determinants O
downstream O
of O
cleavable O
complex O
formation O
that O
affect O
the O
sensitivity O
of O
tumor O
versus O
normal O
cells O
to O
topo O
drugs O
in O
particular O
and O
DNA-damaging O
agents O
in O
general O
are O
little O
known O
. O

ethchlorvynol B-drug
; O

Injection O
of O
estradiol B-drug
5 O
min O
before O
a O
nonlethal O
dose O
of O
endotoxin B-drug_n
changed O
the O
serum O
sex O
steroid O
hormone O
response O
of O
male O
rats O
to O
endotoxin B-drug_n
. O

Additive O
depressant O
effect O
when O
used O
with O
general O
anesthetics B-group
, O
sedatives B-group
, O
antianxiety B-group
drugs I-group
, O
hypnotics B-group
, O
alcohol B-drug
, O
and O
other O
opiate B-group
analgesics I-group
. O

Antagonism O
has O
been O
demonstrated O
between O
clindamycin B-drug
and O
erythromycin B-drug
in O
vitro O
. O

It O
may O
also O
interact O
with O
amantadine B-drug
or O
other O
anticholinergic B-group
drugs I-group
or O
MAOIs B-group
, O
which O
may O
intensify O
the O
anticholinergic O
action O
. O

Oral O
Anticoagulants B-group
: O
In O
some O
normal O
volunteers O
, O
the O
concomitant O
administration O
of O
diflunisal B-drug
and O
warfarin B-drug
, O
acenocoumarol B-drug
, O
or O
phenprocoumon B-drug
resulted O
in O
prolongation O
of O
prothrombin O
time O
. O

Rifabutin I-drug
and O
its O
metabolite O
concentrationswere O
moderately O
increased O
. O

The O
concomitant O
use O
of O
sodium B-drug
cephalothin I-drug
and O
Coly-Mycin B-brand
M I-brand
Parenteral O
should O
be O
avoided O
. O

for O
some O
strains O
combinations O
were O
synergistic O
. O

The O
absorption O
of O
tetracycline B-drug
, O
furosemide B-drug
, O
penicillin B-drug
G I-drug
, O
hydrochlorothiazide B-drug
, O
and O
gemfibrozil B-drug
was O
significantly O
decreased O
when O
given O
simultaneously O
with O
colestipol B-drug
hydrochloride I-drug
; O

The O
results O
indicate O
that O
a O
spinal O
naloxone-sensitive B-drug
endorphinergic O
system O
is O
involved O
in O
the O
production O
of O
beta-endorphin B-drug_n
but O
not O
morphine-induced B-drug
tail-flick O
inhibition O
, O
and O
suggest O
that O
intraventricular O
beta-endorphin B-drug_n
and O
morphine B-drug
elicit O
their O
pharmacological O
actions O
via O
the O
activation O
of O
different O
descending O
pain O
inhibitory O
systems O
; O

Effects O
of O
Other O
Drugs O
on O
Aliskiren B-drug
Based O
on O
in-vitro O
studies O
, O
aliskiren B-drug
is O
metabolized O
by O
CYP O
3A4 O
. O

Combined O
treatment O
with O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
and O
TAM B-drug_n
enhances O
the O
degree O
of O
apoptosis O
assessed O
using O
morphological O
markers O
that O
identify O
chromatin O
and O
nuclear O
matrix O
protein O
condensation O
. O

At O
0.3 O
mg/kg O
, O
the O
diarrhea-inducing O
effects O
of O
dmPGE2 B-drug_n
were O
more O
pronounced O
in O
cecectomized O
than O
in O
control O
rats O
. O

Tissue O
culture O
and O
animal O
studies O
indicate O
that O
ELSPAR B-brand
can O
diminish O
or O
abolish O
the O
effect O
of O
methotrexate B-drug
on O
malignant O
cells.14 O
This O
effect O
on O
methotrexate B-drug
activity O
persists O
as O
long O
as O
plasma O
asparagine O
levels O
are O
suppressed O
. O

Therefore O
, O
the O
use O
of O
genetic O
data O
in O
these O
instances O
has O
to O
be O
regulated O
. O

- O
Quinine B-drug
( O
e.g. O
, O
Quinamm B-brand
) O
or O

Drug-drug O
interactions O
have O
not O
been O
observed O
between O
Argatroban B-drug
and O
digoxin B-drug
or O
erythromycin B-drug
. O

Probenecid B-drug
depresses O
tubular O
secretion O
of O
certain O
weak O
acids O
such O
as O
PAH B-drug
. O

Particular O
caution O
should O
be O
observed O
with O
digitalis B-group
preparations I-group
since O
there O
are O
conflicting O
results O
for O
the O
effect O
of O
colestipol B-drug
hydrochloride I-drug
on O
the O
availability O
of O
digoxin B-drug
and O
digitoxin B-drug
. O

While O
taking O
beta B-group
blockers I-group
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O

Rifampin B-drug
: O
When O
a O
single O
375-mg O
dose O
of O
Aprepitant B-drug
was O
administered O
on O
Day9 O
of O
a O
14-day O
regimen O
of O
600 O
mg/day O
of O
rifampin B-drug
, O
a O
strong O
CYP3A4 O
inducer O
, O
the O
AUC O
of O
aprepitant B-drug
decreased O
approximately O
11-fold O
and O
the O
mean O
terminal O
half-life O
decreased O
approximately O
3-fold O
. O

For O
patients O
receiving O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
see O
CONTRAINDICATIONS O
. O

If O
used O
concomitantly O
, O
closely O
monitor O
serum O
electrolytes O
and O
cardiac O
function O
. O

Interactions O
with O
the O
drugs O
listed O
below O
have O
not O
been O
reported O
in O
clinical O
trials O
with O
azithromycin B-drug
; O

Propranolol B-drug
attenuated O
the O
heart O
rate O
increase O
following O
administration O
of O
immediate O
release O
nisoldipine B-drug
. O

Ethinyl B-drug
estradiol I-drug

ELLENCE B-brand
when O
used O
in O
combination O
with O
other O
cytotoxic O
drugs O
may O
show O
on-treatment O
additive O
toxicity O
, O
especially O
hematologic O
and O
gastrointestinal O
effects O
. O

poor O
metabolizers O
of O
debrisoquin B-drug
: O
Interactions O
of O
carvedilol B-drug
with O
strong O
inhibitors O
of O
CYP2D6 O
( O
such O
as O
quinidine B-drug
, O
fluoxetine B-drug
, O
paroxetine B-drug
, O
and O
propafenone B-drug
) O
have O
not O
been O
studied O
, O
but O
these O
drugs O
would O
be O
expected O
to O
increase O
blood O
levels O
of O
the O
R O
( O
+ O
) O
enantiomer O
of O
carvedilol B-drug
. O

- O
Indomethacin B-drug
: O
Indomethacin B-drug
blunts O
the O
increases O
in O
urine O
volume O
and O
sodium O
excretion O
seen O
during O
bumetanide B-drug
treatment O
and O
inhibits O
the O
bumetanide-induced B-drug
increase O
in O
plasma O
renin O
activity O
. O

anaphylaxis O

It O
has O
been O
reported O
that O
results O
of O
studies O
in O
animals O
indicate O
that O
dopamine-induced B-drug
ventricular O
arrhythmias O
during O
anesthesia O
can O
be O
reversed O
by O
propranolol B-drug
. O

Calcium B-group
Channel I-group
Blockers I-group
: O
Isolated O
cases O
of O
conduction O
disturbance O
( O
rarely O
with O
hemodynamic O
compromise O
) O
have O
been O
observed O
when O
COREG B-brand
is O
co-administered O
with O
diltiazem B-drug
. O

Verapamil B-drug
: O
Coadministration O
of O
almotriptan B-drug
and O
verapamil B-drug
resulted O
in O
a O
24 O
% O
increase O
in O
plasma O
concentrations O
of O
almotriptan B-drug
. O

The O
elevated O
plasma O
alprazolam B-drug
concentrations O
resulted O
in O
decreased O
psychomotor O
performance O
and O
memory O
. O

The O
potential O
for O
binding O
of O
these O
drugs O
if O
given O
concomitantly O
is O
present O
. O

Intraventricular O
injection O
of O
naloxone B-drug
at O
doses O
of O
1.2 O
to O
12 O
micrograms O
equally O
antagonized O
in O
a O
dose-dependent O
manner O
the O
tail-flick O
inhibition O
induced O
by O
intraventricular O
beta-endorphin B-drug_n
and O
morphine B-drug
. O

Lamivudine B-drug
and O
zalcitabine B-drug
may O
inhibit O
the O
intracellular O
phosphorylation O
of O
one O
another O
. O

Coadministration O
of O
fluoxetine B-drug
significantly O
decreased O
cisapride B-drug
plasma O
concentrations O
. O

decreased O
levels O
of O
anti-factor O
Xa O
and O
antithrombin O
III O
, O
decreased O
antithrombin O
III O
activity O
; O

Some O
95 O
% O
of O
a O
single O
dosage O
of O
fluvastatin B-drug
is O
excreted O
via O
the O
biliary O
route O
, O
with O
less O
than O
2 O
% O
of O
this O
being O
the O
parent O
compound O
. O

. O

higher O
doses O
decreased O
FI O
and O
FR O
responding O
in O
both O
species O
. O

ERYTHROMYCIN B-drug
: O
In O
hypercholesterolemic O
patients O
, O
steady-state O
cerivastatin B-drug
AUC O
and O
Cmax O
increased O
approximately O
50 O
% O
and O
24 O
% O
respectively O
after O
10 O
days O
with O
co-administration O
of O
erythromycin B-drug
, O
a O
known O
inhibitor O
of O
cytochrome O
P450 O
3A4 O
. O

As O
a O
false-negative O
result O
may O
occur O
in O
the O
ferricyanide O
test O
, O
it O
is O
recommended O
that O
either O
the O
glucose O
oxidase O
or O
hexokinase O
method O
be O
used O
to O
determine O
blood O
plasma O
glucose O
levels O
in O
patients O
receiving O
cefuroxime B-drug
. O

Norpace B-brand
does O
not O
increase O
serum O
digoxin B-drug
levels O
. O

Although O
the O
interactions O
observed O
in O
these O
studies O
do O
not O
appear O
to O
be O
of O
major O
clinical O
importance O
, O
BREVIBLOC B-brand
should O
be O
titrated O
with O
caution O
in O
patients O
being O
treated O
concurrently O
with O
digoxin B-drug
, O
morphine B-drug
, O
succinylcholine B-drug
or O
warfarin B-drug
. O

Carcinogenesis O
, O
Mutagenesis O
, O
and O
Fertility O

[ O
Dose-time O
effects O
of O
competitive O
displacement O
of O
radiopertechnetate B-drug
by O
sodium B-drug_n
perchlorate I-drug_n
following O
oral O
and O
intravenous O
administration O
] O
The O
effect O
of O
various O
doses O
of O
sodium B-drug_n
perchlorate I-drug_n
in O
several O
dose O
fractions O
on O
the O
extent O
and O
the O
time O
scale O
of O
displacement O
of O
radiopertechnetate B-drug
, O
in O
dependence O
on O
application O
mode O
, O
was O
studied O
. O

oral O
contraceptives B-group
; O

CONCLUSIONS O
: O
Single-dose O
diltiazem B-drug
coadministration O
leads O
to O
higher O
sirolimus B-drug
exposure O
, O
presumably O
by O
inhibition O
of O
the O
first-pass O
metabolism O
of O
sirolimus B-drug
. O

methylphenidate B-drug
; O

Diuretic B-group
: O
Hydrochlorothiazide B-drug
, O
given O
concomitantly O
with O
ketoprofen B-drug
, O
produces O
a O
reduction O
in O
urinary O
potassium O
and O
chloride O
excretion O
compared O
to O
hydrochlorothiazide B-drug
alone O
. O

Drugs O
Metabolized O
by O
Cytochrome O
P450 O
Enzymes O
The O
drug O
interaction O
study O
evaluating O
the O
effect O
of O
grepafloxacin B-drug
on O
theophylline B-drug
indicates O
that O
grepafloxacin B-drug
inhibits O
theophylline B-drug
metabolism O
, O
which O
is O
mediated O
by O
CYP1A2 O
. O

When O
such O
combined O
therapy O
is O
contemplated O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O

Serum O
digitalis B-group
levels O
may O
be O
decreased O
in O
hyperthyroidism O
or O
when O
a O
hypothyroid O
patient O
becomes O
euthyroid O
. O

Nafazodone B-drug
, O
fluvoxamine B-drug
, O
cimetidine B-drug
( O
consider O
Xanax B-brand
dose O
reduction O
) O
. O

When O
the O
CYP3A4 O
inhibitor O
is O
withdrawn O
from O
the O
combination O
therapy O
, O
aripiprazole B-drug
dose O
should O
then O
be O
increased O
. O

Sildenafil B-drug
is O
contraindicated O
in O
patients O
using O
long-acting B-group
nitrates I-group
or O
who O
may O
need O
to O
use O
short-acting B-group
nitrates I-group
, O
because O
the O
combination O
may O
cause O
a O
sharp O
fall O
of O
the O
blood O
pressure O
. O

In O
patients O
with O
mild O
to O
moderate O
hypertension O
, O
administration O
of O
25 O
mg O
daily O
of O
VIOXX B-brand
with O
the O
ACE B-group
inhibitor I-group
benazepril B-drug
, O
10 O
to O
40 O
mg O
for O
4 O
weeks O
, O
was O
associated O
with O
an O
average O
increase O
in O
mean O
arterial O
pressure O
of O
about O
3 O
mm O
Hg O
compared O
to O
ACE B-group
inhibitor I-group
alone O
. O

The O
effects O
seen O
are O
poorly O
understood O
and O
depend O
upon O
a O
variety O
of O
factors O
such O
as O
dose O
and O
type O
of O
thyroid B-group
preparations I-group
and O
endocrine O
status O
of O
the O
patient O
. O

Midazolam B-drug
Synergism O

Moreover O
, O
the O
acquisition O
of O
tasks O
that O
are O
facilitated O
by O
hippocampal O
lesions O
( O
or O
dysfunction O
) O
is O
nevertheless O
associated O
, O
in O
intact O
subjects O
, O
with O
specific O
neurobiological O
alterations O
in O
the O
hippocampus O
. O

Tolazamide B-drug
: O
A O
case O
of O
severe O
hypoglycemia O
has O
been O
reported O
in O
a O
type O
II O
diabetic O
patient O
maintained O
on O
tolazamide B-drug
( O
1 O
gm/day O
) O
11 O
days O
after O
the O
addition O
of O
doxepin B-drug
( O
75 O
mg/day O
) O
. O

In O
situations O
when O
concurrent O
therapy O
is O
necessary O
, O
careful O
patient O
monitoring O
is O
essential O
. O

Oral O
Anticoagulants B-group
Interaction O
studies O
with O
warfarin B-drug
and O
acenocoumarol B-drug
failed O
to O
identify O
any O
clinically O
important O
effects O
on O
the O
serum O
concentrations O
or O
clinical O
effects O
of O
these O
anticoagulants B-group
. O

( O
Cancer O
Res. O
, O
38 O
: O
2003-2010 O
, O
1978 O
) O
have O
reported O
that O
a O
single O
, O
small O
pulse O
of O
carcinogen O
can O
induce O
early O
and O
numerous O
liver O
tumors O
when O
administered O
neonatally O
to O
mice O
with O
a O
genetic O
predisposition O
to O
hepatotumorigenesis O
. O

As O
with O
most O
psychoactive O
medications O
, O
patients O
should O
be O
advised O
to O
avoid O
alcohol B-drug
while O
taking O
ABILIFY B-brand

This O
decrease O
in O
absorption O
results O
in O
a O
36 O
% O
and O
50 O
% O
lower O
AUC O
for O
trovafloxacin B-drug
and O
ciprofloxacin B-drug
, O
respectively O
, O
which O
could O
cause O
clinical O
failures O
. O

A O
pregnancy O
test O
must O
be O
repeated O
each O
month O
prior O
to O
the O
female O
patient O
receiving O
each O
prescription O

The O
interaction O
of O
Exjade B-brand
with O
hydroxyurea B-drug
has O
not O
been O
formally O
studied O
. O

In O
addition O
to O
bleeding O
associated O
with O
heparin B-drug
and O
vitamin B-group
K I-group
antagonists I-group
, O
drugs O
that O
alter O
platelet O
function O
( O
such O
as O
acetylsalicylic B-drug
acid I-drug
, O
dipyridamole B-drug
and O
Abciximab B-drug
) O
may O
increase O
the O
risk O
of O
bleeding O
if O
administered O
prior O
to O
, O
during O
, O
or O
after O
Activase B-brand
therapy O
. O

Although O
the O
pressor O
activity O
of O
Desmopressin B-drug
is O
very O
low O
compared O
to O
its O
antidiuretic O
activity O
, O
large O
doses O
of O
Desmopressin B-drug
Tablets O
should O
be O
used O
with O
other O
pressor O
agents O
only O
with O
careful O
patient O
monitoring O
. O

No O
formal O
drug O
interaction O
studies O
with O
anti-neoplastic B-group
agents I-group
have O
been O
conducted O
. O

Digoxin B-drug
: O
Coadministration O
of O
digoxin B-drug
, O
a O
P-glycoprotein O
substrate O
, O
with O
oral O
conivaptan B-drug
resulted O
in O
a O
reduction O
in O
clearance O
and O
an O
increase O
in O
digoxin B-drug
Cmax O
and O
AUC O
values O
. O

Cephalosporins-Cephalosporins B-group
containing O
side O
chains O
of O
N-methylthiotetrazole O
( O
cefmenoxime B-drug
, O
cefoperazone B-drug
, O
cefotetan B-drug
, O
cefamandole B-drug
, O
latamoxef B-drug
) O
or O
methylthiadiazole O
( O
cefazolin B-drug
) O
can O
cause O
vitamin O
K O
deficiency O
and O
hypoprothrombinemia O
. O

May O
interact O
with O
the O
following O
: O
cholestyramine B-drug
, O
colestipol B-drug
( O
use O
with O
thiazide B-group
diuretics I-group
may O
prevent O
the O
diuretic B-group
from O
working O
properly O
; O

although O
combinations O
are O
sometimes O
used O
for O
therapeutic O
advantage O
, O
when O
used O
concurrently O
, O
patient O
should O
be O
closely O
monitored O
. O

It O
is O
concluded O
that O
neurotensin B-drug_n
modulates O
in O
an O
opposite O
way O
the O
function O
of O
the O
enkephalinergic O
neurons O
and O
the O
central O
action O
of O
tuftsin B-drug_n
. O

Intensive O
monitoring O
of O
renal O
function O
is O
recommended O
in O
patients O
requiring O
any O
combination O
of O
nephrotoxic O
medications O
. O

Thus O
cimetidine B-drug
appeared O
to O
alter O
the O
renal O
excretion O
of O
both O
gabapentin B-drug
and O
creatinine O
, O
an O
endogenous O
marker O
of O
renal O
function O
. O

May O
interact O
with O
other O
creams O
, O
lotions O
, O
or O
skin O
medicines O
when O
placed O
on O
the O
same O
areas O
of O
your O
skin O
that O
you O
are O
using O
bentoquatam B-drug_n
. O

Neuroleptic B-group
Drugs I-group
- O
L-phenylalanine B-drug
may O
potentiate O
the O
tardive O
dyskinesia O
side O
reactions O
of O
neuroleptic B-group
drugs I-group
if O
used O
concomitantly O
with O
them O
. O

Beta B-group
blockers I-group
may O
exacerbate O
the O
rebound O
hypertension O
which O
can O
follow O
the O
withdrawal O
of O
clonidine B-drug
. O

MAO B-group
inhibitors I-group
prolong O
and O
intensify O
the O
effects O
of O
antihistamines B-group
. O

Other O
5-HT1B/1D B-group
Agonists I-group
Concomitant O
use O
of O
other O
5-HT1B/1D B-group
agonists I-group
within O
24 O
hours O
of O
treatment O
with O
AXERT B-brand
is O
contraindicated O
. O

The O
following O
agents O
may O
increase O
certain O
actions O
or O
side O
effects O
of O
anticholinergic B-group
drugs I-group
. O
amantadine B-drug
antiarrhythmic B-group
agents I-group
of O
class O
( O
e.g O
. O
quinidine B-drug
) O
, O
antihistamines B-group
antipsychotic I-group
agents I-group
( O
e.g O
. O
phenothiazines B-group
) O
, O
benzodiazepines B-group
. O

Effect O

The O
utilization O
of O
digitoxin B-drug
for O
such O
patients O
may O
be O
considered O
as O
an O
alternative O
. O

Type O
2 O
diabetes O
mellitus O
is O
a O
growing O
problem O
not O
only O
in O
the O
United O
States O
but O
also O
across O
the O
world O
. O

No O
pharmacodynamic O
effects O
of O
either O
histamine B-group
H2 I-group
receptor I-group
antagonist I-group
were O
observed O
. O

BACKGROUND O
. O

Neuroleptic B-group
: O
pimozide B-drug

These O
results O
indicate O
that O
dosage O
adjustment O
of O
quetiapine B-drug
may O
be O
necessary O
when O
the O
two O
drugs O
are O
given O
concurrently O
and O
that O
caution O
may O
be O
required O
when O
administering O
other O
drugs O
that O
inhibit O
or O
induce O
cytochromes O
, O
particularly O
P450 O
3A4 O
. O

Therefore O
, O
if O
concomitant O
use O
of O
these O
agents O
is O
indicated O
because O
of O
demonstrated O
hypokalemia O
, O
they O
should O
be O
used O
with O
caution O
and O
with O
frequent O
monitoring O
of O
serum O
potassium O
. O

Aspirin B-brand
: O
Ketoprofen B-drug
does O
not O
alter O
aspirin B-brand
absorption O
; O

Other O
strong O
inhibitors O
of O
CYP3A4 O
( O
e.g. O
, O
itraconazole B-drug
, O
clarithromycin B-drug
, O
nefazodone B-drug
, O
troleandomycin B-drug
, O
ritonavir B-drug
, O
nelfinavir B-drug
) O
would O
be O
expected O
to O
behave O
similarly O
. O

Effect O
of O
other O
drugs O
on O
Vardenafil B-drug

No O
specific O
drug O
interaction O
studies O
have O
been O
conducted O
. O

Because O
of O
possible O
clinical O
significance O
, O
the O
two O
drugs O
should O
not O
be O
administered O
concurrently O
. O

These O
agents O
may O
also O
prolong O
the O
clinically O
effective O
duration O
of O
action O
by O
up O
to O
25 O
% O
. O

Since O
this O
could O
be O
explained O
either O
by O
enhanced O
absorption O
or O
by O
an O
alteration O
of O
hepatic O
metabolism O
of O
labetalol B-drug
HCl I-drug
, O
special O
care O
should O
be O
used O
in O
establishing O
the O
dose O
required O
for O
blood O
pressure O
control O
in O
such O
patients O
. O

Rifampin B-drug
may O
decrease O
serum O
digoxin B-drug
concentration O
, O
especially O
in O
patients O
with O
renal O
dysfunction O
, O
by O
increasing O
the O
non-renal O
clearance O
of O
digoxin B-drug
. O

Drug O
interaction O
studies O
have O
shown O
that O
esomeprazole B-drug
does O
not O
have O
any O
clinically O
significant O
interactions O
with O
phenytoin B-drug
, O
warfarin B-drug
, O
quinidine B-drug
, O
clarithromycin B-drug
or O
amoxicillin B-drug
. O

In O
patients O
receiving O
concurrent O
therapy O
with O
clonidine B-drug
, O
if O
therapy O
is O
to O
be O
discontinued O
, O
it O
is O
suggested O
that O
ZEBETA B-brand
be O
discontinued O
for O
several O
days O
before O
the O
withdrawal O
of O
clonidine B-drug
. O

Both O
groups O
of O
agents O
lower O
blood O
levels O
and O
efficacy O
of O
amphetamines B-group
. O

METHODS O
: O
Clinical O
studies O
, O
case O
reports O
, O
and O
commentaries O
and O
editorials O
concerning O
sildenafil B-drug
published O
in O
the O
international O
literature O
between O
January O
1999 O
and O
August O
2000 O
were O
identified O
through O
searches O
of O
MEDLINE O
, O
PREMEDLINE O
, O
and O
International O
Pharmaceutical O
Abstracts O
, O
using O
the O
terms O
sildenafil B-drug
, O
Viagra B-brand
, O
and O
erectile O
dysfunction O
. O

Therefore O
, O
if O
digoxin B-drug
is O
administered O
with O
VAPRISOL B-brand
, O
the O
clinician O
should O
be O
alert O
to O
the O
possibility O
of O
increases O
in O
digoxin B-drug
levels O
. O

While O
no O
in O
vivo O
drug-drug O
interaction O
studies O
were O
conducted O
between O
estazolam B-drug
and O
inducers O
of O
CYP3A O
, O
compounds O
that O
are O
potent O
CYP3A O
inducers O
( O
such O
as O
carbamazepine B-drug
, O
phenytoin B-drug
, O
rifampin B-drug
, O
and O
barbiturates B-group
) O
would O
be O
expected O
to O
decrease O
estazolam B-drug
concentrations O
. O

Compounds O
in O
these O
categories O
result O
in O
a O
decreased O
efficacy O
of O
bromocriptine B-drug
mesylate I-drug
: O
phenothiazines B-group
, O
haloperidol B-drug
, O
metoclopramide B-drug
, O
pimozide B-drug
. O

Both O
the O
sedative O
and O
anticholinergic O
effects O
of O
the O
major B-group
tranquilizers I-group
are O
also O
additive O
to O
those O
of O
desipramine B-drug
. O

The O
intravenous O
application O
of O
perchlorate B-drug_n
offers O
advantages O
in O
clinical O
use O
. O

therefore O
, O
the O
disposition O
of O
eszopiclone B-drug
is O
not O
expected O
to O
be O
sensitive O
to O
alterations O
in O
protein O
binding O
. O

Three O
patients O
met O
ACR O
criteria O
for O
liver O
biopsy O
( O
1 O
: O
Roegnik O
Grade O
I O
, O
2 O
: O
Roegnik O
Grade O
IIIa O
) O
. O

Nervous O
System O
: O
Although O
the O
occurrence O
of O
peripheral O
neuropathy O
is O
frequent O
, O
the O
development O
of O
severe O
symptomatology O
is O
unusual O
and O
requires O
a O
dose O
reduction O
of O
20 O
% O
for O
all O
subsequentcourses O
of O
TAXOL B-brand
. O

Effect O
of O
ginsenosides B-drug_n
on O
voltage-dependent O
Ca O
( O
2+ O
) O
channel O
subtypes O
in O
bovine O
chromaffin O
cells O
. O

antiarrhythmic B-group
agents I-group
concentration O

Agents O
that O
induce O
CYP3A4 O
( O
eg O
, O
carbamazepine B-drug
) O
could O
cause O
an O
increase O
in O
aripiprazole B-drug
clearance O
and O
lower O
blood O
levels O
. O

Do O
not O
take O
this O
medicine O
with O
thioridizine O
, O
or O
within O
5 O
weeks O
of O
taking O
fluoxetine B-drug
. O

The O
magnitude O
of O
interaction O
at O
other O
doses O
is O
not O
known O
. O

However O
, O
the O
peak O
plasma O
level O
of O
metformin B-drug
was O
reduced O
by O
approximately O
20 O
% O
when O
taking O
Acarbose B-drug
due O
to O
a O
slight O
delay O
in O
the O
absorption O
of O
metformin B-drug
. O

However O
, O
the O
concomitant O
use O
of O
Argatroban B-drug
and O
warfarin B-drug
( O
5-7.5 O
mg O
initial O
oral O
dose O
followed O
by O
2.5-6 O
mg/day O
orally O
for O
6-10 O
days O
) O
results O
in O
prolongation O
of O
the O
prothrombin O
time O
( O
PT O
) O
and O
International O
Normalized O
Ratio O
( O
INR O
) O
. O

Little O
has O
been O
studied O
of O
the O
adverse O
effects O
of O
the O
exposure O
of O
the O
liver O
to O
the O
interaction O
of O
ethanol B-drug
with O
its O
congeners O
and O
acetaldehyde B-drug_n
, O
coexisting O
in O
the O
contents O
of O
alcoholic O
beverages O
. O

Other O
Drugs O
: O
In O
healthy O
volunteers O
, O
amlodipine B-drug
, O
phenytoin B-drug
, O
glyburide B-drug
, O
ranitidine B-drug
, O
omeprazole B-drug
, O
hormone B-drug
replacement O
therapy O
( O
a O
combination O
of O
conjugated O
estrogens B-group
and O
medroxyprogesterone B-drug
) O
, O
antacid B-group
( O
aluminum O
and O
magnesium B-drug
hydroxides O
) O
and O
theophylline B-drug
did O
not O
affect O
the O
pharmacokinetics O
of O
TIKOSYN B-brand
. O

Anticoagulants B-group
, O
oral O

Although O
there O
are O
no O
study O
data O
to O
evaluate O
the O
possibility O
, O
nitric B-group
oxide I-group
donor I-group
compounds I-group
, O
including O
sodium B-drug
nitroprusside I-drug
and O
nitroglycerin B-drug
, O
may O
have O
an O
additive O
effect O
with O
INOmax B-brand
on O
the O
risk O
of O
developing O
methemoglobinemia O
. O

n-dodecyl B-drug
gallate I-drug
showed O
the O
most O
potent O
inhibition O
( O
66 O
% O
inhibition O
at O
10 O
microM O
) O
, O
which O
was O
far O
more O
potent O
than O
that O
of O
crude O
tannic B-drug
acid I-drug
. O

Inhibitors O
of O
this O
isoenzyme O
( O
e.g. O
, O
macrolide B-group
antibiotics I-group
, O
azole B-group
antifungal I-group
agents I-group
, O
protease B-group
inhibitors I-group
, O
serotonin B-group
reuptake I-group
inhibitors I-group
, O
amiodarone B-drug
, O
cannabinoids B-group
, O
diltiazem B-drug
, O
grapefruit O
juice O
, O
nefazadone B-drug
, O
norfloxacin B-drug
, O
quinine B-drug
, O
zafirlukast B-drug
) O
should O
be O
cautiously O
coadministered O
with O
TIKOSYN B-brand
as O
they O
can O
potentially O
increase O
dofetilide B-drug
levels O
. O

Electroconvulsive O
Therapy O
( O
ECT O
) O
- O
There O
are O
no O
clinical O
studies O
of O
the O
combined O
use O
of O
ECT O
and O
escitalopram B-drug
. O

Midazolam B-drug
: O
Aprepitant B-drug
increased O
the O
AUC O
of O
midazolam B-drug
, O
a O
sensitive O
CYP3A4 O
substrate O
, O
by O
2.3-fold O
on O
Day O
1 O
and O
3.3-fold O
on O
Day O
5 O
, O
when O
a O
single O
oral O
dose O
of O
midazolam B-drug
2 O
mg O
was O
coadministered O
on O
Day O
1 O
and O
Day O
5 O
of O
a O
regimen O
of O
Aprepitant B-drug
125 O
mg O
on O
Day O
1 O
and O
80 O
mg/day O
on O
Days O
2 O
through O
5 O
. O

NNRTI-based B-group
regimens O
may O
have O
several O
advantages O
over O
PI-based B-group
therapy O
for O
initial O
or O
prolonged O
therapy O
, O
including O
more O
convenient O
administration O
regimens O
, O
lower O
tablet O
volume O
, O
fewer O
drug O
interactions O
, O
and O
central O
nervous O
system O
penetration O
. O

The O
clearance O
of O
salicylates B-group
may O
be O
increased O
with O
concurrent O
use O
of O
corticosteroids B-group
. O

As O
with O
all O
drugs O
, O
care O
should O
be O
exercised O
when O
treating O
patients O
with O
multiple O
medications O
. O

Caution O
should O
be O
exercised O
when O
considering O
the O
use O
of O
BREVIBLOC B-brand
and O
verapamil B-drug
in O
patients O
with O
depressed O
myocardial O
function O
. O

For O
a O
4-fold O
range O
of O
everolimus B-drug
doses O
there O
were O
no O
differential O
effects O
on O
cyclosporine B-drug
dosing O
or O
pharmacokinetics O
. O

An O
increase O
in O
serum O
lithium B-drug
concentration O
has O
been O
reported O
during O
concomitant O
administration O
of O
lithium B-drug
with O
ATACAND B-brand
, O
so O
careful O
monitoring O
of O
serum O
lithium B-drug
levels O
is O
recommended O
during O
concomitant O
use O
. O

Neuropathy O
has O
occurred O
more O
frequently O
in O
patients O
with O
a O
history O
of O
neuropathy O
or O
neurotoxic O
drug O
therapy O
, O
including O
stavudine B-drug
, O
and O
these O
patients O
may O
be O
at O
increased O
risk O
of O
neuropathy O
during O
VIDEX B-brand
therapy O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

This O
interference O
may O
result O
in O
an O
apparent O
factor O
concentration O
that O
is O
lower O
than O
the O
true O
concentration O
. O

oral O
clearance O
was O
reduced O
by O
about O
50 O
% O
. O

Antacids B-group
containing O
magnesium B-drug
trisilicate I-drug
, O
when O
administered O
concomitantly O
with O
nitrofurantoin B-drug
, O
reduce O
both O
the O
rate O
and O
extent O
of O
absorption O
. O

An O
initial O
dose O
of O
5 O
mg O
should O
be O
given O
to O
patients O
who O
are O
concomitantly O
being O
treated O
with O
cimetidine B-drug
. O

there O
was O
no O
significant O
change O
in O
prothrombin O
test O
results O
during O
the O
trials O
of O
chloral B-drug
hydrate I-drug
and O
methaqualone B-drug
. O

Patients O
treated O
with O
a O
beta-adrenergic B-group
receptor I-group
blocking I-group
agent I-group
plus O
a O
catecholamine O
depletor O
should O
therefore O
be O
closely O
observed O
for O
evidence O
of O
hypotension O
or O
marked O
bradycardia O
, O
which O
may O
produce O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O

Diuretics B-group
: O
Studies O
in O
normal O
volunteers O
have O
shown O
that O
flurbiprofen B-drug
like O
other O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
, O
can O
interfere O
with O
the O
effects O
of O
furosemide B-drug
. O

Usually O
, O
the O
dosage O
of O
the O
anticoagulant B-group
should O
be O
reduced O
by O
one-half O
( O
depending O
on O
the O
individual O
case O
) O
to O
maintain O
the O
prothrombin O
time O
at O
the O
desired O
level O
to O
prevent O
bleeding O
complications O
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

A O
1-month O
washout O
period O
was O
inserted O
between O
the O
treatment O
periods O
. O

The O
pharmacokinetics O
of O
naltrexone B-drug
and O
its O
major O
metabolite O
6-beta-naltrexol B-drug_n
were O
unaffected O
following O
co-administration O
with O
Acamprosate B-drug
. O

cimetidine B-drug
; O

they O
also O
suggest O
that O
alcoholic O
beverages O
are O
not O
equivalent O
in O
their O
potential O
to O
cause O
liver O
damage O
. O

Results O
of O
preliminary O
studies O
in O
humans O
and O
rats O
suggest O
that O
nonabsorbable O
antacids B-group
given O
concurrently O
with O
lactulose B-drug
may O
inhibit O
the O
desired O
lactulose-induced B-drug
drop O
in O
colonic O
pH O
. O

Histamine B-group
H2 I-group
antagonists I-group
: O
Cimetidine B-drug
inhibits O
CYP3A4 O
and O
can O
increase O
serum O
amiodarone B-drug
levels O
. O

Cyclosporine B-drug
: O
Modest O
increases O
in O
mean O
trough O
cyclosporine B-drug
concentrations O
were O
observed O
following O
initiation O
of O
carvedilol B-drug
treatment O
in O
21 O
renal O
transplant O
patients O
suffering O
from O
chronic O
vascular O
rejection O
. O

. O

These O
reactions O
have O
been O
observed O
more O
frequently O
with O
the O
24-hour O
infusion O
than O
with O
the O
3-hour O
infusion O
. O

Altered O
responsiveness O
to O
alcohol B-drug
after O
exposure O
to O
organic O
lead O
. O

At O
37 O
degrees O
C O
the O
non-myelinated O
axons O
contained O
28.4 O
plus O
or O
minus O
0.8 O
S.E.M O
. O

Drugs O
that O
may O
alter O
imatinib B-drug
plasma O
concentrations O
Drugs O
that O
may O
increase O
imatinib B-drug
plasma O
concentrations O
: O
Caution O
is O
recommended O
when O
administering O
Gleevec B-brand
with O
inhibitors O
of O
the O
CYP3A4 O
family O
( O
e.g. O
, O
ketoconazole B-drug
, O
itraconazole B-drug
, O
erythromycin B-drug
, O
clarithromycin B-drug
) O
. O

Indinavir B-drug
concentrations O
may O
be O
decreased O
in O
the O
presence O
of O
nevirapine B-drug
. O

Trileptal B-brand
dose O
( O
mg/day O
) O

It O
is O
recommended O
that O
these O
tests O
be O
performed O
at O
weekly O
or O
biweekly O
intervals O
until O
the O
lipid O
response O
to O
Accutane B-brand
is O
established O
. O

Untreated O
hypothyroidism O
may O
interfere O
with O
the O
growth O
response O
to O
somatrem B-drug
or O
somatropin B-drug
. O

In O
patients O
receiving O
a O
potent O
CYP3A4 O
inducer O
such O
as O
rifampicin B-drug
or O
phenytoin B-drug
, O
a O
dose O
increase O
to O
500 O
mg O
daily O
should O
be O
considered O
in O
the O
absence O
of O
severe O
adverse O
drug O
reaction O
, O
and O
clinical O
response O
and O
adverse O
events O
should O
be O
carefully O
monitored O
( O
see O
CLINICAL O
PHARMACOLOGY-Pharmacokinetics-Drug-Drug O
Interactions O
and O
DOSAGE O
AND O
ADMINISTRATION-Dosage O
Adjustment O
sections O
) O
. O

These O
pharmacokinetic O
effects O
did O
not O
result O
in O
clinically O
meaningful O
changes O
in O
ECG O
, O
heart O
rate O
or O
blood O
pressure O
beyond O
those O
changes O
induced O
by O
diltiazem B-drug
alone O
. O

Agents O
that O
Inhibit O
Cytochrome O
P450 O
Isoenzymes O
and/or O
Epoxide O
Hydrolase O
Carbamazepine B-drug
is O
metabolized O
mainly O
by O
cytochrome O
P450 O
( O
CYP O
) O
3A4 O
to O
the O
active O
carbamazepine B-drug
10,11-epoxide I-drug
, O
which O
is O
further O
metabolized O
to O
the O
trans-diol O
by O
epoxide O
hydrolase O
. O

leukopenia O

Drugs O
That O
Alter O
Renal O
Excretion O
Ibuprofen B-drug
: O
Ibuprofen B-drug
is O
known O
to O
affect O
renal O
function O
and O
, O
consequently O
, O
alter O
the O
renal O
excretion O
of O
other O
drugs O
. O

Misonidazole B-drug_n
also O
reduced O
the O
" O
early O
" O

. O

There O
was O
no O
evidence O
of O
any O
pharmacokinetic O
interactions O
between O
ERBITUX B-brand
and O
irinotecan B-drug
. O

Drug-Drug O
Interactions O
Cimetidine B-drug
: O
Concomitant O
use O
of O
cimetidine B-drug
is O
contraindicated O
. O

. O

The O
possibility O
of O
hypotensive O
effects O
with O
captopril B-drug
can O
be O
minimized O
by O
either O
discontinuing O
the O
diuretic B-group
or O
increasing O
the O
salt O
intake O
approximately O
one O
week O
prior O
to O
initiation O
of O
treatment O
with O
captopril B-drug
( O
captopril B-drug
tablets O
, O
USP O
) O
or O
initiating O
therapy O
with O
small O
doses O
( O
6.25 O
or O
12.5 O
mg O
) O
. O

Two O
percent O
of O
patients O
treated O
concurrently O
with O
Kineret B-brand
and O
etanercept B-drug
developed O
neutropenia O
( O
ANC O
1 O
x O
109/L O
) O
. O

COPAXONE B-brand
has O
not O
been O
formally O
evaluated O
in O
combination O
with O
Interferon B-drug
beta I-drug
. O

Estrogens B-group
, O
including O
oral O
contraceptives B-group
: O
Estrogens B-group
may O
decrease O
the O
hepatic O
metabolism O
of O
certain O
corticosteroids B-group
, O
thereby O
increasing O
their O
effect O
. O

Potential O
differences O
in O
cyclosporine B-drug
dosing O
and O
pharmacokinetics O
at O
different O
levels O
of O
everolimus B-drug
exposure O
were O
assessed O
in O
the O
context O
of O
ANOVA O
. O

Monitoring O
of O
anticoagulation O
levels O
is O
recommended O
. O

These O
data O
emphasize O
that O
apoptosis O
can O
be O
induced O
in O
MCF-7 O
cells O
either O
by O
activation O
of O
vitamin-D-mediated B-group
signalling O
or O
disruption O
of O
estrogen-dependent B-group
signalling O
. O

Antithyroid B-group
agents I-group
may O
decrease O
thyroidal O
uptake O
of O
sodium B-drug
iodide I-drug
I131 I-drug
, O
a O
rebound O
in O
uptake O
may O
occur O
up O
to O
5 O
days O
after O
sudden O
withdrawal O
of O
Carbimazole B-drug
. O

5HT3 B-group
Antagonists I-group
: O
Based O
on O
reports O
of O
profound O
hypotension O
and O
loss O
of O
consciousness O
when O
apomorphine B-drug
was O
administered O
with O
ondansetron B-drug
, O
the O
concomitant O
use O
of O
apomorphine B-drug
with O
drugs O
of O
the O
5HT3 B-group
antagonist I-group
class I-group
( O
including O
, O
for O
example O
, O
ondansetron B-drug
, O
granisetron B-drug
, O
dolasetron B-drug
, O
palonosetron B-drug
, O
and O
alosetron B-drug
) O
is O
contraindicated O
. O

Severe O
anemia O
( O
Grade O
3-4 O
according O
to O
the O
World O
Health O
Organization O
criteria O
) O
was O
significantly O
greater O
in O
the O
patients O
who O
received O
CHOP-HAART O
compared O
with O
the O
patients O
who O
received O
CHOP O
alone O
( O
33 O
% O
vs. O
7 O
% O
, O
respectively O
; O
P O
= O
0.001 O
) O
. O

atazanavir I-drug

Magnesium B-drug
infusions O
can O
only O
be O
envisaged O
in O
intensive O
care O
units O
with O
careful O
monitoring O
of O
pulse O
, O
arterial O
pressure O
, O
deep O
tendon O
reflexes O
, O
hourly O
diuresis O
, O
electrocardiogram O
and O
respiratory O
recordings O
. O

As O
MHD B-drug_n
, O
the O
predominant O
plasma O
substrate O
, O
is O
only O
a O
weak O
inducer O
of O
UDP-glucuronyl O
transferase O
, O
it O
is O
unlikely O
to O
have O
an O
effect O
on O
drugs O
that O
are O
mainly O
eliminated O
by O
conjugation O
through O
UDP-glucuronyl O
transferase O
( O
e.g. O
, O
valproic B-drug
acid I-drug
, O
lamotrigine B-drug
) O
. O

Other O
concomitant O
therapy O
Although O
specific O
interaction O
studies O
were O
not O
performed O
, O
finasteride B-drug
doses O
of O
1 O
mg O
or O
more O
were O
concomitantly O
used O
in O
clinical O
studies O
with O
acetaminophen B-drug
, O
acetylsalicylic B-drug
acid I-drug
, O
a-blockers O
, O
analgesics B-group
, O
angiotensin-converting B-group
enzyme I-group
( I-group
ACE I-group
) I-group
inhibitors I-group
, O
anticonvulsants B-group
, O
benzodiazepines B-group
, O
beta B-group
blockers I-group
, O
calcium-channel B-group
blockers I-group
, O
cardiac O
nitrates B-group
, O
diuretics B-group
, O
H2 B-group
antagonists I-group
, O
HMG-CoA B-group
reductase I-group
inhibitors I-group
, O
prostaglandin B-group
synthetase I-group
inhibitors I-group
( O
also O
referred O
to O
as O
NSAIDs B-group
) O
, O
and O
quinolone B-group
anti-infectives I-group
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O

however O
, O
it O
is O
not O
known O
if O
other O
phenothiazines B-group
produce O
a O
similar O
response O
. O

Inhibition O
of O
CYP3A4 O
metabolic O
reactions O
was O
not O
detected O
in O
in O
vitro O
experiments O
. O

Patients O
should O
take O
other O
drugs O
at O
least O
one O
hour O
before O
or O
four O
hours O
after O
COLESTID B-brand
Tablets O
to O
avoid O
impeding O
their O
absorption O
. O

Nevertheless O
, O
there O
may O
be O
the O
potential O
for O
clinically O
important O
alterations O
of O
blood O
levels O
of O
coadministered O
drugs O
. O

Injection O
There O
is O
inadequate O
systematic O
experience O
with O
the O
use O
of O
baclofen B-drug
injection O
in O
combination O
with O
other O
medications O
to O
predict O
specific O
drug-drug O
interactions O
. O

N=17 O
) O
were O
not O
different O
and O
neither O
were O
gabapentin B-drug
pharmacokinetic O
parameters O
affected O
by O
valproic B-drug
acid I-drug
. O

Other O
depressasnts O
such O
as O
alcohol B-drug
, O
barbiturates B-group
, O
and O
MAOIs B-group
may O
enhance O
CNS O
depression O
when O
administered O
with O
ethchlorvynol B-drug
. O

Ketoconazole B-drug
: O
Concomitant O
use O
of O
ketoconazole B-drug
is O
contraindicated O
. O

reduced O
serum O
folate O
concentration O
; O

One O
animal O
in O
the O
high O
dose O
group O
developed O
a O
B-cell O
lymphoma O
that O
was O
detected O
after O
28 O
weeks O
of O
dosing O
. O

Clozapine B-drug
may O
potentiate O
the O
hypotensive O
effects O
of O
antihypertensive B-group
drugs I-group
and O
the O
anticholinergic O
effects O
of O
atropine-type B-drug
drugs O
. O

Drug O
Laboratory O
Test O
Interactions O
Interactions O
between O
darifenacin B-drug
and O
laboratory O
tests O
have O
not O
been O
studied O
. O

Ketoconazole B-drug

Increases O
in O
serum O
creatinine O
have O
occurred O
when O
CEFOTAN B-brand
was O
given O
alone O
. O

Therefore O
, O
when O
chlorothiazide B-drug
and O
non-steroidal B-group
anti-inflammatory I-group
agents I-group
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-group
is O
obtained O

Although O
the O
proposed O
methodology O
for O
deriving O
experimental O
designs O
can O
be O
applied O
to O
any O
nonlinear O
regression O
model O
, O
primary O
focus O
is O
given O
to O
the O
additive O
and O
nonadditive O
independent O
joint O
action O
( O
IJA O
) O
models O
for O
individual O
and O
combined O
exposures O
proposed O
by O
Barton O
, O
Braunberg O
, O
and O
Friedman O
( O
1 O
) O
. O

diflunisal B-drug
; O

Potassium B-drug
Supplements O
and O
Potassium-Sparing B-group
Diuretics I-group
: O
Fosinopril B-drug
sodium I-drug
can O
attenuate O
potassium O
loss O
caused O
by O
thiazide B-group
diuretics I-group
. O

a O
reduction O
in O
the O
usual O
anticoagulant B-group
dosage O
may O
be O
required O
in O
patients O
receiving O
both O
drugs O
. O

Delayed O
Adverse O
Reactions O
to O
Iodinated B-group
Contrast I-group
Media I-group
: O
A O
review O
of O
the O
literature O
revealed O
that O
12.6 O
% O
( O
range O
11-28 O
% O
) O
of O
501 O
patients O
treated O
with O
various O
interleukin-2 B-drug
containing O
regimens O
who O
were O
subsequently O
administered O
radiographic B-group
iodinated I-group
contrast I-group
media I-group
experienced O
acute O
, O
atypical O
adverse O
reactions O
. O

Ketoconazole B-drug
: O
When O
a O
single O
125-mg O
dose O
of O
Aprepitant B-drug
was O
administered O
on O
Day5 O
of O
a O
10-day O
regimen O
of O
400 O
mg/day O
of O
ketoconazole B-drug
, O
a O
strong O
CYP3A4 O
inhibitor O
, O
the O
AUC O
of O
aprepitant B-drug
increased O
approximately O
5-fold O
and O
the O
mean O
terminal O
half-life O
of O
aprepitant B-drug
increased O
approximately O
3-fold O
. O

At O
a O
low O
cocaine B-drug
dose O
and O
long O
withdrawal O
period O
( O
10 O
mg/kg O
, O
twice O
a O
day O
for O
5 O
days O
followed O
by O
a O
14-day O
withdrawal O
) O
, O
the O
LST O
mice O
showed O
tolerance O
development O
. O

CONCLUSION O
: O
These O
findings O
indicate O
that O
verapamil B-drug
inhibits O
cancer O
metastasis O
through O
actions O
that O
do O
not O
affect O
the O
growth O
of O
intestinal O
cancers O
. O

It O
is O
recommended O
that O
serum O
lithium B-drug
levels O
be O
monitored O
frequently O
if O
PRINIVIL B-brand
is O
administered O
concomitantly O
with O
lithium B-drug
. O

Similarly O
, O
the O
effects O
of O
phenytoin B-drug
on O
phenobarbital B-drug
, O
valproic B-drug
acid I-drug
and O
sodium O
plasma O
valproate B-drug
concentrations O
are O
unpredictable O

Potential O
for O
Other O
Drugs O
to O
Affect O
Duloxetine B-drug
: O
Both O
CYP1A2 O
and O
CYP2D6 O
are O
responsible O
for O
duloxetine B-drug
metabolism O
. O

This O
medication O
should O
not O
be O
taken O
with O
MAO B-group
inhibitors I-group
. O

Substances O
that O
are O
inducers O
of O
CYP3A4 O
activity O
increase O
the O
metabolism O
of O
gefitinib B-drug
and O
decrease O
its O
plasma O
concentrations O
. O

In O
addition O
, O
patients O
taking O
drugs O
that O
inhibit O
the O
cytochrome O
P450 O
3A4 O
isozyme O
, O
which O
metabolizes O
sildenafil B-drug
, O
may O
experience O
increased O
drug O
concentrations O
and O
possible O
toxicity O
from O
normal O
doses O
of O
sildenafil B-drug
. O

Alpha-blockers B-group
: O
When O
Vardenafil B-drug
10 O
or O
20 O
mg O
was O
given O
to O
healthy O
volunteers O
either O
simultaneously O
or O
6 O
hours O
after O
a O
10 O
mg O
dose O
of O
terazosin B-drug
, O
significant O
hypotension O
developed O
in O
a O
substantial O
number O
of O
subjects O
. O

Drug O
Interactions O
: O
Flupenthixol B-drug
may O
interact O
with O
some O
drugs O
, O
like O
Monoamine B-group
oxidase I-group
inhibitors I-group
( O
MAOI B-group
) O
: O
MAOI B-group
could O
theoretically O
affect O
flupenthixol B-drug
pharmacodynamics O
- O
Arecoline B-drug_n
- O
Eproxindine O
- O
Ethanol B-drug
: O
Flupenthixol B-drug
and O
Ethanol B-drug
cause O
additive O
CNS O
depression O
- O
Tricyclic B-group
antidepressants I-group
: O
Flupenthixol B-drug
increases O
the O
effect O
of O
Tricyclic B-group
antidepressants I-group

Hepatic O
Enzyme O
Inducers O
, O
Inhibitors O
and O
Substrates O
: O
Drugs O
which O
induce O
cytochrome O
P450 O
3A4 O
( O
CYP O
3A4 O
) O
enzyme O
activity O
( O
e.g. O
, O
barbiturates B-group
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
rifampin B-drug
) O
may O
enhance O
the O
metabolism O
of O
corticosteroids B-group
and O
require O
that O
the O
dosage O
of O
the O
corticosteroid B-group
be O
increased O
. O

In O
addition O
, O
the O
transfusion O
practices O
for O
such O
patients O
may O
need O
to O
be O
modified O
given O
the O
increased O
risk O
of O
bleeding O
. O

600-1800 O

See O

If O
this O
is O
not O
possible O
, O
the O
starting O
dose O
should O
be O
reduced O
. O

Until O
data O
on O
possible O
interactions O
between O
verapamil B-drug
and O
disopyramide B-drug
phosphate I-drug
are O
obtained O
, O
disopyramide B-drug
should O
not O
be O
administered O
within O
48 O
hours O
before O
or O
24 O
hours O
after O
verapamil B-drug
administration O
. O

Interaction O
on O
the O
antinociceptive O
effect O
between O
neurotensin B-drug_n
and O
enkephalins B-drug_n
or O
tuftsin B-drug_n
. O

It O
is O
recommended O
that O
these O
tests O
be O
performed O
weekly O
or O
every O
other O
week O
until O
the O
lipid O
response O
to O
Soriatane B-brand
has O
stabilized O
. O

Decreased O
core O
temperature O
in O
female O
rats O
was O
investigated O
as O
one O
possible O
index O
of O
the O
disulfiram-ethanol B-drug
reaction O
( O
DER O
) O
. O

There O
were O
transient O
increases O
in O
liver O
ALT O
and O
AST O
when O
CANCIDAS B-brand
and O
cyclosporine B-drug
were O
co-administered O
. O

Analyses O
of O
this O
sequence O
, O
however O
, O
usually O
give O
little O
consideration O
to O
the O
nature O
of O
the O
target O
cell O
or O
to O
the O
characteristics O
of O
the O
resultant O
tumors O
. O

To O
evaluate O
the O
impact O
of O
chemotherapy O
plus O
HAART O
on O
the O
clinical O
course O
of O
patients O
with O
HIV-related O
, O
systemic O
, O
non-Hodgkin O
lymphoma O
( O
HIV-NHL O
) O
, O
the O
authors O
compared O
retrospectively O
a O
group O
of O
24 O
patients O
with O
HIV-NHL O
who O
were O
treated O
with O
the O
cyclophosphamide B-drug
, O
doxorubicin B-drug
, O
vincristine B-drug
, O
and O
prednisone B-drug
( O
CHOP O
) O
chemotherapy O
regimen O
plus O
HAART O
with O
a O
group O
of O
80 O
patients O
who O
were O
treated O
with O
CHOP O
chemotherapy O
or O
a O
CHOP-like O
regimen O
( O
i.e. O
, O
cyclophosphamide B-drug
, O
doxorubicin B-drug
, O
teniposide B-drug
, O
and O
prednisone B-drug
with O
vincristine B-drug
plus O
bleomycin B-drug
) O
without O
receiving O
antiretroviral B-group
therapy O
. O

indinavir I-drug
concentration O

DRUG O
INTERACTIONS O

Changes O
in O
omeprazole B-drug
pharmacokinetics O
were O
not O
studied O
. O

In O
general O
, O
these O
are O
drugs O
that O
have O
one O
or O
more O
pharmacologic O
activities O
similar O
to O
bepridil B-drug
hydrochloride I-drug
, O
including O
anti-arrhythmic B-group
agents I-group
such O
as O
quinidine B-drug
and O
procainamide B-drug
, O
cardiac B-group
glycosides I-group
and O
tricyclic B-group
anti-depressants I-group
. O

Ranitidine B-drug
produced O
smaller O
, O
nonsignificant O
increases O
. O

Anesthetics/Sedatives/Hypnotics/Opioids B-group
: O
Co-administration O
of O
PRECEDEX B-brand
with O
anesthetics B-group
, O
sedatives B-group
, O
hypnotics B-group
, O
and O
opioids B-group
is O
likely O
to O
lead O
to O
an O
enhancement O
of O
effects O
. O

Drug-Drug O
Interactions O
Given O
the O
primary O
CNS O
effects O
of O
aripiprazole B-drug
, O
caution O
should O
be O
used O
when O
ABILIFY B-brand
is O
taken O
in O
combination O
with O
other O
centrally B-group
acting I-group
drugs I-group
and O
alcohol B-drug
. O

Rhabdomyolysis O
secondary O
to O
a O
drug O
interaction O
between O
simvastatin B-drug
and O
clarithromycin B-drug
. O

Phenytoin B-drug
: O
If O
acitretin B-drug
is O
given O
concurrently O
with O
phenytoin B-drug
, O
the O
protein O
binding O
of O
phenytoin B-drug
may O
be O
reduced O
. O

A O
patient O
had O
phenytoin O
intoxication O
after O
administration O
of O
fluvoxamine B-drug
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
. O

There O
were O
no O
differences O
between O
cecectomized O
and O
control O
rats O
in O
basal O
small O
intestinal O
transits O
or O
in O
dmPGE2 B-drug_n
( O
0.3 O
mg/kg O
, O
p.o O
. O
) O
-induced O
enhancements O
. O

MAO B-group
inhibitors I-group
prolong O
and O
intensify O
the O
anticholinergic O
effects O
of O
antihistamines B-group
. O

Agents O
Affecting O
Sympathetic O
Activity O
The O
sympathetic O
nervous O
system O
may O
be O
especially O
important O
in O
supporting O
blood O
pressure O
in O
patients O
receiving O
captopril B-drug
alone O
or O
with O
diuretics B-group
. O

Concurrent O
use O
of O
flurbiprofen B-drug
and O
aspirin B-brand
is O
therefore O
not O
recommended O
. O

Coadministration O
of O
VIRACEPT B-brand
and O
drugs O
primarily O
metabolized O
by O
CYP3A O
( O
e.g. O
, O
dihydropyridine B-group
calcium I-group
channel I-group
blockers I-group
) O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
other O
drug O
that O
could O
increase O
or O
prolong O
both O
its O
therapeutic O
and O
adverse O
effects O
. O

( O
Note O
: O
All O
patients O
receiving O
theophylline B-drug
should O
be O
monitored O
appropriately O
, O
regardless O
of O
concomitant O
drug O
therapy O
. O
) O

valproate B-drug
and O
gabapentin B-drug
are O
not O
. O

Therefore O
, O
when O
meclofenamate B-drug
sodium I-drug
is O
given O
to O
a O
patient O
receiving O
warfarin B-drug
, O
the O
dosage O
of O
warfarin B-drug
should O
be O
reduced O
to O
prevent O
excessive O
prolongation O
of O
the O
prothrombin O
time O
. O

Lithium B-drug
: O
NSAIDs B-group
have O
produced O
an O
elevation O
of O
plasma O
lithium B-drug
levels O
and O
a O
reduction O
in O
renal O
lithium B-drug
clearance O
. O

65 O
years O
of O
age O
and O
13 O
patients O
were O

The O
minimal O
inhibitory O
concentrations O
of O
clindamycin B-drug
and O
gentamicin B-drug
alone O
and O
in O
combinations O
were O
determined O
by O
a O
microdilution O
method O
for O
163 O
aerobic O
, O
facultative O
, O
and O
anaerobic O
clinical O
isolates O
. O

As O
with O
other O
dialysis B-group
solutions I-group
, O
blood O
concentrations O
of O
dialyzable O
drugs O
may O
be O
reduced O
by O
dialysis O
. O

therefore O
concomitant O
administration O
of O
Itraconazole B-drug
with O
cisapride B-drug
is O
contraindicated O
. O

Particular O
caution O
is O
recommended O
when O
administering O
Gleevec B-brand
with O
CYP3A4 O
substrates O
that O
have O
a O
narrow O
therapeutic O
window O
( O
e.g. O
, O
cyclosporine B-drug
or O
pimozide B-drug
) O
. O

Potassium O
sparing O
agents O
should O
generally O
not O
be O
used O
in O
patients O
with O
heart O
failure O
receiving O
enalapril B-drug
. O

clinically O
significant O
interactions O
with O
other O
drugs O
through O
competition O
for O
protein O
binding O
sites O
are O
therefore O
unlikely O
. O

This O
was O
expected O
because O
zaleplon B-drug
is O
primarily O
metabolized O
and O
renal O
excretion O
of O
unchanged O
zaleplon B-drug
accounts O
for O
less O
than O
1 O
% O
of O
the O
administered O
dose O
. O

A O
muscle O
biopsy O
revealed O
necrotizing O
myopathy O
secondary O
to O
a O
toxin O
. O

Cyclosporine B-drug
: O
Elevated O
serum O
levels O
of O
cyclosporine B-drug
have O
been O
reported O
with O
concomitant O
use O
of O
cyclosporine B-drug
with O
other O
members O
of O
the O
quinolone B-group
class I-group
. O

The O
gastrointestinal O
absorption O
of O
cimetidine B-drug
and O
ranitidine B-drug
is O
accelerated O
when O
they O
are O
coadministered O
with O
cisapride B-drug
. O

Amprenavir B-drug
significantly O
decreases O
clearance O
of O
rifabutin B-drug
and O
25-O-desacetylrifabutin B-drug_n
, O
and O
the O
combination O
is O
poorly O
tolerated O
. O

ACE-inhibitors B-group
: O
Reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE-inhibitors B-group
. O

Therefore O
, O
CYP3A4 O
substrates O
known O
to O
have O
a O
narrow O
therapeutic O
index O
such O
as O
alfentanil B-drug
, O
astemizole B-drug
, O
terfenadine B-drug
, O
cisapride B-drug
, O
cyclosporine B-drug
, O
fentanyl B-drug
, O
pimozide B-drug
, O
quinidine B-drug
, O
sirolimus B-drug
, O
tacrolimus B-drug
, O
or O
ergot B-group
alkaloids I-group
( O
ergotamine B-drug
, O
dihydroergotamine B-drug
) O
should O
be O
administered O
with O
caution O
in O
patients O
receiving O
SPRYCEL B-brand
. O

Thus O
, O
when O
VIOXX B-brand
and O
lithium B-drug
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-drug
toxicity O
. O

aminosalicylic B-drug
acid I-drug
; O

Drug/Laboratory O
Test O
Interactions O
Positive O
direct O
Coombs O
tests O
have O
been O
reported O
during O
treatment O
with O
the O
cephalosporin B-group
antibiotics I-group
. O

Cimetidine B-drug
: O
In O
a O
study O
in O
healthy O
volunteers O
, O
a O
one-week O
course O
of O
cimetidine B-drug
at O
400 O
mg O
b.i.d O
. O
with O
a O
single O
5 O
mg O
dose O
of O
isradipine B-drug
on O
the O
sixth O
day O
showed O
an O
increase O
in O
isradipine B-drug
mean O
peak O
plasma O
concentrations O
( O
36 O
% O
) O
and O
significant O
increase O
in O
area O
under O
the O
curve O
( O
50 O
% O
) O
. O

Synergism O
has O
been O
shown O
between O
halothane B-drug
anesthesia O
and O
intravenously O
administered O
labetalol B-drug
HCl I-drug
. O

Methotrexate B-drug
: O
In O
an O
interaction O
study O
of O
rheumatoid O
arthritis O
patients O
taking O
methotrexate B-drug
, O
CELEBREX B-brand
did O
not O
have O
a O
significant O
effect O
on O
the O
pharmacokinetics O
of O
methotrexate B-drug
. O

Even O
though O
such O
interactions O
have O
not O
been O
seen O
in O
clinical O
studies O
with O
DynaCirc B-brand
( O
isradipine B-drug
) O
, O
an O
increased O
volume O
of O
circulating O
fluids O
might O
be O
required O
if O
such O
an O
interaction O
were O
to O
occur O
. O

Methadone B-drug
levels O
may O
be O
decreased O
; O
increased O
dosages O
may O
be O
required O
to O
prevent O
symptoms O
of O
opiate B-group
withdrawal O
. O
Methadone B-drug
maintained O
patients O
beginning O
nevirapine B-drug
therapy O
should O
be O
monitored O
forevidence O
of O
withdrawal O
and O
methadone B-drug
dose O
should O
be O
adjusted O
accordingly O
. O

Diazoxide I-drug
Hypotension O

However O
, O
prudent O
medical O
practice O
dictates O
careful O
monitoring O
of O
prothrombin O
time O
in O
all O
patients O
treated O
with O
azithromycin B-drug
and O
warfarin B-drug
concomitantly O
. O

The O
preceding O
lists O
of O
drugs O
are O
not O
comprehensive O
. O

In O
an O
in O
vitro O
study O
in O
human O
liver O
microsomes O
, O
inhibition O
of O
CYP2A6 O
hydroxylation O
of O
coumarin B-group
by O
fondaparinux B-drug
( O
200 O
m O
m O
M O
i.e. O
, O
350 O
mg/L O
) O
was O
17-28 O
% O
. O

Chlorpromazine B-drug
: O
Chlorpromazine B-drug
blocks O
dopamine O
and O
norepinephrine O
reuptake O
, O
thus O
inhibiting O
the O
central O
stimulant O
effects O
of O
amphetamines B-group
, O
and O
can O
be O
used O
to O
treat O
amphetamine B-group
poisoning O
. O

In O
this O
study O
, O
the O
effects O
of O
etofibrate B-drug
upon O
chylomicron O
metabolism O
was O
tested O
by O
determination O
of O
the O
plasma O
kinetics O
of O
a O
chylomicron-like O
emulsion O
model O
in O
12 O
patients O
with O
coronary O
artery O
disease O
, O
aged O
59+/-11 O
years O
, O
( O
total O
cholesterol O
: O
240+/-41 O
mg/dl O
; O
triglycerides O
: O
188+/-42 O
mg/dl O
) O
submitted O
to O
a O
randomized O
, O
crossover O
, O
double-blind O
, O
placebo-controlled O
study O
with O
administration O
of O
1 O
g O
per O
day O
etofibrate B-drug
or O
placebo O
for O
1-month O
. O

When O
indinavir B-drug
at O
an O
increased O
dose O
( O
1000 O
mg O
every O
8 O
hours O
) O
was O
given O
with O
SUSTIVA B-brand
( O
600 O
mg O
once O
daily O
) O
, O
the O
indinavir B-drug
AUC O
and O
Cmin O
were O
decreased O
on O
average O
by O
33-46 O
% O
and O
39-57 O
% O
, O
respectively O
, O
compared O
to O
when O
indinavir B-drug
( O
800 O
mg O
every O
8 O
hours O
) O
was O
given O
alone O
. O

Onset O
of O
action O
of O
tricyclics B-group
may O
be O
accelerated O
. O

Fatal O
cardiac O
arrests O
have O
occurred O
in O
patients O
receiving O
both O
drugs O
. O

Drug-Laboratory O
Test O
Interactions O
: O
There O
are O
no O
reported O
drug-laboratory O
test O
interactions O
. O

HEMABATE B-brand
may O
augment O
the O
activity O
of O
other O
oxytocic B-group
agents I-group
. O

Dexrazoxane B-drug
was O
not O
mutagenic O
in O
the O
Ames O
test O
but O
was O
found O
to O
be O
clastogenic O
to O
human O
lymphocytes O
in O
vitro O
and O
to O
mouse O
bone O
marrow O
erythrocytes O
in O
vivo O
( O
micronucleus O
test O
) O
. O

Special O
attention O
should O
be O
given O
to O
electrolyte O
and O
acid-base O
balance O
in O
patients O
experiencing O
severe O
or O
prolonged O
diarrhea O
or O
in O
patients O
receiving O
concomitant O
diuretics B-drug
. O

Many O
other O
medicines O
may O
increase O
or O
decrease O
the O
effects O
of O
glimepiride B-drug
or O
affect O
your O
condition O
. O

- O
Drugs O
that O
may O
either O
increase O
or O
decrease O
plasma O
phenytoin B-drug
concentrations O
include O
: O
phenobarbital B-drug
, O
vaiproic O
acid O
, O
and O
sodium B-drug
valproate I-drug
. O

We O
reviewed O
the O
clinical O
data O
relating O
to O
the O
efficacy O
and O
safety O
of O
pharmacologic O
doses O
of O
ascorbic B-drug
acid I-drug
in O
the O
prevention O
and O
treatment O
of O
the O
common O
cold O
. O

Concomitant O
administration O
of O
naproxen B-drug
and O
aspirin B-brand
is O
not O
recommended O
because O
naproxen B-drug
is O
displaced O
from O
its O
binding O
sites O
during O
the O
concomitant O
administration O
of O
aspirin B-brand
, O
resulting O
in O
lower O
plasma O
concentrations O
and O
peak O
plasma O
levels O
. O

Although O
it O
has O
not O
been O
established O
that O
there O
is O
an O
interaction O
between O
Clozapine B-drug
and O
benzodiazepines B-group
or O
other O
psychotropics B-group
, O
caution O
is O
advised O
when O
clozapine B-drug
is O
initiated O
in O
patients O
taking O
a O
benzodiazepine B-group
or O
any O
other O
psychotropic B-group
drug I-group
. O

In O
addition O
, O
certain O
drugs O
inhibit O
the O
activity O
of O
this O
isozyme O
and O
make O
normal O
metabolizers O
resemble O
poor O
metabolizers O
. O

Aprepitant B-drug
is O
a O
substrate O
for O
CYP3A4 O
; O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-group
concomitantly O
with O
ACE-inhibitors B-group
. O

No O
formal O
assessments O
of O
pharmacokinetic O
drug-drug O
interactions O
between O
TRISENOX B-brand
and O
other O
agents O
have O
been O
conducted O
. O

Studies O
on O
two O
strains O
of O
pointer O
dogs O
have O
demonstrated O
that O
administration O
of O
a O
benzodiazepine B-group
( O
chlordiazepoxide B-drug
) O
facilitates O
acquisition O
of O
goal-directed O
behavior O
in O
" O
genetically O
nervous O
" O

+24 O
% O
+14 O
% O
+43 O
% O
+40 O
% O

Non-steroidal B-group
anti-inflammatory I-group
agents I-group
: O
Seizures O
have O
been O
reported O
in O
patients O
taking O
enoxacin B-drug
concomitantly O
with O
the O
nonsteroidal B-group
anti-inflammatory I-group
drug I-group
fenbufen B-drug
. O

In O
humans O
, O
two O
inhibitors O
of O
P450 O
3A4 O
have O
been O
studied O
. O

However O
, O
it O
may O
be O
important O
also O
in O
case O
of O
medical O
examinations O
for O
insurances O
and O
job O
appointments O
, O
since O
some O
patients O
may O
turn O
out O
to O
need O
expensive O
drugs O
or O
to O
be O
susceptible O
to O
a O
certain O
disease O
. O

Tricyclic B-group
antidepressants I-group
may O
antagonize O
the O
hypotensive O
effects O
of O
clonidine B-drug
. O

Flurbiprofen B-drug
did O
not O
affect O
the O
pharmacokinetic O
profile O
of O
either O
drug O
, O
and O
the O
mechanism O
under O
lying O
the O
interference O
with O
propranolols B-drug
hypotensive O
effect O
is O
unknown O
. O

MEASUREMENTS O
AND O
MAIN O
RESULTS O
: O
In O
December O
1998 O
, O
the O
following O
was O
gathered O
for O
every O
MAC O
with O
more O
than O
one O
drug O
treatment O
: O
age O
, O
sex O
, O
number O
of O
drugs O
, O
intrinsic O
value O
, O
drugs O
prescribed O
, O
daily O
dose O
and O
pharmacological O
interactions O
( O
PI O
) O
, O
classified O
( O
using O
the O
scale O
of O
Hansten O
1996 O
) O
into O
light O
and O
clinically O
relevant O
. O

Drugs O
Metabolized O
by O
P450IID6 O
A O
subset O
( O
3 O
% O
to O
10 O
% O
) O
of O
the O
population O
has O
reduced O
activity O
of O
certain O
drug O
metabolizing O
enzymes O
such O
as O
the O
cytochrome O
P450 O
isoenzyme O
P450IID6 O
. O

( O
Concurrent O
use O
with O
thiazide B-group
diuretics I-group
may O
enhance O
the O
possibility O
of O
digitalis B-group
toxicity O
associated O
with O
hypokalemia O
. O
) O

14 O
% O
increase O
[ O
CI O
: O
2 O
% O
increase O
, O
24 O
% O
increase O
] O
25 O
% O
decrease O
[ O
CI O
: O
12 O
% O
decrease O
, O
51 O
% O
decrease O
] O

Thus O
, O
results O
of O
the O
DST O
should O
be O
interpreted O
with O
caution O
in O
these O
patients O
. O

Furosemide B-drug
: O
Clinical O
studies O
, O
as O
well O
as O
post-marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-group
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-drug
and O
thiazides B-group
in O
some O
patients O
. O

Folic B-drug
acid I-drug
in O
large O
amounts O
may O
counteract O
the O
antiepileptic O
effect O
of O
phenobarbital B-drug
, O
phenytoin B-drug
and O
primidone B-drug
, O
and O
increase O
the O
frequency O
of O
seizures O
in O
susceptible O
pediatric O
patients O
. O

It O
is O
important O
that O
health O
care O
professionals O
be O
aware O
of O
the O
potential O
for O
medications O
to O
interfere O
with O
clinical O
laboratory O
tests O
. O

Antidiabetic B-group
Agents I-group
( O
Insulin B-drug
, O
Sulfonylureas B-group
) O
: O
Requirements O
for O
insulin B-drug
or O
oral O
antidiabetic B-group
agents I-group
may O
be O
reduced O
in O
hypothyroid O
patients O
with O
diabetes O
mellitus O
and O
may O
subsequently O
increase O
with O
the O
initiation O
of O
thyroid O
hormone O
replacement O
therapy O
. O

Antihypertensives B-drug
: O
Amiodarone B-drug
should O
be O
used O
with O
caution O
in O
patients O
receiving O
-receptor B-drug
blocking O
agents O
( O
e.g. O
, O
propranolol B-drug
, O
a O
CYP3A4 B-drug
inhibitor O
) O
or O
calcium B-drug
channel I-drug
antagonists O
( O
e.g. O
, O
verapamil B-drug
, O
a O
CYP3A4 B-drug
substrate O
, O
and O
diltiazem B-drug
, O
a O
CYP3A4 B-drug
inhibitor O
) O
because O
of O
the O
possible O
potentiation O
of O
bradycardia O
, O
sinus O
arrest O
, O
and O
AV O
block O
; O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
No O
long-term O
carcinogenicity O
studies O
have O
been O
carried O
out O
with O
dexrazoxane B-drug
in O
animals O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
Rebif B-brand
. O

Recurrence O
of O
skin O
reactions O
at O
a O
site O
of O
previous O
extravasation O
following O
administration O
of O
TAXOL B-brand
at O
a O
different O
site O
, O
ie O
, O
recall O
, O
has O
been O
reported O
rarely O
. O

Pharmacokinetic O
studies O
document O
no O
clinically O
relevant O
interactions O
with O
other O
agents O
given O
concomitantly O
, O
including O
thiazide B-group
diuretics I-group
, O
digoxin B-drug
, O
and O
cimetidine B-drug
. O

When O
therapeutic O
concentrations O
of O
furosemide B-drug
, O
propranolol B-drug
, O
dipyridamole B-drug
, O
warfarin B-drug
, O
quinidine B-drug
, O
or O
naproxen B-drug
were O
added O
to O
human O
plasma O
( O
in O
vitro O
) O
, O
the O
plasma O
protein O
binding O
of O
nicardipine B-drug
HCl I-drug
was O
not O
altered O
. O

Drugs O
which O
inhibit O
CYP O
3A4 O
( O
e.g. O
, O
ketoconazole B-drug
, O
macrolide B-group
antibiotics I-group
such O
as O
erythromycin B-drug
) O
have O
the O
potential O
to O
result O
in O
increased O
plasma O
concentrations O
of O
corticosteroids B-group
. O

No O
dosage O
adjustment O
is O
required O
for O
Fluvoxamine B-drug
Tablets O
. O

Antimycobacterial B-group
Agents I-group
: O
rifampin B-drug
CONTRAINDICATED O
since O
the O
coadministration O
of O
this O
product O
with O
saquinavir B-drug
in O
an O
antiretroviral B-group
regimen O
reduces O
the O
plasma O
concentrations O
of O
saquinavir B-drug
. O

Ethyl B-drug
alcohol I-drug
is O
known O
to O
effect O
the O
functional O
integrity O
of O
the O
limbic O
system O
, O
particularly O
the O
hippocampus O
, O
and O
to O
alter O
behaviors O
which O
are O
thought O
to O
be O
mediated O
through O
limbic O
function O
. O

Prothrombin O
times O
were O
not O
affected O
by O
tiagabine B-drug
. O

The O
specific O
pharmacokinetic O
changes O
that O
occur O
with O
co-administration O
of O
nevirapine B-drug
and O
other O
drugs O
are O
listed O
in O
CLINICAL O
PHARMACOLOGY O
, O
Table O
1 O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
with O
RAPTIVA B-brand
. O

The O
disposition O
of O
theophylline B-drug
was O
not O
altered O
by O
concomitant O
cetirizine B-drug
administration O
. O

. O

Toxicodynamic O
interference O
between O
solvents O
can O
give O
rise O
to O
additive O
, O
potentiation O
, O
synergistic O
, O
antagonistic O
effects O
. O

Similarly O
, O
nateglinide B-drug
had O
no O
influence O
on O
the O
serum O
protein O
binding O
of O
propranolol B-drug
, O
glyburide B-drug
, O
nicardipine B-drug
, O
warfarin B-drug
, O
phenytoin B-drug
, O
acetylsalicylic B-drug
acid I-drug
, O
and O
tolbutamide B-drug
in O
vitro O
. O

Dantrium B-brand
is O
metabolized O
by O
the O
liver O
, O
and O
it O
is O
theoretically O
possible O
that O
its O
metabolism O
may O
be O
enhanced O
by O
drugs O
known O
to O
induce O
hepatic O
microsomal O
enzymes O
. O

Oral O
neomycin B-drug
inhibits O
the O
gastrointestinal O
absorption O
of O
penicillin B-drug
V I-drug
, O
oral O
vitamin B-drug
B-12 I-drug
, O
methotrexate B-drug
and O
5-fluorouracil B-drug
. O

If O
concomitant O
treatment O
with O
sumatriptan B-drug
and O
an O
SSRI B-group
( O
e.g. O
, O
fluoxetine B-drug
, O
fluvoxamine B-drug
, O
paroxetine B-drug
, O
sertraline B-drug
, O
citalopram B-drug
, O
escitalopram B-drug
) O
is O
clinically O
warranted O
, O
appropriate O
observation O
of O
the O
patient O
is O
advised O
. O

however O
, O
the O
second O
contraction O
was O
potentiated O
. O

Nevertheless O
, O
caution O
is O
indicated O
in O
the O
co-administration O
of O
TCA5 O
with O
any O
of O
the O
SSRIs B-group
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O

- O
a O
beta-blocker B-group
such O
as O
propranolol B-drug
( O
Inderal B-brand
) O
, O
atenolol B-drug
( O
Tenormin B-brand
) O
, O
acebutolol B-drug
( O
Sectral B-brand
) O
, O
metoprolol B-drug
( O
Lopressor B-brand
) O
, O
and O
others O
; O

Caution O
is O
recommended O
in O
patients O
with O
hepatic O
impairment O
. O

transaminases O
( O
AST O

In O
this O
study O
there O
was O
no O
evidence O
of O
a O
blunting O
of O
the O
antihypertensive O
action O
of O
VASOTEC B-brand
. O

The O
effects O
of O
DCG-IV B-drug_n
were O
very O
strong O
and O
completely O
depressed O
the O
PCP-induced B-drug_n
hyperlocomotion O
. O

Carbamazepine B-drug

It O
is O
recommended O
that O
glucose O
tests O
based O
on O
enzymatic O
glucose O
oxidase O
reactions O
( O
such O
as O
Clinistix O
** O
or O
Tes-Tape O
** O
) O
be O
used O
. O

Therefore O
, O
concomitant O
use O
of O
ribavirin B-drug
with O
either O
of O
these O
drugs O
should O
be O
avoided O
. O

No O
trials O
specifically O
examining O
potential O
drug O
interactions O
with O
Natrecor B-brand
were O
conducted O
, O
although O
many O
concomitant O
drugs O
were O
used O
in O
clinical O
trials O
. O

Theophylline B-drug
: O
A O
single O
10 O
mg O
dose O
of O
tiagabine B-drug
did O
not O
affect O
the O
pharmacokinetics O
of O
theophylline B-drug
at O
steady O
state O
. O

Valproic B-drug
acid I-drug
diminished O
binding O
of O
phenobarbital B-drug
by O
a O
net O
change O
of O
9.9 O
% O
( O
percentage O
increase O
in O
FDF O
, O
21.2 O
% O
) O
at O
1732 O
micromol/L O
. O

Ibogaine B-drug_n
produces O
whole O
body O
tremors O
and O
, O
at O
high O
doses O
( O
> O
or O
= O
100 O
mg/kg O
) O
, O
cerebellar O
damage O
; O

The O
use O
of O
NIMBEX B-brand
before O
succinylcholine B-drug
to O
attenuate O
some O
of O
the O
side O
effects O
of O
succinylcholine B-drug
has O
not O
been O
studied O
. O

Additionally O
, O
saquinavir B-drug
is O
a O
substrate O
for O
P-Glycoprotein O
( O
Pgp O
) O
. O

[ O
The O
GABA-ergic O
system O
and O
brain O
edema O
] O
It O
has O
been O
shown O
in O
rats O
with O
experimental O
toxic O
and O
traumatic O
edemas O
that O
picrotoxin B-drug_n
( O
1 O
mg/kg O
) O
removes O
the O
antiedematous O
action O
of O
diazepam B-drug
, O
phenazepam B-drug_n
, O
phenibut B-drug_n
and O
amizyl B-drug_n
and O
reduces O
the O
action O
of O
phentolamine B-drug
. O

Patients O
on O
warfarin-type B-group
anticoagulant I-group
therapy O
may O
require O
dosage O
adjustment O
of O
the O
anticoagulant O
during O
and O
after O
griseofulvin B-drug
therapy O
. O

Concomitant O
administration O
of O
rifampin B-drug
with O
ketoconazole B-drug
tablets O
reduces O
the O
blood O
levels O
of O
the O
latter O
. O

No O
data O
are O
available O
regarding O
interactions O
with O
other O
drugs O
that O
have O
renal O
clearance O
mechanisms O
similar O
to O
that O
of O
lamivudine B-drug
. O

In O
13-day-old O
embryos O
, O
glycine B-drug
was O
ineffective O
in O
both O
doses O
. O

Triazolam B-drug
: O
Erythromycin B-drug
has O
been O
reported O
to O
decrease O
the O
clearance O
of O
triazolam B-drug
and O
, O
thus O
, O
may O
increase O
the O
pharmacologic O
effect O
of O
triazolam B-drug
. O

( O
Thiazide B-group
diuretics I-group
may O
raise O
blood O
glucose O
levels O
; O

Consequently O
, O
the O
combination O
of O
methotrexate B-drug
with O
acitretin B-drug
is O
also O
contraindicated O
. O

The O
role O
of O
norepinephrine B-drug
uptake-1 O
was O
studied O
in O
electrically O
stimulated O
( O
1 O
Hz O
, O
37 O
degrees O
C O
) O
human O
ventricular O
cardiac O
preparations O
and O
isolated O
myocardial O
membranes O
. O

Drugs O
that O
induce O
CYP3A4 O
activity O
would O
be O
expected O
to O
increase O
the O
clearance O
of O
indinavir B-drug
, O
resulting O
in O
lowered O
plasma O
concentrations O
of O
indinavir B-drug
. O

Fluconazole B-drug
: O
Concomitant O
administration O
of O
fluconazole B-drug
at O
200 O
mg O
QD O
resulted O
in O
a O
two-fold O
increase O
in O
celecoxib B-drug
plasma O
concentration O
. O

Starlix B-brand
is O
a O
potential O
inhibitor O
of O
the O
CYP2C9 O
isoenzyme O
in O
vivo O
as O
indicated O
by O
its O
ability O
to O
inhibit O
the O
in O
vitro O
metabolism O
of O
tolbutamide B-drug
. O

Healthcare O
prescribers O
are O
advised O
to O
consult O
the O
package O
inserts O
of O
medication O
administered O
concomitantly O
with O
oral O
contraceptives B-group
. O

Catecholamine-depleting O
Agents O
: O
Patients O
taking O
both O
agents B-group
with I-group
b-blocking I-group
properties I-group
and O
a O
drug O
that O
can O
deplete O
catecholamines O
( O
e.g. O
, O
reserpine B-drug
and O
monoamine B-group
oxidase I-group
inhibitors I-group
) O
should O
be O
observed O
closely O
for O
signs O
of O
hypotension O
and/or O
severe O
bradycardia O
. O

Drugs O
Metabolized O
by O
CYP3A O
: O
Results O
of O
in O
vitro O
studies O
demonstrate O
that O
duloxetine B-drug
does O
not O
inhibit O
or O
induce O
CYP3A O
activity O
. O

astemizole B-drug
, O
bepridil B-drug
, O
sparfloxacin B-drug
, O
and O
terodiline B-drug
. O

for O
adult-onset O
diabetics O
, O
dosage O
adjustment O
of O
hypoglycemic B-group
medications I-group
may O
be O
necessary O
during O
and O
after O
thiazide B-group
diuretic I-group
therapy O
; O

Beta B-group
Blockers I-group
: O
Although O
the O
results O
of O
a O
clinical O
study O
did O
not O
indicate O
a O
safe O
problem O
associated O
with O
the O
administration O
of O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
to O
subjects O
already O
receiving O
propranolol B-drug
, O
there O
have O
been O
reports O
that O
propranolol B-drug
may O
potentiate O
the O
vasoconstrictive O
action O
of O
ergotamine B-drug
by O
blocking O
the O
vasodilating O
property O
of O
epinephrine O
. O

May O
interact O
with O
skin O
products O
or O
shampoos O
for O
dandruff O
or O
psoriasis O
. O

No O
data O
are O
available O
for O
the O
coadministration O
of O
INVIRASE/ritonavir B-brand
or O
FORTOVASE/ritonavir B-brand
and O
garlic O
capsules O
. O

There O
was O
no O
evidence O
of O
toxicity O
. O

BROVANA B-brand
, O
as O
with O
other O
beta2-agonists B-group
, O
should O
be O
administered O
with O
extreme O
caution O
to O
patients O
being O
treated O
with O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
tricyclic B-group
antidepressants I-group
, O
or O
drugs O
known O
to O
prolong O
the O
QTc O
interval O
because O
the O
action O
of O
adrenergic B-group
agonists I-group
on O
the O
cardiovascular O
system O
may O
be O
potentiated O
by O
these O
agents O
. O

Drug O
laboratory O
Test O
Interactions O
Serum O
Salicylate O
Assays O
: O
Caution O
should O
be O
used O
in O
interpreting O
the O
results O
of O
serum O
salicylate O
assays O
when O
diflunisal B-drug
is O
present O
. O

CANCIDAS B-brand
did O
not O
increase O
the O
plasma O
levels O
of O
cyclosporine B-drug
. O

Levetiracetam B-drug
and O
its O
major O
metabolite O
, O
at O
concentrations O
well O
above O
cmax O
levels O
achieved O
within O
the O
therapeutic O
dose O
range O
, O
are O
neither O
inhibitors O
of O
nor O
high O
affinity O
substrates O
for O
human O
liver O
cytochrome O
P450 O
isoforms O
, O
epoxide O
hydrolase O
or O
UDP-glucuronidation O
enzymes O
. O

Beta-adrenergic B-group
blocking I-group
agents I-group
: O
Coadministration O
of O
beta-adrenergic B-group
blocking I-group
agents I-group
did O
not O
have O
any O
effect O
on O
either O
the O
safety O
or O
efficacy O
of O
ibutilide B-drug
in O
the O
clinical O
trials O
. O

co-administration O
of O
phenytoin B-drug
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O

whereas O
urinary O
excretion O
was O
decreased O
in O
both O
cases O
. O

A O
drug-drug O
interaction O
study O
evaluated O
the O
effect O
of O
the O
use O
of O
ACZONE B-brand
Gel O
, O
5 O
% O
, O
in O
combination O
with O
double O
strength O
( O
160 O
mg/800 O
mg O
) O
trimethoprim/sulfamethoxazole B-drug
( O
TMP/SMX B-drug
) O
. O

An O
intravenous O
dose O
of O
50 O
mg O
perchlorate B-drug_n
was O
in O
respect O
of O
competitive O
suppression O
of O
organs O
actively O
concentrating O
pertechnetate B-drug
as O
effective O
as O
intravenous O
1000 O
mg O
ClO-4- O
simultaneously O
or O
1000 O
mg O
orally O
30 O
min O
before O
the O
injection O
of O
radiopertechnetate B-drug
. O

The O
glucocorticoid-induced O
gene O
transcription O
was O
strongly O
suppressed O
by O
synthetic O
alkyl O
esters O
; O

Administration O
of O
diltiazem B-drug
hydrochloride I-drug
concomitantly O
with O
propranolol B-drug
in O
five O
normal O
volunteers O
resulted O
in O
increased O
propranolol B-drug
levels O
in O
all O
subjects O
and O
bioavailability O
of O
propranolol B-drug
was O
increased O
approximately O
50 O
% O
. O

In O
patients O
in O
whom O
CYP3A4 O
inducers O
( O
eg O
, O
dexamethasone B-drug
, O
phenytoin B-drug
, O
carbamazepine B-drug
, O
rifampicin B-drug
, O
phenobarbital B-drug
) O
are O
indicated O
, O
alternative O
agents O
with O
less O
enzyme O
induction O
potential O
should O
be O
used O
. O

There O
is O
no O
evidence O
that O
EPA B-drug
supplements O
have O
detrimental O
effects O
on O
glucose O
tolerance O
, O
insulin O
secretion O
or O
insulin O
resistance O
in O
non-diabetic O
subjects O
. O

The O
behavioral O
effects O
of O
the O
stereoisomers O
of O
N-allylnormetazocine B-drug_n
( O
NANM B-drug_n
) O
were O
compared O
with O
those O
of O
phencyclidine B-drug_n
( O
PCP B-drug_n
) O
in O
pigeons O
and O
squirrel O
monkeys O
responding O
under O
a O
multiple O
fixed-interval O
fixed-ratio O
( O
FI O
FR O
) O
schedule O
of O
food O
presentation O
. O

The O
pharmacokinetics O
and O
protein O
binding O
of O
fosphenytoin B-drug
, O
phenytoin B-drug
, O
and O
diazepam B-drug
were O
not O
altered O
when O
diazepam B-drug
and O
Cerebyx B-brand
were O
concurrently O
administered O
in O
single O
submaximal O
doses O
. O

Since O
higher O
doses O
of O
ketoconazole B-drug
( O
400 O
mg O
daily O
) O
may O
result O
in O
higher O
increases O
in O
Cmax O
and O
AUC O
, O
a O
single O
2.5 O
mg O
dose O
of O
Vardenafil B-drug
should O
not O
be O
exceeded O
in O
a O
24-hour O
period O
when O
used O
in O
combination O
with O
ketoconazole B-drug
400 O
mg O
daily O
. O

Also O
, O
concomitant O
administration O
of O
quinolones B-group
with O
products O
containing O
iron B-drug
, O
multivitamins B-group
containing O
zinc B-drug
, O
or O
Videx B-brand
( O
didanosine B-drug
) O
chewable/buffered O
tablets O
or O
the O
pediatric O
powder O
for O
oral O
solution O
may O
result O
in O
low O
urine O
levels O
. O

The O
risk O
of O
this O
interaction O
may O
be O
reduced O
if O
digoxin B-drug
is O
given O
as O
capsules O
. O

CHOLESTYRAMINE B-drug
: O
The O
influence O
of O
the O
bile-acidsequestering O
agent O
cholestyramine B-drug
on O
the O
pharmacokinetits O
of O
cerivastatin B-drug
sodium I-drug
was O
evaluated O
in O
12 O
healthy O
males O
in O
2 O
separate O
randomized O
crossover O
studies O
. O

Cimetidine B-drug
: O
Cimetidine B-drug
increases O
nicardipine B-drug
HCl I-drug
plasma O
levels O
. O

Catecholamine-depleting O
drugs O
, O
e.g. O
, O
reserpine B-drug
, O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta B-group
blocking I-group
agents I-group
. O

Higher O
dosage O
of O
oral O
hypoglycemic B-group
agents I-group
may O
be O
required O
. O

( O
In O
some O
patients O
, O
the O
steroidal B-group
anti-inflammatory I-group
agent I-group
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop O
, O
potassium O
sparing O
, O
and O
thiazide B-group
diuretics I-group
. O

Care O
should O
be O
taken O
if O
labetalol B-drug
is O
used O
concomitantly O
with O
calcium B-group
antagonists O
of O
the O
verapamil B-drug
type O
. O

There O
are O
reports O
of O
enhanced O
as O
well O
as O
diminished O
effects O
of O
anticoagulants B-group
when O
given O
concurrently O
with O
corticosteroids B-group
. O

Effect O
of O
probenecid B-drug
on O
the O
apparent O
volume O
of O
distribution O
and O
elimination O
of O
cloxacillin B-drug
. O

They O
may O
be O
administered O
alternately O
when O
the O
preceding O
effect O
of O
other O
such O
drug O
has O
subsided O
. O

The O
role O
of O
AMEVIVE B-brand
in O
the O
development O
of O
the O
lymphoid O
malignancy O
and O
the O
hyperplasia O
observed O
in O
non-human O
primates O
and O
the O
relevance O
to O
humans O
is O
unknown O
. O

Impaired O
glucose O
tolerance O
. O

ethinyl I-drug
estradiol I-drug
concentration O

There O
was O
a O
small O
decrease O
in O
the O
clearance O
of O
cetirizine B-drug
caused O
by O
a O
400-mg O
dose O
of O
theophylline B-drug
; O

These O
drugs O
should O
be O
coadministered O
with O
caution O
, O
and O
frequent O
monitoring O
of O
serum O
lithium B-drug
levels O
is O
recommended O
. O

Alcohol B-drug
( O
increases O
bioavailability O
by O
50 O
% O
) O
, O
cimetidine B-drug
, O
and O
valproates O
. O

Other O
: O
Instances O
of O
rash O
, O
pruritus O
, O
ankle O
edema O
, O
excessive O
perspiration O
, O
weight O
gain O
, O
nasal O
congestion O
. O

Therefore O
, O
MAO B-group
inhibitors I-group
should O
be O
discontinued O
at O
least O
two O
weeks O
prior O
to O
the O
cautious O
initiation O
of O
therapy O
with O
SINEQUAN B-brand
. O

Cimetidine B-drug

ADL B-drug
8-2698 I-drug
, O
a O
trans-3,4-dimethyl-4- O
( O
3-hydroxyphenyl O
) O
piperidine O
, O
prevents O
gastrointestinal O
effects O
of O
intravenous O
morphine B-drug
without O
affecting O
analgesia O
. O

The O
change O
in O
furosemide B-drug
clearance O
value O
is O
not O
likely O
to O
be O
clinically O
significant O
. O

Methotrexate B-drug
- O
There O
is O
one O
report O
that O
methotrexate B-drug
may O
decrease O
the O
possible O
effectiveness O
of O
supplemental O
L-glutamine B-drug
for O
chemotherapy-induced O
mucositis O
. O

Methadone B-drug

Plasma O
concentrations O
and O
effects O
potentially O
increased O
or O
decreased O
by O
SUSTIVA B-brand
. O

The O
clearance O
by O
means O
of O
4-hydroxytolbutamide B-drug_n
and O
carboxytolbutamide B-drug_n
was O
significantly O
reduced O
in O
both O
groups O
( O
ie O
, O
from O
901 O
mL/h O
to O
318 O
mL/h O
in O
the O
group O
that O
received O
150 O
mg O
of O
tolbutamide B-drug
per O
day O
and O
from O
723 O
mL/h O
to O
457 O
mL/h O
in O
the O
group O
that O
received O
75 O
mg O
of O
tolbutamide B-drug
per O
day O
) O
. O

Aspirin B-brand
: O
Concurrent O
administration O
of O
aspirin B-brand
and O
flurbiprofen B-drug
resulted O
in O
50 O
% O
lower O
serum O
flurbiprofen B-drug
concentrations O
. O

Therefore O
, O
simultaneous O
use O
of O
creams O
, O
ointments O
or O
oils O
should O
be O
avoided O
. O

Aspirin B-brand
, O
warfarin B-drug
, O
heparin B-drug
, O
NSAIDs B-group

Approximately O
2/3 O
of O
the O
patients O
in O
the O
Phase O
3 O
study O
received O
either O
prophylactic O
low O
dose O
heparin B-drug
( O
unfractionated B-drug
heparin I-drug
up O
to O
15,000 O
units/day O
) O
or O
prophylactic O
doses O
of O
low B-group
molecular I-group
weight I-group
heparins I-group
as O
indicated O
in O
the O
prescribing O
information O
for O
the O
specific O
products O
. O

Patients O
receiving O
SPRYCEL B-brand
should O
not O
take O
St. O
Johns O
wort O
. O

Alternatively O
, O
provide O
medical O
supervision O
for O
at O
least O
one O
hour O
after O
the O
initial O
dose O
. O

The O
effects O
of O
HMG-CoA B-group
reductase I-group
inhibitors I-group
on O
male O
fertility O
have O
not O
been O
studied O
in O
adequate O
numbers O
of O
patients O
. O

No O
drug O
, O
nutritional O
supplement O
, O
food O
or O
herb O
interactions O
are O
known O
. O

In O
long O
surgical O
procedures O
during O
enflurane B-drug
or O
isoflurane B-drug
anesthesia O
, O
less O
frequent O
maintenance O
dosing O
, O
lower O
maintenance O
doses O
, O
or O
reduced O
infusion O
rates O
of O
NIMBEX B-brand
may O
be O
necessary O
. O

Other O
substances O
: O
Grapefruit O
juice O
given O
to O
healthy O
volunteers O
increased O
amiodarone B-drug
AUC O
by O
50 O
% O
and O
Cmax O
by O
84 O
% O
, O
resulting O
in O
increased O
plasma O
levels O
of O
amiodarone B-drug
. O

With O
simultaneous O
dosing O
of O
Vardenafil B-drug
20 O
mg O
and O
terazosin B-drug
10 O
mg O
, O
2 O
of O
9 O
subjects O
experienced O
a O
standing O
systolic O
blood O
pressure O
of O
less O
than O
85 O
mm O
Hg O
. O

Auranofin B-drug
should O
not O
be O
used O
together O
with O
penicillamine B-drug
( O
Depen B-brand
, O
Cuprimine B-brand
) O
, O
another O
arthritis O
medication O
. O

This O
practice O
resulted O
in O
no O
apparent O
increase O
in O
local O
breast O
cancer O
recurrence O
relative O
to O
published O
accounts O
in O
the O
literature O
. O

Continuous O
cardiac O
monitoring O
is O
not O
required O
except O
for O
patients O
with O
serious O
conduction O
abnormalities O
. O

Agents O
Affecting O
Cytochrome O
P450 O
3A4 O
Isoenzyme O
System O
Fentanyl B-drug
is O
metabolized O
mainly O
via O
the O
human O
cytochrome O
P450 O
3A4 O
isoenzyme O
system O
( O
CYP3A4 O
) O
, O
therefore O
potential O
interactions O
may O
occur O
when O
DURAGESIC B-brand
is O
given O
concurrently O
with O
agents O
that O
affect O
CYP3A4 O
activity O
. O

Thiolated B-drug_n
carboxymethylcellulose I-drug_n
: O
in O
vitro O
evaluation O
of O
its O
permeation O
enhancing O
effect O
on O
peptide O
drugs O
. O

Ethoxzolamide B-drug
may O
increase O
the O
action O
of O
tricyclics B-group
, O
amphetamines B-group
, O
procainamide B-drug
, O
and O
quinidine B-drug
. O

General O
: O
Significant O
interactions O
may O
occur O
when O
celecoxib B-drug
is O
administered O
together O
with O
drugs O
that O
inhibit O
P450 O
2C9 O
. O

Commonly O
used O
drugs O
such O
as O
phenylpropanolamine B-drug
and O
pseudoephedrine B-drug
have O
been O
specifically O
studied O
. O

May O
interact O
with O
the O
following O
: O
beta-adrenergic B-group
blocking I-group
agents I-group
( O
these O
medicines O
may O
make O
your O
condition O
worse O
and O
prevent O
the O
adrenergic B-group
bronchodilators I-group
from O
working O
properly O
) O
and O
disopyramide B-drug
, O
quinidine B-drug
, O
phenothiazines B-group
, O
and O
procainamide B-drug
( O
these O
medicines O
may O
increase O
the O
risk O
of O
heart O
problems O
) O
. O

However O
, O
in O
another O
study O
in O
healthy O
volunteers O
, O
the O
pharmacokinetics O
of O
butorphanol B-drug
were O
significantly O
altered O
( O
29 O
% O
decrease O
in O
AUC O
and O
38 O
% O
decrease O
in O
Cmax O
) O
when O
a O
1-mg O
dose O
of O
STADOL B-brand
NS I-brand
was O
administered O
1 O
minute O
after O
a O
20-mg O
dose O
of O
sumatriptan B-drug
nasal O
spray O
. O

( O
The O
two O
drugs O
were O
administered O
in O
opposite O
nostrils O
. O
) O

Limited O
data O
in O
patients O
receiving O
known O
enzyme O
inducers O
( O
phenytoin B-drug
, O
phenobarbital B-drug
, O
carbamazepine B-drug
) O
indicate O
only O
a O
30 O
% O
increase O
in O
the O
rate O
of O
flecainide B-drug
elimination O
. O

Dosage O
of O
the O
drugs O
mentioned O
above O
and O
other O
similarly O
metabolized O
drugs O
, O
particularly O
those O
of O
low O
therapeutic O
ratio O
or O
in O
patients O
with O
renal O
and/or O
hepatic O
impairment O
, O
may O
require O
adjustment O
when O
starting O
or O
stopping O
concomitantly O
administered O
Tagamet B-brand
to O
maintain O
optimum O
therapeutic O
blood O
levels O
. O

However O
, O
because O
some O
quinolones B-group
have O
been O
reported O
to O
enhance O
the O
effects O
of O
warfarin B-drug
or O
its O
derivatives O
, O
prothrombin O
time O
or O
other O
suitable O
anticoagulation O
test O
should O
be O
monitored O
closely O
if O
a O
quinolone B-group
antimicrobial I-group
is O
administered O
with O
warfarin B-drug
or O
its O
derivatives O
. O

In O
five O
men O
, O
terfenadine B-drug
levels O
were O
undetectable O
( O
5 O
ng/mL O
) O
throughout O
the O
study O
; O

Therefore O
, O
chloroprocaine B-drug
should O
not O
be O
used O
in O
any O
condition O
in O
which O
a O
sulfonamide B-group
drug I-group
is O
being O
employed O
. O

Pletal B-brand
does O
not O
, O
however O
, O
appear O
to O
cause O
increased O
blood O
levels O
of O
drugs O
metabolized O
by O
CYP3A4 O
, O
as O
it O
had O
no O
effect O
on O
lovastatin B-drug
, O
a O
drug O
with O
metabolism O
very O
sensitive O
to O
C.P.A O
. O
inhibition O
. O

When O
administering O
other O
drugs O
for O
which O
alterations O
in O
blood O
levels O
could O
have O
a O
clinically O
significant O
effect O
on O
safety O
or O
efficacy O
, O
physicians O
should O
consider O
monitoring O
drug O
levels O
or O
effects O
. O

Tacrolimus O
Felodipine B-drug
may O
increase O
the O
blood O
concentration O
of O
tacrolimus B-drug
. O

Drugs O
That O
Inhibit O
Alprazolam B-drug
Metabolism O
Via O
Cytochrome O
P450 O
3A O
: O
The O
initial O
step O
in O
alprazolam B-drug
metabolism O
is O
hydroxylation O
catalyzed O
by O
cytochrome O
P450 O
3A O
( O
CYP O
3A O
) O
. O

In O
patients O
who O
have O
received O
muscle B-group
relaxants I-group
, O
doxapram B-drug
may O
temporarily O
mask O
the O
residual O
effects O
of O
muscle B-group
relaxant I-group
drugs I-group
. O

Co-administration O
of O
probenecid B-drug
with O
acyclovir B-drug
has O
been O
shown O
to O
increase O
the O
mean O
half-life O
and O
the O
area O
under O
the O
concentration-time O
curve O
. O

Pressor O
agents O
- O
Because O
of O
possible O
effects O
on O
blood O
pressure O
, O
STRATTERA B-brand
should O
be O
used O
cautiously O
with O
pressor O
agents O
. O

Increased O
plasma O
HDL O
and O
HDL2 O
cholesterol O
subfraction O
concentrations O
, O
reduced O
LDL O
cholesterol O
concentration O
, O
increased O
triglyceride O
levels O
. O

Iron B-group
Supplements I-group
and O
Foods O
Fortified O
With O
Iron B-drug
Concomitant O
administration O
of O
cefdinir B-drug
with O
a O
therapeutic O
iron B-group
supplement I-group
containing O
60 O
mg O
of O
elemental O
iron B-drug
( O
as O
FeSO4 O
) O
or O
vitamins B-group
supplemented O
with O
10 O
mg O
of O
elemental O
iron B-drug
reduced O
extent O
of O
absorption O
by O
80 O
% O
and O
31 O
% O
, O
respectively O
. O

Use O
in O
Conjunction O
with O
Other O
Antiepileptic B-group
Drugs I-group
: O
The O
addition O
of O
Felbatol B-brand
to O
antiepileptic B-group
drugs I-group
( O
AEDs B-group
) O
affects O
the O
steady-state O
plasma O
concentrations O
of O
AEDs B-group
. O

- O
isoniazid B-drug
( O
Nydrazid B-brand
) O
; O

Specific O
Effects O
of O
Felbatol B-brand
on O
Other O
Antiepileptic B-group
Drugs I-group
Phenytoin B-drug
: O
Felbatol B-brand
causes O
an O
increase O
in O
steady-state O
phenytoin B-drug
plasma O
concentrations O
. O

There O
were O
no O
significant O
effects O
on O
QTc O
intervals O
, O
and O
no O
reports O
of O
sedation O
or O
syncope O
. O

monitor O
closely O
for O
evidence O
of O
hypotension O
and/or O
excessive O
bradycardia O
( O
e.g. O
, O
vertigo O
, O
syncope O
, O
postural O
hypotension O
) O
. O

Unmodified O
NaCMC B-drug_n
( O
1 O
% O
m/v O
) O
significantly O
improved O
the O
transport O
ratio O
( O
R= O
P O
( O
app O
) O
polymer/ O
P O
( O
app O
) O
control O
) O
of O
NaFlu B-drug
to O
1.3 O
and O
1 O
% O
( O
m/v O
) O
NaCMC B-drug_n
conjugated O
with O
cysteine B-drug
further O
enhanced O
the O
permeation O
. O

To O
each O
preparation O
was O
added O
one O
additional O
drug O
at O
three O
concentrations O
ranging O
from O
therapeutic O
to O
toxic O
. O

To O
investigate O
the O
effect O
of O
disease O
states O
or O
concomitant O
drug O
administration O
on O
a O
patient O
's O
response O
to O
etodolac B-drug
, O
additional O
pharmacokinetic O
studies O
were O
carried O
out O
in O
special O
populations O
. O

No O
clinical O
drug O
interaction O
studies O
have O
been O
conducted O
. O

Ergotamine B-drug
: O
Concurrent O
use O
of O
erythromycin B-drug
and O
ergotamine B-drug
or O
dihydroergotamine B-drug
has O
been O
associated O
in O
some O
patients O
with O
acute O
ergot O
toxicity O
characterized O
by O
severe O
peripheral O
vasospasm O
and O
dysesthesia O
. O

Herbal O
remedies O
, O
nephropathies O
, O
and O
renal O
disease O
. O

Diclofenac B-drug
is O
a O
prostaglandin O
synthetase O
inhibitor O
, O
however O
, O
and O
all O
drugs O
that O
inhibit O
prostaglandin O
synthesis O
interfere O
with O
platelet O
function O
to O
some O
degree O
; O

nonetheless O
, O
the O
possibility O
that O
causative O
factors O
may O
interact O
synergistically O
to O
increase O
the O
risk O
and/or O
severity O
of O
bone O
marrow O
suppression O
warrants O
consideration O
. O

In O
studies O
in O
female O
rats O
at O
doses O
0.01 O
mg/kg/day O
( O
IM O
; O

Mean O
T O
max O
and O
mean O
plasma O
elimination O
half-life O
of O
albendazole B-drug
sulfoxide I-drug
were O
unchanged O
. O

Sildenafil B-drug
dose O
should O
not O
exceed O
a O
maximum O
of O
25 O
mg O
in O
a O
48- O
hour O
period O
in O
patients O
receiving O
concomitant O
indinavir B-drug
therapy O
. O

Herb/Nutraceutical O
: O
St O
Johns O
wort O
may O
decrease O
the O
effectiveness O
of O
combination B-group
hormonal I-group
contraceptives I-group
by O
inducing O
hepatic O
enzymes O
. O

urticaria O

Caverject B-brand
: O
The O
potential O
for O
pharmacokinetic O
drug-drug O
interactions O
between O
alprostadil B-drug
and O
other O
agents O
has O
not O
been O
formally O
studied O
. O

therefore O
, O
it O
should O
be O
recognized O
that O
a O
positive O
Coombs O
test O
may O
be O
due O
to O
the O
drug O
. O

Although O
no O
drug-drug O
interaction O
studies O
have O
been O
conducted O
in O
vivo O
, O
it O
is O
expected O
that O
no O
significant O
interaction O
would O
occur O
when O
nitazoxanide B-drug
is O
co-administered O
with O
drugs O
that O
either O
are O
metabolized O
by O
or O
inhibit O
cytochrome O
P450 O
enzymes O
. O

There O
are O
no O
clinical O
data O
on O
concomitant O
use O
of O
NUROMAX B-brand
and O
other O
nondepolarizing O
neuromuscular B-group
blocking I-group
agents I-group
. O

Administration O
of O
thiazide B-group
diuretics I-group
to O
hypoparathyroid O
patients O
who O
are O
concurrently O
being O
treated O
with O
dihydrotachysterol B-drug
may O
cause O
hypercalcemia O
. O

antibiotics B-group
; O

These O
agents O
should O
not O
be O
used O
in O
patients O
treated O
with O
NIZORAL B-brand
Tablets O
. O

Amiodarone B-drug
, O
disopyramide B-drug
, O
lidocaine B-drug

The O
pharmacokinetics O
of O
ethanol B-drug
were O
not O
affected O
by O
multiple-dose O
administration O
of O
tiagabine B-drug
. O

The O
CNS O
effects O
of O
butalbital B-drug
may O
be O
enhanced O
by O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
. O

Indinavir B-drug
may O
be O
taken O
with O
a O
light O
meal O
1 O
h O
following O
the O
administration O
of O
400 O
mg O
of O
didanosine B-drug
. O

Nitrates B-group
: O
The O
concomitant O
use O
of O
Bepridil B-drug
with O
long- O
and O
short-acting O
nitrates B-group
has O
been O
safely O
tolerated O
in O
patients O
with O
stable O
angina O
pectoris O
. O

The O
results O
we O
present O
clearly O
show O
that O
the O
drug O
alters O
the O
cellular O
permeability O
, O
and O
thus O
the O
exogenous O
respiration O
becomes O
sensitive O
to O
the O
drug O
. O

Vardenafil B-drug
( O
20 O
mg O
) O
did O
not O
potentiate O
the O
hypotensive O
effects O
of O
alcohol B-drug
during O
the O
4-hour O
observation O
period O
in O
healthy O
volunteers O
when O
administered O
with O
alcohol B-drug
( O
0.5 O
g/kg O
body O
weight O
) O
. O

In O
addition O
to O
this O
pharmacological O
interaction O
, O
this O
report O
describes O
a O
novel O
chemical O
reaction O
between O
temazepam B-drug
( O
a O
benzodiazepine B-group
) O
and O
ethanol B-drug
under O
acidic O
conditions O
similar O
to O
those O
found O
in O
vivo O
, O
resulting O
in O
a O
3-ethoxylated O
product O
. O

MEASUREMENTS O
and O
MAIN O
RESULTS O
: O
Blood O
samples O
were O
drawn O
and O
12-lead O
electrocardiograms O
performed O
at O
specified O
time O
points O
after O
the O
last O
morning O
dose O
of O
cisapride B-drug
in O
phases O
1 O
and O
3 O
. O

increased O
liver O

Still O
other O
pathways O
have O
been O
proposed O
. O

Sympathomimetic B-group
Agents I-group
: O
Possible O
increased O
risk O
of O
coronary O
insufficiency O
in O
patients O
with O
coronary O
artery O
disease O
. O

In O
addition O
, O
new O
cases O
of O
diabetes O
have O
been O
diagnosed O
during O
Accutane B-brand
therapy O
, O
although O
no O
causal O
relationship O
has O
been O
established O

This O
may O
potentiate O
and O
prolong O
hypnotic O
and O
sedative O
effects O
, O
especially O
with O
repeated O
dosing O
or O
chronic O
administration O
of O
these O
agents O
. O

Several O
of O
the O
tricyclic B-group
antidepressants I-group
have O
been O
cited O
in O
these O
reports O
. O

Bleeding O
from O
a O
number O
of O
sites O
may O
be O
a O
complication O
of O
warfarin B-drug
treatment O
and O
GI O
bleeding O
a O
complication O
of O
ketoprofen B-drug
treatment O
. O

. O

Between O
1988 O
and O
1993 O
, O
more O
than O
7,000 O
patients O
were O
diagnosed O
and O
treated O
. O

Therefore O
, O
monitoring O
of O
theophylline B-drug
plasma O
levels O
should O
be O
considered O
and O
dosage O
of O
theophylline B-drug
adjusted O
, O
as O
required O
. O

Both O
CYP3A4 O
and O
CYP2D6 O
are O
responsible O
for O
aripiprazole B-drug
metabolism O
. O

Separating O
the O
doses O
of O
antacid B-group
and O
lomefloxacin B-drug
minimizes O
this O
decrease O
in O
bioavailability O
; O

TCAs B-group
decrease O
the O
hypotensive O
effect O
of O
guanfacine B-drug
. O

Poor O
metabolizers O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-group
antidepressants I-group
( O
TCAs B-group
) O
when O
given O
usual O
doses O
. O

Non-selective B-group
monoamine I-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
- O
including O
phenelzine B-drug
sulfate I-drug
, O
tranylcypromine B-drug
sulfate I-drug
and O
pargyline B-drug
HC1 O
. O

However O
, O
this O
sample O
size O
is O
too O
small O
to O
allow O
for O
any O
conclusions O
to O
be O
drawn O
regarding O
the O
risk O
of O
rashes O
with O
concomitant O
AUGMENTIN B-brand
XR I-brand
and O
allopurinol B-drug
use O
. O

The O
introductory O
chapter O
discusses O
the O
advantages O
and O
disadvantages O
of O
POCs B-group
and O
the O
magnitude O
and O
prevalence O
of O
their O
use O
. O

Theophylline B-drug
: O
The O
effect O
of O
steady-state O
fluvoxamine B-drug
l50 O
mg O
bid O
on O
the O
pharmacokinetics O
of O
a O
single O
dose O
of O
Theophylline B-drug
( O
375 O
mg O
) O
as O
442 O
mg O
aminophylline B-drug
was O
evaluated O
in O
12 O
healthy O
non-smoking O
, O
male O
volunteers O
. O

The O
effects O
of O
supplementary O
oral O
cobalt B-drug
and O
iron B-drug
, O
as O
well O
as O
the O
interaction O
between O
both O
at O
the O
absorption O
site O
, O
fecal O
and O
urinary O
excretion O
as O
well O
as O
the O
retention O
of O
these O
trace O
elements O
were O
determined O
by O
using O
four O
diets O
containing O
either O
9 O
or O
63 O
micrograms/kg O
of O
Co B-drug
and O
48 O
or O
446 O
mg/kg O
of O
Fe B-drug
over O
a O
period O
of O
19 O
days O
in O
a O
total O
of O
24 O
rats O
. O

These O
fulvestrant B-drug
doses O
correspond O
to O
approximately O
2- O
, O
3- O
, O
and O
3-fold O
the O
systemic O
exposure O
[ O
AUC0-30 O
days O
] O
achieved O
in O
women O
. O

This O
review O
discusses O
the O
actions O
of O
the O
two O
drugs O
on O
certain O
brain O
chemical O
( O
i.e. O
, O
neurotransmitter O
) O
systems O
and O
the O
extent O
to O
which O
the O
effects O
of O
the O
two O
drugs O
may O
interact O
. O

Cholestyramine B-drug
: O
Cholestyramine B-drug
binds O
both O
T4 B-drug
and O
T3 B-drug
in O
the O
intestine O
, O
thus O
impairing O
absorption O
of O
these O
thyroid B-group
hormones I-group
. O

The O
use O
of O
Adenocard B-brand
in O
patients O
receiving O
digitalis B-group
may O
be O
rarely O
associated O
with O
ventricular O
fibrillation O
. O

Cisapride B-drug

The O
patient O
was O
also O
chronically O
receiving O
phenytoin B-drug
, O
phenobarbital B-drug
, O
digoxin B-drug
, O
and O
levothyroxine B-drug
sodium I-drug
. O

Pregnancy O
: O
Category O
X O
: O
Use O
With O
Ribavirin B-drug
( O
see O
CONTRAINDICATIONS O
) O
Significant O
teratogenic O
and/or O
embryocidal O
effects O
have O
been O
demonstrated O
in O
all O
animal O
species O
exposed O
to O
ribavirin B-drug
. O

When O
Itraconazole B-drug
was O
coadministered O
with O
phenytoin B-drug
, O
rifampin B-drug
, O
or O
H2antagonists O
, O
reduced O
plasma O
concentrations O
of O
itraconazole B-drug
were O
reported O
. O

. O

phenytoin B-drug
; O

Azithromycin B-drug
had O
no O
significant O
impact O
on O
the O
Cmax O
and O
AUC O
of O
zidovudine B-drug
, O
although O
it O
significantly O
decreased O
the O
zidovudine B-drug
tmax O
by O
44 O
% O
and O
increased O
the O
intracellular O
exposure O
to O
phosphorylated O
zidovudine B-drug
by O
110 O
% O
. O

At O
similar O
median O
follow-up O
, O
opportunistic O
infection O
( O
OI O
) O
rates O
and O
mortality O
were O
significantly O
lower O
in O
the O
CHOP-HAART O
patients O
than O
in O
the O
CHOP O
patients O
( O
18 O
% O
vs. O
52 O
% O
, O
respectively O
; O
P O
= O
0.05 O
; O
and O
38 O
% O
vs. O
85 O
% O
, O
respectively O
; O
P O
= O
0.001 O
) O
. O

If O
ProSom B-brand
is O
given O
concomitantly O
with O
other O
drugs O
acting O
on O
the O
central O
nervous O
system O
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
all O
agents O
. O

Patients O
taking O
Acamprosate B-drug
concomitantly O
with O
antidepressants B-group
more O
commonly O
reported O
both O
weight O
gain O
and O
weight O
loss O
, O
compared O
with O
patients O
taking O
either O
medication O
alone O
. O

however O
, O
no O
specific O
drug O
interaction O
studies O
have O
been O
performed O
to O
evaluate O
potential O
drug-drug O
interaction O
. O

No O
well-known O
drug O
interactions O
with O
glutamic B-drug
acid I-drug

It O
was O
established O
that O
both O
angiotensins O
inhibited O
gastric O
acid O
secretion O
stimulated O
by O
pentagastrin B-drug
but O
not O
by O
histamine B-drug
. O

As O
with O
other O
agents O
which O
prolong O
ECG O
intervals O
, O
caution O
should O
be O
exercised O
in O
patients O
taking O
drugs O
which O
prolong O
ECG O
intervals O
, O
particularly O
QTc O
. O

Other O
interactions O
: O
Vardenafil B-drug
had O
no O
effect O
on O
the O
pharmacodynamics O
of O
glyburide B-drug
( O
glucose O
and O
insulin O
concentrations O
) O
and O
warfarin B-drug
( O
prothrombin O
time O
or O
other O
pharmacodynamic O
parameters O
) O
. O

Patients O
treated O
with O
TENORMIN B-brand
plus O
a O
catecholamine O
depletor O
should O
therefore O
be O
closely O
observed O
for O
evidence O
of O
hypotension O
and/or O
marked O
bradycardia O
which O
may O
produce O
vertigo O
, O
syncope O
, O
or O
postural O
hypotension O
. O

diazoxide B-drug
; O

Aspirin B-brand
: O
Concurrent O
administration O
of O
aspirin B-brand
may O
lower O
meclofenamate B-drug
sodium I-drug
plasma O
levels O
, O
possibly O
by O
competing O
for O
protein-binding O
sites O
. O

Gentamicin B-drug
is O
an O
aminoglycoside B-group
antibiotic I-group
used O
to O
treat O
a O
wide O
variety O
of O
infections O
caused O
by O
gram-negative O
organisms O
, O
but O
it O
is O
potentially O
toxic O
to O
the O
kidneys O
. O

Drug/Laboratory O
Test O
Interactions O
None O
known O
. O

Interactions O
attributed O
to O
the O
combined O
use O
of O
baclofen B-drug
injection O
and O
epidural O
morphine B-drug
include O
hypotension O
and O
dyspnea O
. O

Antiarrhythmics B-group

Isocarboxazid B-drug
should O
be O
administered O
with O
caution O
to O
patients O
receiving O
Antabuse B-brand
( O
disulfiram B-drug
, O
Wyeth-Ayerst O
Laboratories O
) O
. O

Since O
acetaminophen B-drug
in O
high O
doses O
has O
been O
associated O
with O
hepatotoxicity O
, O
concomitant O
administration O
of O
diflunisal B-drug
and O
acetaminophen B-drug
should O
be O
used O
cautiously O
, O
with O
careful O
monitoring O
of O
patients O
. O

The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O

These O
observations O
are O
discussed O
in O
reference O
to O
possible O
deleterious O
effects O
following O
the O
administration O
of O
pargyline B-drug
to O
patients O
with O
Parkinson O
's O
Disease O
. O

There O
was O
evidence O
for O
longitudinal O
stability O
in O
AUC O
of O
everolimus B-drug
during O
the O
course O
of O
the O
study O
. O

It O
is O
recommended O
that O
the O
combination O
of O
intravenous O
dantrolene B-drug
sodium I-drug
and O
calcium B-group
channel I-group
blockers I-group
, O
such O
as O
verapamil B-drug
, O
not O
be O
used O
together O
during O
the O
management O
of O
malignant O
hyperthermia O
crisis O
until O
the O
relevance O
of O
these O
findings O
to O
humans O
is O
established O
. O

L-glutamine B-drug
has O
orphan O
drug O
status O
for O
this O
indication O
. O

BACKGROUND O
: O
The O
feasibility O
and O
efficacy O
of O
concomitant O
chemotherapy O
and O
highly B-group
active I-group
antiretroviral I-group
therapy O
( O
HAART O
) O
is O
still O
unknown O
in O
patients O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
-related O
malignancies O
. O

Coadministration O
of O
SULAR B-brand
with O
phenytoin B-drug
or O
any O
known O
CYP3A4 O
inducer O
should O
be O
avoided O
and O
alternative O
antihypertensive B-group
therapy O
should O
be O
considered O
. O

The O
concomitant O
use O
of O
other O
CYP3A4 O
inhibitors O
such O
as O
diltiazem B-drug
and O
erythromycin B-drug
with O
transdermal O
fentanyl B-drug
may O
also O
result O
in O
an O
increase O
in O
fentanyl B-drug
plasma O
concentrations O
, O
which O
could O
increase O
or O
prolong O
adverse O
drug O
effects O
and O
may O
cause O
serious O
respiratory O
depression O
. O

This O
information O
should O
be O
considered O
when O
changing O
from O
intravenous O
amiodarone B-drug
to O
oral O
amiodarone B-drug
. O

Alcohol B-drug
: O
Alcohol B-drug
( O
0.5 O
g/kg O
body O
weight O
: O
approximately O
40 O
mL O
of O
absolute O
alcohol O
in O
a O
70 O
kg O
person O
) O
and O
vardenafil B-drug
plasma O
levels O
were O
not O
altered O
when O
dosed O
simultaneously O
. O

Ketoconazole B-drug
: O
Ketoconazole B-drug
may O
inhibit O
both O
synthetic O
and O
catabolic O
enzymes O
of O
vitamin B-group
D I-group
. O

Although O
the O
mechanism O
of O
interaction O
between O
fenoprofen B-drug
and O
aspirin B-brand
is O
not O
totally O
known O
, O
enzyme O
induction O
and O
displacement O
of O
fenoprofen B-drug
from O
plasma O
albumin O
binding O
sites O
are O
possibilities O
. O

In O
evaluating O
the O
potential O
for O
interactions O
among O
co-administered O
antiepilepsy O
drugs O
( O
AEDs B-group
) O
, O
whether O
or O
not O
an O
AED B-group
induces O
or O
does O
not O
induce O
metabolic O
enzymes O
is O
an O
important O
consideration O
. O

Other O
drugs O
that O
increase O
gastrointestinal O
motility O
may O
produce O
similar O
effects O
. O

Bromocriptine B-drug
mesylate I-drug
may O
interact O
with O
dopamine B-group
antagonists I-group
, O
butyrophenones B-group
, O
and O
certain O
other O
agents O
. O

Inhibition O
and O
stimulation O
of O
the O
effect O
of O
oxytocin B-drug
on O
milk O
ejection O
by O
vasopressin O
was O
demonstrated O
. O

Accelerated O
prothrombin O
time O
, O
partial O
thromboplastin O
time O
, O
and O
platelet O
aggregation O
time O
; O

Care O
should O
be O
taken O
when O
using O
immunoanalytical O
methods O
to O
measure O
plasma O
phenytoin B-drug
concentrations O
following O
Cerebyx B-brand
administration O
. O

Organometals O
also O
compromise O
the O
limbic O
system O
and O
result O
in O
deficits O
in O
learning O
and O
memory O
. O

Furthermore O
it O
has O
been O
proposed O
that O
isoniazid B-drug
resulted O
In O
induction O
of O
P-450IIE1 O
in O
the O
patients O
liver O
which O
, O
in O
turn O
, O
resulted O
in O
a O
greater O
proportion O
of O
the O
ingested O
acetaminophen B-drug
being O
converted O
to O
the O
toxic O
metabolites O
. O

Based O
on O
the O
above O
data O
from O
in O
vitro O
and O
in O
vivo O
studies O
, O
it O
is O
unlikely O
that O
alosetron B-drug
will O
inhibit O
the O
hepatic O
metabolic O
clearance O
of O
drugs O
metabolized O
by O
the O
major O
CYP O
enzyme O
3A4 O
, O
as O
well O
as O
the O
CYP O
enzymes O
2D6 O
, O
2C9 O
, O
2C19 O
, O
2E1 O
, O
or O
1A2 O
. O

This O
may O
lead O
to O
reduced O
clearance O
of O
caffeine B-drug
and O
the O
prolongation O
of O
its O
plasma O
half-life O
. O

Cimetidine B-drug
- O
In O
subjects O
who O
had O
received O
21 O
days O
of O
40 O
mg/day O
racemic O
citalopram B-drug
, O
combined O
administration O
of O
400 O
mg/day O
cimetidine B-drug
for O
8 O
days O
resulted O
in O
an O
increase O
in O
citalopram B-drug
AUC O
and O
Cmax O
of O
43 O
% O
and O
39 O
% O
, O
respectively O
. O

- O
Methotrexate B-drug
( O
e.g. O
, O
Mexate B-brand
) O
Use O
of O
methotrexate B-drug
with O
sulfapyridine B-drug
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O
and/or O
the O
side O
effects O
of O
methotrexate B-drug

Norepinephrine B-drug
: O
Amphetamines B-group
enhance O
the O
adrenergic O
effect O
of O
norepinephrine B-drug
. O

A O
possible O
interaction O
has O
been O
suggested O
with O
hormonal B-group
contraceptives I-group
and O
the O
herbal O
supplement O
St. O
Johns O
Wort O
based O
on O
some O
reports O
of O
oral O
contraceptive B-group
users O
experiencing O
breakthrough O
bleeding O
shortly O
after O
starting O
St. O
Johns O
Wort O
. O

In O
an O
emergency O
situation O
when O
opioid O
analgesia O
must O
be O
administered O
to O
a O
patient O
receiving O
REVIA B-brand
, O
the O
amount O
of O
opioid B-group
required O
may O
be O
greater O
than O
usual O
, O
and O
the O
resulting O
respiratory O
depression O
may O
be O
deeper O
and O
more O
prolonged O
. O

The O
net O
effect O
of O
these O
interactions O
is O
summarized O
in O
the O
following O
table O
: O
AED B-group
AED I-group
Felbatol B-brand

In O
these O
patients O
, O
approximately O
half O
of O
the O
CPK O
elevations O
returned O
to O
normal O
within O
2 O
weeks O
and O
half O
returned O
to O
normal O
within O
4 O
weeks O
. O

Studies O
on O
the O
mechanism O
of O
action O
of O
miconazole B-drug
: O
effect O
of O
miconazole B-drug
on O
respiration O
and O
cell O
permeability O
of O
Candida O
albicans O
. O

Concurrent O
use O
of O
these O
agents O
should O
generally O
be O
avoided O
. O

- O
Mephenytoin B-drug
( O
e.g. O
, O
Mesantoin B-brand
) O
Use O
of O
sulfapyridine B-drug
with O
these O
medicines O
may O
increase O
the O
chance O
of O
side O
effects O
of O
these O
medicines O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
allergic O
reaction O
. O

1- O
adrenergic O
receptor O
antagonism O
, O
aripiprazole B-drug
has O
the O
potential O
to O
enhance O
the O
effect O
of O
certain O
antihypertensive B-group
agents I-group
. O

Nephrotoxicity O
and O
ototoxicity O
were O
not O
noted O
when O
ceftazidime B-drug
was O
given O
alone O
in O
clinical O
trials O
. O

Median O
gastric O
pH O
was O
significantly O
higher O
when O
indinavir B-drug
was O
taken O
after O
didanosine B-drug
administration O
; O

carbamazepine B-drug
; O

Patients O
taking O
other O
drugs O
that O
are O
substrates O
of O
CYP450 O
3A4 O
, O
especially O
patients O
with O
renal O
and/or O
hepatic O
impairment O
, O
may O
require O
dosage O
adjustment O
when O
starting O
or O
stopping O
concomitantly O
administered O
diltiazem B-drug
in O
order O
to O
maintain O
optimum O
therapeutic O
blood O
levels O
. O

The O
initiated O
cells O
that O
result O
from O
this O
hit O
may O
vary O
from O
those O
that O
demonstrate O
very O
little O
progression O
in O
cell O
type O
and O
may O
or O
may O
not O
require O
exogenous O
enhancement O
of O
growth O
to O
those O
that O
can O
progress O
very O
rapidly O
to O
fully O
malignant O
behavior O
. O

Exert O
particular O
caution O
in O
combining O
chlorprothixene B-drug
with O
other O
anticholinergic B-group
drugs I-group
( O
tricyclic B-group
antidepressants I-group
and O
antiparkinsonian B-group
agents I-group
) O
: O
Particularly O
the O
elderly O
may O
develop O
delirium O
, O
high O
fever O
, O
severe O
obstipation O
, O
even O
ileus O
and O
glaucoma O
. O

Poor O
metabolizers O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-group
antidepressants I-group
( O
TCAs B-group
) O
when O
given O
usual O
doses O
. O

14C-cholesterol O
ester O
fractional O
clearance O
rate O
was O
260 O
% O
greater O
after O
etofibrate B-drug
than O
after O
placebo O
. O

The O
mean O
( O
SD O
) O
cumulative O
urinary O
excretion O
of O
immunoreactive O
digoxin B-drug
after O
concurrent O
treatment O
with O
rofecoxib B-drug
or O
placebo O
was O
228.2 O
( O
+/- O
30.8 O
) O
and O
235.1 O
( O
+/- O
39.1 O
) O
micrograms/120 O
hours O
, O
respectively O
. O

Therefore O
, O
ketoconazole B-drug
should O
be O
administered O
with O
caution O
with O
intranasal O
ciclesonide B-drug
. O

Since O
the O
renal O
excretion O
of O
unchanged O
dasatinib B-drug
and O
its O
metabolites O
is O
4 O
% O
, O
a O
decrease O
in O
total O
body O
clearance O
is O
not O
expected O
in O
patients O
with O
renal O
insufficiency O
. O

Estrogen B-group
, O
Oral O
Contraceptives B-group
: O
Estrogens B-group
tend O
to O
increase O
serum O
thyroxine-binding O
globulin O
( O
TBg O
) O
. O

Although O
acid-base O
and O
electrolyte O
disturbances O
were O
not O
reported O
in O
the O
clinical O
trials O
with O
dorzolamide B-drug
, O
these O
disturbances O
have O
been O
reported O
with O
oral O
carbonic B-group
anhydrase I-group
inhibitors I-group
and O
have O
, O
in O
some O
instances O
, O
resulted O
in O
drug O
interactions O
( O
e.g. O
, O
toxicity O
associated O
with O
high-dose O
salicylate B-group
therapy O
) O
. O

This O
is O
also O
to O
be O
considered O
when O
leflunomide B-drug
treatment O
is O
followed O
by O
such O
drugs O
without O
a O
drug O
elimination O
procedure O
. O

Consequently O
, O
plasma O
concentrations O
of O
drugs O
metabolized O
by O
these O
two O
isoenzymes O
will O
be O
decreased O
when O
TRACLEER B-brand
is O
co-administered O
. O

Heparin B-drug
: O
No O
human O
drug O
interaction O
studies O
with O
heparin B-drug
were O
conducted O
. O

The O
effects O
of O
mixing O
NovoLog B-brand
with O
insulins B-group
of O
animal O
source O
or O
insulin B-drug
preparations O
produced O
by O
other O
manufacturers O
have O
not O
been O
studied O
. O

astemizole B-drug
midazolam I-drug
, O
triazolam B-drug
cisapride I-drug
ergot O
derivatives O
voriconazole B-drug

In O
a O
study O
in O
normal O
volunteers O
, O
concomitant O
administration O
of O
buspirone B-drug
HCl I-drug
and O
haloperidol B-drug
resulted O
in O
increased O
serum O
haloperidol B-drug
concentrations O
. O

The O
inhibitory O
potential O
of O
ciclesonide B-drug
on O
CYP450 O
isoenzymes O
has O
not O
been O
studied O
. O

prolonged O
hot O
weather O
; O

Thus O
, O
smaller O
doses O
of O
adenosine B-drug
may O
be O
effective O
in O
the O
presence O
of O
dipyridamole B-drug
. O

Drugs O
Prolonging O
the O
QT/QTc O
Interval O
Caution O
should O
be O
exercised O
when O
prescribing O
apomorphine B-drug
concomitantly O
with O
drugs O
that O
prolong O
the O
QT/QTc O
interval O
. O

In O
healthy O
subjects O
receiving O
cimetidine B-drug
( O
1 O
gm O
daily O
) O
for O
one O
week O
, O
plasma O
flecainide B-drug
levels O
increased O
by O
about O
30 O
% O
and O
half-life O
increased O
by O
about O
10 O
% O
. O

The O
effects O
celecoxib B-drug
on O
the O
pharmacokinetics O
and/or O
pharmacodynamics O
of O
glyburide B-drug
, O
ketoconazole B-drug
, O
methotrexate B-drug
, O
phenytoin B-drug
, O
tolbutamide B-drug
, O
and O
warfarin B-drug
have O
been O
studied O
in O
vivo O
and O
clinically O
important O
interactions O
have O
not O
been O
found O
. O

Albuterol B-drug
, O
Antihistamines B-group
, O
antidiabetic B-group
drugs I-group
, O
diuretics B-group
, O
digitalis B-group
. O

Animal O
data O
indicated O
that O
bupropion B-drug
may O
be O
an O
inducer O
of O
drug-metabolizing O
enzymes O
in O
humans O
. O

600-1800 O

Age O
( O
range O
, O
17-69 O
years O
) O
, O
weight O
( O
range O
, O
49-106 O
kg O
) O
, O
and O
sex O
( O
65 O
men O
and O
36 O
women O
) O
were O
not O
significant O
contributors O
to O
variability O
. O

Therefore O
, O
if O
concomitant O
administration O
of O
these O
agents O
is O
indicated O
, O
dosing O
should O
be O
separated O
by O
2 O
hours O
. O

No O
separate O
information O
available O

Therefore O
the O
, O
combination O
of O
anakinra B-drug
with O
other O
TNF-blocking B-group
agents I-group
, O
including O
HUMIRA B-brand
, O
may O
also O
result O
i O
n O
similar O
toxicities O
. O

Co-administration O
of O
aliskiren B-drug
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
lovastatin B-drug
, O
digoxin B-drug
, O
valsartan B-drug
, O
amlodipine B-drug
, O
metformin B-drug
, O
celecoxib B-drug
, O
atenolol B-drug
, O
atorvastatin B-drug
, O
ramipril B-drug
or O
hydrochlorothiazide B-drug
. O

The O
onset O
of O
neuromuscular O
blockade O
by O
succinylcholine B-drug
was O
unaffected O
by O
BREVIBLOC B-brand
, O
but O
the O
duration O
of O
neuromuscular O
blockade O
was O
prolonged O
from O
5 O
minutes O
to O
8 O
minutes O
. O

Therefore O
, O
patients O
concurrently O
taking O
antiseizure O
medication O
and O
Mefloquine B-drug
should O
have O
the O
blood O
level O
of O
their O
antiseizure O
medication O
monitored O
and O
the O
dosage O
adjusted O
appropriately O
. O

Therefore O
, O
drugs O
that O
affect O
CYP3A4 O
and/or O
Pgp O
, O
may O
modify O
the O
pharmacokinetics O
of O
saquinavir B-drug
. O

There O
is O
no O
clinical O
experience O
to O
date O
on O
the O
use O
of O
Femara B-brand
in O
combination O
with O
other O
anticancer O
agents O
. O

Due O
to O
wide O
interindividual O
variability O
in O
the O
dose O
adjustment O
required O
, O
it O
is O
recommended O
that O
cyclosporine B-drug
concentrations O
be O
monitored O
closely O
after O
initiation O
of O
carvedilol B-drug
therapy O
and O
that O
the O
dose O
of O
cyclosporine B-drug
be O
adjusted O
as O
appropriate O
. O

Patients O
who O
are O
treated O
with O
ZYVOX B-brand
and O
concomitant O
serotonergic B-group
agents I-group
should O
be O
closely O
observed O
for O
signs O
and O
symptoms O
of O
serotonin O
syndrome O
( O
e.g. O
, O
cognitive O
dysfunction O
, O
hyperpyrexia O
, O
hyperreflexia O
, O
incoordination O
) O
. O

Misonidazole B-drug_n
protects O
mouse O
tumour O
and O
normal O
tissues O
from O
the O
toxicity O
of O
oral O
CCNU B-drug
. O

Serial O
pharmacokinetic O
dosing O
has O
been O
proposed O
as O
a O
method O
to O
accomplish O
this O
goal O
. O

clarithromycin I-drug
concentration O

Among O
494 O
subjects O
who O
received O
Angiomax B-brand
in O
clinical O
trials O
and O
were O
tested O
for O
antibodies O
, O
2 O
subjects O
had O
treatment-emergent O
positive O
bivalirudin B-drug
antibody O
tests O
. O

The O
effect O
of O
theophylline B-drug
on O
the O
pharmacokinetics O
of O
citalopram B-drug
was O
not O
evaluated O
. O

Safety O
and O
effectiveness O
in O
children O
has O
not O
been O
established O
. O

Except O
in O
life-threatening O
situations O
, O
avoid O
this O
combination O
. O

Evoked O
hind O
limb O
digital O
extensor O
tension O
( O
hoof O
twitch O
) O
was O
maintained O
at O
40 O
% O
of O
baseline O
for O
1 O
h O
by O
atracurium B-drug
infusion O
in O
7 O
horses O
anaesthetised O
with O
halothane B-drug
. O

Ritonavir B-drug
- O
Combined O
administration O
of O
a O
single O
dose O
of O
ritonavir B-drug
( O
600 O
mg O
) O
, O
both O
a O
CYP3A4 O
substrate O
and O
a O
potent O
inhibitor O
of O
CYP3A4 O
, O
and O
escitalopram B-drug
( O
20 O
mg O
) O
did O
not O
affect O
the O
pharmacokinetics O
of O
either O
ritonavir B-drug
or O
escitalopram B-drug
. O

We O
investigated O
the O
effects O
of O
adenosine O
receptor O
antagonists O
, O
caffeine B-drug
, O
theophylline B-drug
, O
8-phenyltheophylline B-drug_n
, O
and O
8-cyclopentyl-1,3-dipropylxanthine B-drug_n
( O
DPCPX B-drug_n
) O
, O
in O
a O
light/dark O
test O
in O
mice O
. O

b-Adrenergic B-group
Blocking I-group
Agents I-group
: O
Actions O
of O
some O
of O
beta-blocking B-group
agents I-group
may O
be O
impaired O
when O
hypothyroid O
patients O
become O
euthyroid O
. O

In O
these O
trials O
, O
heart O
rate O
and O
systolic O
blood O
pressure O
were O
approximately O
2-3 O
bpm O
and O
6-8 O
mm O
Hg O
higher O
, O
respectively O
, O
in O
subjects O
on O
concomitant O
theophylline B-drug
compared O
with O
the O
overall O
population O
. O

( O
Both O
drugs O
were O
thus O
dosed O
to O
steady O
state O
. O
) O

Efavirenz B-drug

Concomitant O
treatment O
with O
thrombolytics B-group
( O
eg O
, O
rt-PA O
or O
streptokinase B-drug
) O
may O
: O
- O
increase O
the O
risk O
of O
bleeding O
complications O
- O
considerably O
enhance O
the O
effect O
of O
REFLUDAN B-brand
on O
aPTT O
prolongation O

When O
duloxetine B-drug
was O
administered O
( O
at O
a O
dose O
of O
60 O
mg O
BID O
) O
in O
conjunction O
with O
a O
single O
50-mg O
dose O
of O
desipramine B-drug
, O
a O
CYP2D6 O
substrate O
, O
the O
AUC O
of O
desipramine B-drug
increased O
3-fold O
. O

WARFARIN B-drug
: O
Co- O
administration O
of O
warfarin B-drug
and O
cerivastatin B-drug
to O
healthy O
volunteers O
did O
not O
result O
in O
any O
changes O
in O
prothrombin O
time O
or O
clotting O
factor O
VII O
when O
compared O
to O
co-administration O
of O
warfarin B-drug
and O
placebo O
. O

It O
would O
be O
expected O
that O
laxative B-group
use O
during O
therapy O
with O
CAMPTOSAR B-brand
would O
worsen O
the O
incidence O
or O
severity O
of O
diarrhea O
, O
but O
this O
has O
not O
been O
studied O
. O

Pharmacokinetic O
evaluation O
of O
the O
digoxin-amiodarone B-drug
interaction O
. O

Increasing O
the O
indinavir B-drug
dose O
to O
1000 O
mg O
every O
8 O
hours O
does O
not O
compensate O
for O
the O
increased O
indinavir B-drug
metabolism O
due O
to O
SUSTIVA B-brand
. O

Convulsions O
have O
been O
reported O
with O
this O
concurrent O
use O
. O

The O
effect O
of O
desflurane B-drug
on O
the O
disposition O
of O
other O
drugs O
has O
not O
been O
determined O
. O

Hormonal O
contraceptives B-group
Co-administration O
of O
Trileptal B-brand
with O
an O
oral O
contraceptive B-group
has O
been O
shown O
to O
influence O
the O
plasma O
concentrations O
of O
the O
two O
hormonal O
components O
, O
ethinylestradiol B-drug
( O
EE O
) O
and O
levonorgestrel B-drug
( O
LNG O
) O
. O

RAPTIVA B-brand
should O
not O
be O
used O
with O
other O
immunosuppressive B-group
drugs I-group
. O

In O
5 O
other O
schizophrenic O
patients O
treated O
with O
oral O
haloperidol B-drug
and O
rifampin B-drug
, O
discontinuation O
of O
rifampin B-drug
produced O
a O
mean O
3.3-fold O
increase O
in O
haloperidol B-drug
concentrations O
. O

When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
glipizide B-drug
, O
the O
patient O
should O
be O
observed O
closely O
for O
loss O
of O
control O
. O

This O
may O
be O
due O
to O
an O
improved O
glucose O
utilization O
with O
simultaneous O
reduction O
in O
insulin B-drug
requirement O

Cyclopropane B-drug
or O
halogenated B-group
hydrocarbon I-group
anesthetics I-group
increase O
cardiac O
autonomic O
irritability O
and O
may O
sensitize O
the O
myocardium O
to O
the O
action O
of O
certain O
intravenously O
administered O
catecholamines B-group
, O
such O
as O
dopamine B-drug
. O

Esomeprazole B-drug
may O
potentially O
interfere O
with O
CYP2C19 O
, O
the O
major O
esomeprazole B-drug
metabolizing O
enzyme O
. O

Ketoconazole B-drug
: O
Ketoconazole B-drug
may O
inhibit O
both O
synthetic O
and O
catabolic O
enzymes O
of O
vitamin B-group
D I-group
. O

* O
This O
table O
is O
not O
all O
inclusive O
** O
VIRACEPT B-brand
may O
not O
be O
effective O
due O
to O
decreased O
nelfinavir B-drug
plasma O
concentrations O
in O
patients O
taking O
these O
agents O
concomitantly O

The O
effects O
of O
allopurinol B-drug
on O
didanosine B-drug
pharmacokinetics O
in O
subjects O
with O
normal O
renal O
function O
are O
not O
known O
. O

Therefore O
, O
diphenoxylate B-drug
has O
the O
potential O
to O
prolong O
the O
biological O
half-lives O
of O
drugs O
for O
which O
the O
rate O
of O
elimination O
is O
dependent O
on O
the O
microsomal O
drug O
metabolizing O
enzyme O
system O
. O

Digoxin B-drug
- O
In O
subjects O
who O
had O
received O
21 O
days O
of O
40 O
mg/day O
racemic O
citalopram B-drug
, O
combined O
administration O
of O
citalopram B-drug
and O
digoxin B-drug
( O
single O
dose O
of O
1 O
mg O
) O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
either O
citalopram B-drug
or O
digoxin B-drug
. O

Valproic B-drug
Acid I-drug
: O
The O
mean O
steady-state O
trough O
serum O
valproic B-drug
acid I-drug
concentrations O
prior O
to O
and O
during O
concomitant O
gabapentin B-drug
administration O
( O
400 O
mg O
TID O
; O

Tricyclic B-group
antidepressants I-group
have O
been O
reported O
to O
blunt O
the O
hypotensive O
effect O
of O
systemic O
clonidine.It B-drug
is O
not O
known O
whether O
the O
concurrent O
use O
of O
these O
agents O
with O
ALPHAGAN B-brand
P I-brand
in O
humans O
can O
lead O
to O
resulting O
interference O
with O
the O
IOP O
lowering O
effect O
. O

DIAGNOSTIC O
INTERFERENCE O
With O
expected O
physiologic O
effects O
: O
Blood O
and O
urine O
glucose O
levels O
( O
usually O
only O
in O
patients O
with O
a O
predisposition O
for O
glucose O
intolerance O
) O
and O
Serum O
bilirubin O
levels O
( O
by O
displacement O
from O
albumin O
binding O
) O
and O
Serum O
calcium O
levels O
( O
thiazide B-group
diuretics I-group
should O
be O
discontinued O
before O
parathyroid-function O
tests O
are O
carried O
out O
) O
and O
Serum O
uric O
acid O
levels O
( O
may O
be O
increased O
) O
Serum O
magnesium O
, O
potassium O
, O
and O
sodium O
levels O
( O
may O
be O
decreased O
; O

Anastrozole B-drug
did O
not O
inhibit O
P450 O
2A6 O
or O
the O
polymorphic O
P450 O
2D6 O
in O
human O
liver O
microsomes O
. O

In O
addition O
, O
oxcarbazepine B-drug
and O
MHD B-drug_n
induce O
a O
subgroup O
of O
the O
cytochrome O
P450 O
3A O
family O
( O
CYP3A4 O
and O
CYP3A5 O
) O
responsible O
for O
the O
metabolism O
of O
dihydropyridine B-group
calcium I-group
antagonists I-group
and O
oral O
contraceptives B-group
, O
resulting O
in O
a O
lower O
plasma O
concentration O
of O
these O
drugs O
. O

Gentamicin B-drug
did O
not O
interfere O
with O
the O
activity O
of O
clindamycin B-drug
within O
the O
range O
of O
concentrations O
tested O
( O
0.1 O
to O
100 O
mug/ml O
) O
; O

Plasma O
concentrations O
may O
be O
increased O
by O
CRIXIVAN B-brand
. O

Intraventricular O
injection O
of O
beta-endorphin B-drug_n
and O
morphine B-drug
produced O
an O
inhibition O
of O
the O
tail-flick O
response O
to O
the O
heat O
stimulus O
in O
rats O
. O

Interaction O
of O
GABITRIL B-brand
with O
Other O
Drugs O
: O
Cimetidine B-drug
: O
Co-administration O
of O
cimetidine B-drug
( O
800 O
mg/day O
) O
to O
patients O
taking O
tiagabine B-drug
chronically O
had O
no O
effect O
on O
tiagabine B-drug
pharmacokinetics O
. O

The O
following O
are O
examples O
of O
substances O
that O
may O
increase O
the O
blood-glucose-lowering O
effect O
and O
susceptibility O
to O
hypoglycemia O
: O
oral O
antidiabetic B-group
products I-group
, O
ACE B-group
inhibitors I-group
, O
disopyramide B-drug
, O
fibrates B-group
, O
fluoxetine B-drug
, O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
, O
propoxyphene B-drug
, O
salicylates B-group
, O
somatostatin B-group
analog I-group
( O
e.g. O
, O
octreotide B-drug
) O
, O
sulfonamide B-group
antibiotics I-group
. O

However O
, O
the O
pharmacodynamic O
effect O
increased O
by O
190 O
% O
( O
QTc O
increase O
over O
time O
) O
and O
by O
84 O
% O
( O
Maximum O
QTc O
increase O
) O
. O

Mutagenesis O
PEGASYS B-brand
did O
not O
cause O
DNA O
damage O
when O
tested O
in O
the O
Ames O
bacterial O
mutagenicity O
assay O
and O
in O
the O
in O
vitro O
chromosomal O
aberration O
assay O
in O
human O
lymphocytes O
, O
either O
in O
the O
presence O
or O
absence O
of O
metabolic O
activation O
. O

Ganciclovir B-drug
: O
Administration O
of O
VIDEX B-brand
2 O
hours O
prior O
to O
or O
concurrent O
with O
oral O
ganciclovir B-drug
was O
associated O
with O
a O
111 O
( O
114 O
) O
% O
increase O
in O
the O
steady-state O
AUC O
of O
didanosine B-drug
( O
n O
= O
12 O
) O
. O

In O
addition O
, O
certain O
drugs O
that O
are O
metabolized O
by O
this O
isoenzyme O
, O
including O
many O
antidepressants B-group
( O
tricyclic B-group
antidepressants I-group
, O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
, O
and O
others O
) O
, O
may O
inhibit O
the O
activity O
of O
this O
isoenzyme O
, O
and O
thus O
may O
make O
normal O
metab-olizers O
resemble O
poor O
metabolizers O
with O
regard O
to O
concomitant O
therapy O
with O
other O
drugs O
metabolized O
by O
this O
enzyme O
system O
, O
leading O
to O
drug O
interactions O
. O

in O
one O
man O
, O
the O
C O
max O
of O
terfenadine B-drug
was O
8.1 O
ng/mL O
with O
terfenadine B-drug
alone O
and O
7.2 O
ng/mL O
with O
terfenadine B-drug
plus O
dirithromycin B-drug
. O

The O
mechanism O
( O
s O
) O
of O
altered O
topo O
I O
expression O
in O
certain O
tumor O
types O
is O
unknown O
, O
but O
may O
be O
related O
to O
the O
central O
importance O
of O
topoisomerases O
in O
proliferating O
cell O
functions O
( O
transcription O
, O
replication O
, O
etc O
. O
) O
, O
and O
the O
aberrant O
and O
chronic O
activation O
of O
these O
functions O
as O
a O
result O
of O
specific O
tumorigenic O
alterations O
. O

All O
subjects O
received O
amprenavir B-drug
( O
1,200 O
mg O
twice O
a O
day O
) O
for O
4 O
days O
, O
followed O
by O
a O
7-day O
washout O
period O
, O
followed O
by O
either O
rifabutin B-drug
( O
300 O
mg O
once O
a O
day O
[ O
QD O
] O
) O
( O
cohort O
1 O
) O
or O
rifampin B-drug
( O
600 O
mg O
QD O
) O
( O
cohort O
2 O
) O
for O
14 O
days O
. O

Prospective O
, O
long-term O
studies O
on O
concomitant O
administration O
of O
VIOXX B-brand
and O
aspirin B-brand
have O
not O
been O
conducted O
. O

therefore O
, O
it O
is O
theoretically O
possible O
that O
lansoprazole B-drug
may O
interfere O
with O
the O
absorption O
of O
drugs O
where O
gastric O
pH O
is O
an O
important O
determinant O
of O
bioavailability O
( O
e.g O
. O
ketoconazole B-drug
, O
ampicillin B-drug
esters O
, O
iron B-drug
salts O
, O
digoxin B-drug
) O
. O

Use O
of O
MAO B-group
inhibitors I-group
may O
cause O
an O
excessive O
increase O
in O
blood O
pressure O
and O
heart O
stimulation O
. O

Dosage O
adjustment O
of O
STRATTERA B-brand
may O
be O
necessary O
when O
coadministered O
with O
CYP2D6 O
inhibitors O
, O
e.g. O
, O
paroxetine B-drug
, O
fluoxetine B-drug
, O
and O
quinidine B-drug
. O

Data O
from O
a O
randomized O
trial O
of O
HEXALEN B-brand
and O
cisplatin B-drug
plus O
or O
minus O
pyridoxine B-drug
in O
ovarian O
cancer O
indicated O
that O
pyridoxine B-drug
significantly O
reduced O
neurotoxicity O
; O

May O
lead O
to O
loss O
of O
virologic O
response O
and O
possible O
resistance O
to O
CRIXIVAN B-brand
or O
to O
the O
class O
of O
protease B-group
inhibitors I-group
. O

Antineoplastic B-group
agents I-group
( O
e. O
g. O
, O
nitrogen B-drug
mustard I-drug
, O
etc O
. O
) O
should O
be O
given O
concomitantly O
only O
with O
great O
caution O
. O

These O
observations O
suggest O
that O
exogenous O
co-factors O
could O
be O
involved O
in O
the O
occurrence O
of O
ARE O
. O

bromelains B-drug
; O

Anticholinesterases B-group
( O
neostgmine O
, O
physostigmine B-drug
) O
, O
lignocaine B-drug
, O
quinine B-drug
, O
procainamide B-drug
can O
enhance O
toxicity O
and O
cause O
cardio O
respiratory O
depression O
. O

increased O
norepinephrine-induced O
platel O
et O
aggregation O
; O

Vardenafil B-drug

Binding O
to O
Serum O
Proteins O
: O
The O
following O
agents O
may O
either O
inhibit O
levothyroxine B-drug
sodium I-drug
binding O
to O
serum O
proteins O
or O
alter O
the O
concentrations O
of O
serum O
binding O
proteins O
: O
androgens B-group
and O
related O
anabolic B-group
hormones I-group
, O
asparaginase B-drug
, O
clofibrate B-drug
, O
estrogens B-group
and O
estrogen-containing B-group
compounds I-group
, O
5-fluorouracil B-drug
, O
furosemide B-drug
, O
glucocorticoids B-group
, O
meclofenamic B-drug
acid I-drug
, O
mefenamic B-drug
acid I-drug
, O
methadone B-drug
, O
perphenazine B-drug
, O
phenylbutazone B-drug
, O
phenytoin B-drug
, O
salicylates B-group
, O
tamoxifen B-drug
. O

Paroxetine B-drug
: O
Coadministration O
of O
once O
daily O
doses O
of O
aprepitant B-drug
, O
as O
a O
tablet O
formulation O
comparable O
to O
85 O
mg O
or O
170 O
mg O
of O
the O
capsule O
formulation O
, O
with O
paroxetine B-drug
20 O
mg O
once O
daily O
, O
resulted O
in O
a O
decrease O
in O
AUC O
by O
approximately O
25 O
% O
and O
Cmax O
, O
by O
approximately O
20 O
% O
of O
both O
aprepitant B-drug
and O
paroxetine B-drug
. O

Sumatriptan B-drug
: O
Sumatriptan B-drug
has O
been O
reported O
to O
cause O
coronary O
artery O
vasospasm O
, O
and O
its O
effect O
could O
be O
additive O
with O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
. O

It O
was O
shown O
that O
neurotensin B-drug_n
antagonized O
evidently O
the O
antinociceptive O
effect O
of O
enkephalins B-drug_n
and O
their O
analogue O
. O

If O
signs O
and O
symptoms O
suggestive O
of O
digoxin B-drug
toxicity O
occur O
when O
enoxacin B-drug
and O
digoxin B-drug
are O
given O
concomitantly O
, O
physicians O
are O
advised O
to O
obtain O
serum O
digoxin B-drug
levels O
and O
adjust O
digoxin B-drug
doses O
appropriately O
. O

Antidiabetic B-group
drugs I-group
( O
oral O
agents O
and O
insulin B-drug
) O
: O
hypoglycemia O
or O
hyperglycemia O
; O

The O
effect O
of O
rifampin B-drug
on O
the O
warfarin B-drug
requirement O
of O
our O
patient O
appeared O
to O
be O
maximal O
5 O
to O
7 O
days O
after O
the O
initiation O
of O
rifampin B-drug
and O
extended O
a O
similar O
length O
of O
time O
after O
rifampin B-drug
withdrawal O
. O

The O
ratio O
between O
the O
liver O
weight O
and O
body O
weight O
was O
found O
to O
be O
lower O
in O
the O
treated O
animals O
than O
in O
the O
control O
group O
. O

Other O
Potentially O
Clinically O
Significant O
Drug O
or O
Herbal O
Product O
Interactions O
With O
SUSTIVAb O

With O
oral O
dapsone B-drug
treatment O
, O
folic B-group
acid I-group
antagonists I-group
such O
as O
pyrimethamine B-drug
have O
been O
noted O
to O
possibly O
increase O
the O
likelihood O
of O
hematologic O
reactions O

Ketoconazole B-drug
increased O
mean O
alosetron B-drug
plasma O
concentrations O
( O
AUC O
) O
by O
29 O
% O
. O

Although O
the O
specific O
drug O
interaction O
was O
not O
studied O
in O
a O
clinical O
trial O
, O
there O
have O
been O
more O
than O
50 O
episodes O
of O
concomitant O
use O
of O
antifibrinolytic O
therapies O
( O
i.e. O
, O
tranexamic B-drug
acid I-drug
, O
aminocaproic B-drug
acid I-drug
) O
and O
NovoSeven B-brand
. O

Urinary O
excretion O
and O
renal O
clearance O
were O
correspondingly O
reduced O
. O

During O
transfer O
to O
oral O
amiodarone B-drug
, O
the O
dose O
levels O
of O
previously O
administered O
agents O
should O
be O
reduced O
by O
30 O
to O
50 O
% O
several O
days O
after O
the O
addition O
of O
oral O
amiodarone B-drug
. O

Ketoconazole B-drug
: O
Coadministration O
of O
ketoconazole B-drug
( O
200 O
mg/day O
for O
14 O
days O
) O
with O
a O
15-mg O
single O
dose O
of O
aripiprazole B-drug
increased O
the O
AUC O
of O
aripiprazole B-drug
and O
its O
active O
metabolite O
by O
63 O
% O
and O
77 O
% O
, O
respectively O
. O

Survanta B-brand
also O
increased O
rate O
of O
dissolution O
, O
in O
a O
manner O
similar O
to O
sodium B-drug_n
dodecyl I-drug_n
sulfate I-drug_n
. O

Since O
drowsiness O
may O
occur O
with O
use O
of O
this O
drug O
, O
patients O
should O
be O
warned O
of O
this O
possibility O
and O
cautioned O
against O
driving O
a O
car O
or O
operating O
dangerous O
machinery O
while O
taking O
Atarax B-brand
. O

Dolasetron B-drug
mesylate I-drug
did O
not O
inhibit O
the O
antitumor O
activity O
of O
four O
chemotherapeutic B-group
agents I-group
( O
cisplatin B-drug
, O
5-fluorouracil B-drug
, O
doxorubicin B-drug
, O
cyclophosphamide B-drug
) O
in O
four O
murine O
models O
. O

Bisphosphonates B-group
are O
known O
to O
interfere O
with O
the O
use O
of O
bone-imaging O
agents O
. O

An O
additive O
hypotensive O
effect O
has O
been O
reported O
with O
the O
combination O
of O
systemic O
clonidine B-drug
and O
neuroleptic B-group
therapy O
. O

Nizatidine B-drug
does O
not O
inhibit O
the O
cytochrome O
P-450-linked O
drug-metabolizing O
enzyme O
system O
; O

Aspirin B-brand
should O
be O
used O
cautiously O
in O
conjunction O
with O
cortico-steroids B-group
in O
patients O
suffering O
from O
hypopro-thrombinemia O
. O

RATIONALE O
: O
Stress O
and O
glucocorticoids B-group
facilitate O
and O
reinstate O
psychostimulant O
self-administration O
in O
rodents O
. O

Methotrexate B-drug
: O
NSAIDs B-group
have O
been O
reported O
to O
competitively O
inhibit O
methotrexate B-drug
accumulation O
in O
rabbit O
kidney O
slices O
. O

However O
, O
co-administration O
of O
Duloxetine B-drug
with O
aluminum- B-drug
and O
magnesium-containing B-drug
antacids B-group
( O
51 O
mEq O
) O
or O
Duloxetine B-drug
with O
famotidine B-drug
, O
had O
no O
significant O
effect O
on O
the O
rate O
or O
extent O
of O
duloxetine B-drug
absorption O
after O
administration O
of O
a O
40-mg O
oral O
dose O
. O

It O
is O
indicated O
that O
the O
first O
and O
second O
contractile O
responses O
to O
PTX B-drug_n
have O
entirely O
different O
properties O
. O

Dopamine O
( O
DA O
) O
levels O
did O
not O
differ O
significantly O
in O
either O
striatum O
( O
STR O
) O
or O
nucleus O
accumbens O
( O
NAC O
) O
for O
the O
cocaine-treated B-drug
animals O
to O
their O
corresponding O
saline-treated O
controls O
. O

Other O
: O
Coadministration O
of O
grapefruit O
juice O
with O
cisapride B-drug
increases O
the O
bioavailability O
of O
cisapride B-drug
and O
concomitant O
use O
should O
be O
avoided O
. O

ACE B-group
inhibitors I-group
: O
Reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
Angiotensin B-group
Converting I-group
Enzyme I-group
( I-group
ACE I-group
) I-group
inhibitors I-group
. O

Similarly O
, O
the O
acute O
toxicity O
was O
also O
diminished O
by O
a O
DMF O
of O
0.74 O
. O

Therefore O
, O
careful O
monitoring O
of O
blood O
glucose O
is O
recommended O
when O
these O
agents O
are O
coadministered O
. O

Drug-drug O
interactions O
In O
vitro O
studies O
using O
human O
liver O
microsomes O
indicate O
that O
fenofibrate B-drug
and O
fenofibric B-drug_n
acid I-drug_n
are O
not O
inhibitors O
of O
cytochrome O
( O
CYP O
) O
P450 O
isoforms O
CYP3A4 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
or O
CYP1A2 O
. O

Drugs O
that O
may O
have O
their O
plasma O
concentration O
altered O
by O
dasatinib B-drug
CYP3A4 O
Substrates O
: O
Dasatinib B-drug
is O
a O
time-dependent O
inhibitor O
of O
CYP3A4 O
. O

Evidence O
for O
reduction O
of O
norepinephrine B-drug
uptake O
sites O
in O
the O
failing O
human O
heart O
. O

metabolizers O
. O

The O
effects O
of O
tricyclic B-group
antidepressants I-group
on O
clonidines B-drug
analgesic O
actions O
are O
not O
known O
. O

All O
subjects O
received O
glipizide B-drug
alone O
and O
following O
treatment O
with O
100 O
mg O
of O
fluconazole B-drug
as O
a O
single O
daily O
oral O
dose O
for O
seven O
days O
. O

Therefore O
FORADIL B-brand
should O
not O
be O
given O
together O
with O
-adrenergic O
blockers O
( O
including O
eye O
drops O
) O
unless O
there O
are O
compelling O
reasons O
for O
their O
use O
. O

In O
addition O
, O
deaths O
have O
been O
reported O
rarely O
with O
concomitant O
administration O
of O
terfenadine B-drug
and O
erythromycin B-drug
. O

It O
reduced O
the O
number O
of O
deaths O
induced O
by O
nonlethal O
( O
2 O
mg/kg O
) O
dose O
of O
endotoxin B-drug_n
but O
increased O
the O
number O
of O
deaths O
induced O
by O
a O
highly O
lethal O
dose O
( O
8 O
mg/kg O
) O
. O

and O
phase O
3 O
( O
days O
45-52 O
) O
: O
cisapride B-drug
10 O
mg O
4 O
times/day O
( O
days O
45-51 O
) O
plus O
fluoxetine B-drug
20 O
mg/day O
( O
days O
45-52 O
) O
. O

Digoxin B-drug
: O
Concomitant O
administration O
of O
tiagabine B-drug
did O
not O
affect O
the O
steady-state O
pharmacokinetics O
of O
digoxin B-drug
or O
the O
mean O
daily O
trough O
serum O
level O
of O
digoxin B-drug
. O

No O
dose O
relationship O
has O
been O
observed O
. O

Acetazolamide B-drug
may O
prevent O
the O
urinary O
antiseptic O
effect O
of O
methenamine B-drug
. O

When O
administered O
concurrently O
, O
the O
following O
drugs O
may O
interact O
with O
amphotericin B-drug
B I-drug
: O
Antineoplastic B-group
agents I-group
: O
may O
enhance O
the O
potential O
for O
renal O
toxicity O
, O
bronchospasm O
and O
hypotension O
. O

The O
last O
4 O
chapters O
cover O
interactions O
with O
drugs O
and O
laboratory O
tests O
, O
common O
side O
effects O
, O
breast O
feeding O
, O
and O
effective O
use O
of O
POCs B-group
. O

Patients O
who O
have O
previously O
received O
pelvic/ O
abdominal O
irradiation O
are O
at O
increased O
risk O
of O
severe O
myelosuppression O
following O
the O
administration O
of O
CAMPTOSAR B-brand
. O

Five O
days O
of O
dofetilide B-drug
treatment O
did O
not O
significantly O
affect O
steady-state O
pharmacokinetic O
variables O
of O
digoxin B-drug
compared O
with O
placebo O
; O

For O
patients O
with O
advanced O
HIV O
disease O
and O
poor-risk O
AIDS-related O
Kaposi O
s O
sarcoma O
, O
TAXOL B-brand
, O
at O
the O
recommended O
dose O
for O
this O
disease O
, O
can O
be O
initiated O
and O
repeated O
if O
the O
neutrophil O
count O
is O
at O
least O
1000 O
cells/mm3 O
. O

If O
co-administration O
is O
essential O
, O
close O
monitoring O
may O
be O
appropriate O
. O

These O
results O
suggest O
that O
the O
analgesic O
effect O
of O
STADOL B-brand
NS I-brand
may O
be O
diminished O
when O
it O
is O
administered O
shortly O
after O
sumatriptan B-drug
nasal O
spray O
, O
but O
by O
30 O
minutes O
any O
such O
reduction O
in O
effect O
should O
be O
minimal O
. O

Clinical O
significance O
of O
reduced O
efavirenz B-drug
concentrations O
unknown O
. O

Acetylsalicylic B-drug
acid I-drug
did O
not O
alter O
the O
clearance O
( O
pharmacokinetics O
) O
of O
iloprost B-drug
. O

Anticoagulants B-group
predispose O
a O
patient O
to O
bleeding O
problems O
. O

Review O
of O
these O
case O
reports O
indicates O
that O
the O
patients O
were O
mainly O
receiving O
thiazide B-group
diuretics I-group
for O
hypertension O
and O
that O
tests O
to O
rule O
out O
decreased O
renal O
function O
secondary O
to O
hypertensive O
nephropathy O
were O
not O
often O
performed O
. O

Inhibitors O
of O
CYP1A2 O
: O
Concomitant O
use O
of O
duloxetine B-drug
with O
fluvoxamine B-drug
, O
an O
inhibitor O
of O
CYP1A2 O
, O
results O
in O
approximately O
a O
6-fold O
increase O
in O
AUC O
and O
about O
a O
2.5-fold O
increase O
in O
Cmax O
of O
duloxetine B-drug
. O

Benzodiazepines B-group
were O
administered O
to O
mice O
30 O
min O
before O
applying O
the O
analgesic B-group
drugs I-group
. O

We O
previously O
reported O
that O
seeds O
of O
Artocarpus O
integrifolia O
( O
jackfruit O
) O
contain O
a O
lectin O
, O
which O
we O
call O
jacalin B-drug_n
, O
that O
is O
both O
a O
potent O
T O
cell O
mitogen O
and O
an O
apparently O
T O
cell-independent O
activator O
of O
human O
B O
cells O
for O
the O
secretion O
of O
immunoglobulins O
. O

Thus O
in O
order O
to O
avoid O
bleeding O
, O
reduced O
dosage O
of O
heparin B-drug
is O
recommended O
during O
treatment O
with O
antithrombin B-drug
III I-drug
( O
human O
) O
. O

Phosphate-Binding O
Agents O
: O
Since O
vitamin B-group
D I-group
also O
has O
an O
effect O
on O
phosphate O
transport O
in O
the O
intestine O
, O
kidneys O
and O
bones O
, O
the O
dosage O
of O
phosphate-binding O
agents O
must O
be O
adjusted O
in O
accordance O
with O
the O
serum O
phosphate O
concentration O
. O

Limited O
clinical O
experience O
indicates O
that O
requirements O
for O
volatile B-group
inhalation I-group
anesthetics I-group
are O
reduced O
by O
30 O
to O
50 O
% O
for O
the O
first O
sixty O
( O
60 O
) O
minutes O
following O
ALFENTA B-brand
induction O
The O
concomitant O
use O
of O
erythromycin B-drug
with O
ALFENTA B-brand
can O
significantly O
inhibit O
ALFENTA B-brand
clearance O
and O
may O
increase O
the O
risk O
of O
prolonged O
or O
delayed O
respiratory O
depression O
. O

The O
clinical O
significance O
of O
this O
finding O
is O
unknown O
. O

When O
paroxetine B-drug
, O
a O
potent O
inhibitor O
of O
CYP2D6 O
, O
was O
co-administered O
with O
BROVANA B-brand
at O
steady-state O
, O
exposure O
to O
either O
drug O
was O
not O
altered O
. O

This O
effect O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
by O
ibuprofen B-drug
. O

While O
additional O
research O
is O
needed O
, O
the O
initial O
clinical O
data O
in O
kidney O
recipients O
suggest O
that O
sirolimus B-drug
, O
in O
combination O
with O
cyclosporine B-drug
or O
tacrolimus B-drug
, O
might O
have O
the O
potential O
to O
reduce O
the O
frequency O
of O
rejection O
episodes O
, O
permit O
reductions O
in O
cyclosporine B-drug
or O
tacrolimus B-drug
dosage O
, O
and O
permit O
steroid O
withdrawal O
( O
Kelly O
, O
1999 O
) O
. O

The O
findings O
of O
these O
studies O
are O
summarized O
in O
the O
following O
table O
: O
Effects O
on O
steady-state O
fexofenadine B-drug
pharmacokinetics O
after O
7 O
days O
of O
co-administration O
with O
fexofenadine B-drug
hydrochloride I-drug
120 O
mg O
every O
12 O
hours O
( O
two O
times O
the O
recommended O
twice O
daily O
dose O
) O
in O
healthy O
volunteers O
( O
n=24 O
) O

Apraclonidine B-drug
should O
not O
be O
used O
in O
patients O
receiving O
MAO B-group
inhibitors.. O

Corticosteroids B-group
: O
A O
relationship O
of O
functional O
antagonism O
exists O
between O
vitamin B-group
D I-group
analogues O
, O
which O
promote O
calcium O
absorption O
, O
and O
corticosteroids B-group
, O
which O
inhibit O
calcium O
absorption O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
performed O
with O
ZEVALIN B-brand
. O

In O
patients O
receiving O
nonselective O
monoamine B-group
oxidase I-group
inhibitors I-group
( O
MAOIs B-group
) O
( O
e.g. O
, O
selegiline B-drug
hydrochloride I-drug
) O
in O
combination O
with O
serotoninergic B-group
agents I-group
( O
e.g. O
, O
fluoxetine B-drug
, O
fluvoxamine B-drug
, O
paroxetine B-drug
, O
sertraline B-drug
, O
venlafaxine B-drug
) O
, O
there O
have O
been O
reports O
of O
serious O
, O
sometimes O
fatal O
, O
reactions O
. O

In O
a O
first O
experiment O
, O
male O
adult O
Wistar O
rats O
were O
fasted O
for O
12 O
h O
. O

In O
a O
study O
with O
concomitant O
administration O
of O
aspirin B-brand
and O
fosinopril B-drug
sodium I-drug
, O
the O
bioavailability O
of O
unbound O
fosinoprilat B-drug_n
was O
not O
altered O
. O

The O
toxicity O
of O
cadmium O
, O
zinc B-drug
and O
cadmium/zinc O
mixtures O
at O
concentrations O
ranging O
from O
1000 O
to O
50000 O
microg/l O
were O
investigated O
against O
cercariae O
and O
metacercariae O
of O
Parorchis O
acanthus O
obtained O
from O
the O
dog O
whelk O
Nucella O
lapillus O
. O

The O
emerging O
roles O
of O
non-nucleoside B-group
reverse I-group
transcriptase I-group
inhibitors I-group
in O
antiretroviral B-group
therapy O
. O

The O
safety O
and O
efficacy O
of O
anakinra B-drug
used O
in O
combination O
with O
HUMIRA B-brand
has O
not O
been O
studied O
. O

Both O
ibogaine B-drug_n
and O
18-MC B-drug_n
ameliorate O
opioid B-group
withdrawal O
signs O
. O

Rofecoxib B-drug
did O
not O
influence O
the O
plasma O
pharmacokinetics O
or O
renal O
elimination O
of O
a O
single O
oral O
dose O
of O
digoxin B-drug
. O

Resting O
membrane O
potential O
, O
input O
impedance O
and O
the O
proportion O
of O
neurons O
displaying O
transient O
outward O
rectification O
were O
each O
significantly O
altered O
for O
neurons O
recorded O
with O
1 O
% O
but O
not O
0.05-0.2 O
% O
biocytin O
. O

Anticholinergic B-group
drugs I-group
may O
antagonize O
the O
effects O
of O
the O
drugs O
that O
alter O
gastrointestinal O
motility O
, O
such O
as O
metoclopramide B-drug
. O

In O
clinical O
trials O
, O
FLOLAN B-brand
was O
used O
with O
digoxin B-drug
, O
diuretics B-group
, O
anticoagulants B-group
, O
oral O
vasodilators B-group
, O
and O
supplemental O
oxygen.In B-drug
a O
pharmacokinetic O
substudy O
in O
patients O
with O
congestive O
heart O
failure O
receiving O
furosemide B-drug
or O
digoxin B-drug
in O
whom O
therapy O
with O
FLOLAN B-brand
was O
initiated O
, O
apparent O
oral O
clearance O
values O
for O
furosemide B-drug
( O
n O
= O
23 O
) O
and O
digoxin B-drug
( O
n O
= O
30 O
) O
were O
decreased O
by O
13 O
% O
and O
15 O
% O
, O
respectively O
, O
on O
the O
second O
day O
of O
therapy O
and O
had O
returned O
to O
baseline O
values O
by O
day O
87 O
. O

The O
changes O
in O
plasma O
levels O
were O
within O
the O
range O
of O
plasma O
levels O
achieved O
in O
adequate O
and O
well-controlled O
clinical O
trials O
. O

. O

In O
an O
uncontrolled O
study O
of O
over O
200 O
patients O
with O
congestive O
heart O
failure O
during O
which O
digoxin B-drug
blood O
levels O
were O
not O
measured O
, O
digitalis O
toxicity O
was O
not O
observed O
. O

Cyclophosphamide B-drug
used O
concurrently O
with O
Cerubidine B-brand
may O
also O
result O
in O
increased O
cardiotoxicity O
. O

Naproxen B-drug
: O
The O
concomitant O
administration O
of O
diflunisal B-drug
and O
naproxen B-drug
in O
normal O
volunteers O
had O
no O
effect O
on O
the O
plasma O
levels O
of O
naproxen B-drug
, O
but O
significantly O
decreased O
the O
urinary O
excretion O
of O
naproxen B-drug
and O
its O
glucuronide O
metabolite O
. O

Drug O
Class O
: O
Drug O
Name O
Clinical O
Comment O

phenobarbital B-drug
reduced O
it O
by O
a O
net O
change O
of O
6.6 O
% O
( O
percentage O
increase O
in O
FDF O
, O
8.5 O
% O
) O
at O
431 O
micromol/L O
. O

No O
clinically O
important O
pharmacokinetic O
interactions O
occurred O
when O
PRINIVIL B-brand
was O
used O
concomitantly O
with O
propranolol B-drug
or O
hydrochlorothiazide B-drug
. O

Experience O
with O
nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
( O
NSAIDs B-group
) O
suggests O
the O
potential O
for O
interactions O
with O
furosemide B-drug
and O
ACE B-group
inhibitors I-group
. O

Drug/Laboratory O
Test O
Interactions O
The O
administration O
of O
cefepime B-drug
may O
result O
in O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
when O
using O
Clinitest O
tablets O
. O

Furosemide B-drug
: O
Clinical O
studies O
, O
as O
well O
as O
random O
observations O
, O
have O
shown O
that O
ibuprofen B-drug
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-drug
and O
thiazides B-group
in O
some O
patients O
. O

Aminoglutethimide B-drug
diminishes O
the O
effect O
of O
coumarin B-group
and O
warfarin B-drug
. O

There O
was O
no O
effect O
of O
ZEBETA B-brand
on O
prothrombin O
time O
in O
patients O
on O
stable O
doses O
of O
warfarin B-drug
. O

To O
avoid O
potentiation O
, O
the O
physician O
wishing O
to O
terminate O
treatment O
with O
Isocarboxazid B-drug
and O
begin O
therapy O
with O
another O
agent O
should O
allow O
for O
an O
interval O
of O
10 O
days O
. O

Studies O
in O
healthy O
volunteers O
have O
shown O
that O
Acarbose B-drug
has O
no O
effect O
on O
either O
the O
pharmacokinetics O
or O
pharmacodynamics O
of O
digoxin B-drug
, O
nifedipine B-drug
, O
propranolol B-drug
, O
or O
ranitidine B-drug
. O

CONCLUSIONS O
: O
Sildenafil B-drug
is O
an O
effective O
first-line O
therapy O
for O
erectile O
dysfunction O
in O
men O
. O

Monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
such O
as O
isocarboxazid B-drug
( O
e.g. O
, O
Marplan B-brand
) O
, O
phenelzine B-drug
( O
e.g. O
, O
Nardil B-brand
) O
, O
procarbazine B-drug
( O
e.g. O
, O
Matulane B-brand
) O
, O
selegiline B-drug
( O
e.g. O
, O
Eldepryl B-brand
) O
, O
and O
tranylcypromine B-drug
( O
e.g. O
, O
Parnate B-brand
) O
: O
Using O
these O
medicines O
with O
L-tryptophan B-drug
may O
increase O
the O
chance O
of O
side O
effects O
. O

Furthermore O
, O
whenever O
one O
of O
these O
other O
drugs O
is O
withdrawn O
from O
co-therapy O
, O
an O
increased O
dose O
of O
tricyclic B-drug
antidepressant I-drug
may O
be O
required O
. O

These O
in O
vitro O
studies O
suggest O
that O
concomitant O
administration O
of O
zalcitabine B-drug
and O
lamivudine B-drug
in O
humans O
may O
result O
in O
sub-therapeutic O
concentrations O
of O
active O
phosphorylated O
zalcitabine B-drug
, O
which O
may O
lead O
to O
a O
decreased O
antiretroviral B-group
effect O
of O
zalcitabine B-drug
. O

CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
prolonged O
or O
increased O
sedation O
or O
respiratory O
depression O
. O

Pancreatic O
content O
after O
perfusion O
did O
not O
correlate O
with O
release O
during O
perfusion O
. O

Patients/Guardians O
should O
be O
given O
the O
following O
information O
: O
i O
. O

Epidemiological O
studies O
of O
the O
case-control O
and O
cohort O
design O
that O
have O
demonstrated O
an O
association O
between O
use O
of O
psychotropic B-group
drugs I-group
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
upper O
gastrointestinal O
bleeding O
have O
also O
shown O
that O
concurrent O
use O
of O
an O
NSAID B-group
or O
aspirin B-brand
potentiated O
the O
risk O
of O
bleeding O
. O

Carbamazepine B-drug

Plasma O
concentrations O
( O
AUC O
0-24 O
hrs O
) O
of O
erythromycin B-drug
decreased O
15 O
% O
with O
coadministration O
of O
loratadine B-drug
relative O
to O
that O
observed O
with O
erythromycin B-drug
alone O
. O

Relative O
to O
the O
general O
population O
, O
plasma O
concentrations O
of O
fluvastatin B-drug
do O
not O
vary O
as O
a O
function O
of O
either O
age O
or O
gender O
. O

Patients O
who O
are O
applying O
Panretin B-brand
gel O
should O
not O
concurrently O
use O
products O
that O
contain O
DEET B-drug
( O
N O
, O
N-diethyl-m-toluamide B-drug
) O
, O
a O
common O
component O
of O
insect O
repellent O
products O
. O

- O
Alcohol B-drug
, O
barbiturates B-group
, O
or O
narcotics B-group
: O
Potentiation O
of O
otthostatic O
hypotension O
may O
occur O

The O
concomitant O
use O
of O
alcohol B-drug
or O
other O
central B-group
nervous I-group
system I-group
depressants I-group
may O
have O
an O
additive O
effect O
. O

Fluconazole B-drug

Therefore O
, O
serum O
levels O
of O
methotrexate B-drug
should O
be O
monitored O
in O
patients O
to O
avoid O
drug O
toxicity O
. O

Therefore O
, O
if O
concomitant O
use O
of O
such O
agents O
is O
indicated O
, O
they O
should O
be O
given O
with O
caution O
, O
and O
the O
patients O
serum O
potassium O
should O
be O
monitored O
frequently O
. O

Nelfinavir B-drug

The O
results O
generated O
to O
date O
in O
clinical O
pharmacokinetic O
studies O
with O
fluvastatin B-drug
thus O
support O
its O
use O
in O
a O
broad O
population O
of O
hypercholesterolaemic O
patients O
. O

Ritonavir B-drug
significantly O
prolonged O
the O
half-life O
of O
vardenafil B-drug
to O
26 O
hours O
. O

In O
separate O
studies O
of O
patients O
receiving O
maintenance O
doses O
of O
warfarin B-drug
, O
hydrochlorothiazide B-drug
, O
or O
digoxin B-drug
, O
irbesartan B-drug
administration O
for O
7 O
days O
had O
no O
effect O
on O
the O
pharmacodynamics O
of O
warfarin B-drug
( O
prothrombin O
time O
) O
or O
pharmacokinetics O
of O
digoxin B-drug
. O

Concurrent O
administration O
of O
oxyphenbutazone B-drug
and O
androgens B-group
may O
result O
in O
elevated O
serum O
levels O
of O
oxyphenbutazone B-drug
. O

Potentiation O
occurs O
with O
ganglionic O
or O
peripheral B-group
adrenergic I-group
blocking I-group
drugs I-group
. O

The O
metabolism O
of O
saquinavir B-drug
is O
mediated O
by O
cytochrome O
P450 O
, O
with O
the O
specific O
isoenzyme O
CYP3A4 O
responsible O
for O
90 O
% O
of O
the O
hepatic O
metabolism O
. O

Inhibitors O
of O
CYP3A4-Eplerenone B-drug
metabolism O
is O
predominantly O
mediated O
via O
CYP3A4 O
. O

Like O
isoflurane B-drug
, O
desflurane B-drug
does O
not O
predispose O
to O
premature O
ventricular O
arrhythmias O
in O
the O
presence O
of O
exogenously O
infused O
epinephrine B-drug
in O
swine O
. O

( O
May O
inhibit O
gastrointestinal O
absorption O
of O
the O
thiazide B-group
diuretics I-group
; O

No O
dose O
adjustment O
of O
SUSTIVA B-brand
is O
recommended O
when O
given O
with O
clarithromycin B-drug
. O

By O
contrast O
, O
spermidine B-drug_n
( O
1 O
mM O
) O
and O
putrescine B-drug_n
( O
1 O
mM O
) O
had O
no O
significant O
effect O
on O
the O
translocation O
when O
added O
alone O
. O

Antidepressants B-group
: O
In O
vitro O
data O
indicate O
that O
nefazodone B-drug
inhibits O
the O
metabolism O
of O
cisapride B-drug
, O
which O
can O
result O
in O
an O
increase O
in O
plasma O
cisapride B-drug
levels O
and O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

In O
this O
study O
we O
investigated O
whether O
also O
glycine B-drug
fulfils O
the O
function O
as O
co-activator O
in O
glutamatergic O
activation O
of O
NMDA O
receptors O
in O
the O
neuronal O
apparatus O
of O
spontaneous O
motility O
in O
chick O
embryos O
. O

Treatment O
of O
RAS-3T3 O
cells O
with O
nucleophosmin/B23 O
antisense O
oligomer O
significantly O
potentiated O
the O
apoptosis O
induced O
by O
serum O
deprivation O
. O

However O
, O
when O
addiction O
is O
defined O
as O
compulsion O
, O
loss O
of O
control O
and O
continued O
use O
in O
spite O
of O
adverse O
consequences O
, O
cocaine B-drug
drug O
hunger O
can O
be O
seen O
as O
an O
agent O
of O
addictive O
disease O
. O

Micro-dosed O
Progesterone B-drug
Preparations O
: O
Micro-dosed O
progesterone B-drug
preparations O
( O
minipills O
that O
do O
not O
contain O
an O
estrogen B-group
) O
may O
be O
an O
inadequate O
method O
of O
contraception O
during O
Accutane B-brand
therapy O
. O

. O

The O
use O
of O
NUROMAX B-brand
before O
succinylcholine B-drug
to O
attenuate O
some O
of O
the O
side O
effects O
of O
succinylcholine B-drug
has O
not O
been O
studied O
. O

Drug-drug O
interactions O
with O
Mefloquine B-drug
have O
not O
been O
explored O
in O
detail O
. O

indinavir I-drug
concentration O

Dopamine-induced B-drug
renal O
and O
mesenteric O
vasodilation O
is O
not O
antagonized O
by O
either O
alpha- O
or O
beta-adrenergic B-group
blocking B-drug
agents I-drug
. O

These O
results O
suggest O
that O
acute O
dosing O
with O
clozapine B-drug
would O
not O
affect O
behaviors O
most O
closely O
associated O
with O
PCP B-drug_n
intoxication O
. O

In O
clinical O
trials O
, O
similar O
changes O
in O
carbamazepine B-drug
and O
carbamazepine B-drug_n
epoxide I-drug_n
were O
seen O
. O

However O
, O
it O
has O
been O
established O
that O
acitretin B-drug
interferes O
with O
the O
contraceptive O
effect O
of O
microdosed O
progestin B-drug
minipill O
preparations O
. O

quinidine B-drug
; O

Statistically O
significant O
changes O
in O
prothrombin O
and O
partial O
thromboplastin O
times O
have O
been O
reported O
in O
normal O
volunteers O
. O

Persons O
taking O
most O
antibiotics B-group
, O
methotrexate B-drug
and O
pyrimethamine B-drug
invalidate O
folic B-drug
acid I-drug
and O
vitamin B-drug
B12 I-drug
diagnostic O
blood O
assays O
. O

Other O
plasma O
proteins O
may O
be O
increased O
( O
angiotensinogen/renin O
substrate O
, O
alpha-1-antitrypsin O
, O
ceruloplasmin O
) O
. O

use O
caution O
. O

DRUG/LABORATORY O
TEST O
INTERACTIONS O
: O
EFFECT O
ON O
BLOOD O
COAGULATION O
Ketoprofen B-drug
decreases O
platelet O
adhesion O
and O
aggregation O
. O

Even O
when O
an O
aminoglycoside B-group
and O
a O
penicillin-type B-group
drug O
are O
administered O
separately O
by O
different O
routes O
, O
a O
reduction O
in O
aminoglycoside B-group
serum O
half-life O
or O
serum O
levels O
has O
been O
reported O
in O
patients O
with O
impaired O
renal O
function O
and O
in O
some O
patients O
with O
normal O
renal O
function O
. O

Therefore O
, O
administration O
of O
quinolones B-group
with O
antacids B-group
containing O
calcium B-drug
, O
magnesium B-drug
, O
or O
aluminum B-drug
; O

Substances O
that O
are O
potent O
inhibitors O
of O
CYP3A4 O
activity O
( O
eg O
, O
ketoconazole B-drug
and O
itraconazole B-drug
) O
decrease O
gefitinib B-drug
metabolism O
and O
increase O
gefitinib B-drug
plasma O
concentrations O
. O

Beta-adrenergic B-group
blocking I-group
agents I-group
: O
concurrent O
use O
may O
blunt O
the O
response O
to O
arbutamine B-drug
. O

2 O
. O

Rifampin B-drug
: O
Co-administration O
of O
VIOXX B-brand
with O
rifampin B-drug
600 O
mg O
daily O
, O
a O
potent O
inducer O
of O
hepatic O
metabolism O
, O
produced O
an O
approximate O
50 O
% O
decrease O
in O
rofecoxib B-drug
plasma O
concentrations O
. O

Certain O
endocrine O
and O
liver O
function O
tests O
may O
be O
affected O
by O
estrogen-containing B-group
oral O
contraceptives B-group
. O

Caution O
should O
be O
exercised O
with O
simultaneous O
use O
of O
clonidine B-drug
and O
other O
similar O
pharmacologic O
agents O

Aspirin B-brand
: O
Concomitant O
administration O
of O
low-dose O
aspirin B-brand
with O
VIOXX B-brand
may O
result O
in O
an O
increased O
rate O
of O
GI O
ulceration O
or O
other O
complications O
, O
compared O
to O
use O
of O
VIOXX B-brand
alone O
. O

Although O
additional O
drug O
interaction O
studies O
have O
not O
been O
conducted O
, O
the O
most O
common O
medications O
used O
concomitantly O
with O
anagrelide B-drug
in O
clinical O
trials O
were O
aspirin B-brand
, O
acetaminophen B-drug
, O
furosemide B-drug
, O
iron B-drug
, O
ranitidine B-drug
, O
hydroxyurea B-drug
, O
and O
allopurinol B-drug
. O

Drug O
Class O
: O
Drug O
Name O
Clinical O
Comment O

VIRACEPT B-brand
and O
rifampin B-drug
should O
not O
be O
coadministered O
. O

Potential O
Terfenadine B-drug
, O
Astemizole B-drug
, O
and O
Cisapride B-drug
Interactions O

The O
pharmacokinetics O
of O
praziquantel B-drug
were O
unchanged O
following O
coadministration O
with O
albendazole B-drug
( O
400 O
mg O
) O
. O

- O
Reduced O
serum O
folate O
concentration O

Concurrent O
administration O
of O
dyphylline B-drug
and O
probenecid B-drug
, O
which O
competes O
for O
tubular O
secretion O
, O
has O
been O
shown O
to O
increase O
the O
plasma O
half-life O
of O
dyphylline B-drug
. O

H-2 O
Antagonists O
: O
In O
studies O
with O
human O
volunteers O
, O
co-administration O
of O
cimetidine B-drug
or O
ranitidine B-drug
with O
ibuprofen B-drug
had O
no O
substantive O
effect O
on O
ibuprofen B-drug
serum O
concentrations O
. O

dextran B-drug
; O

Caution O
should O
be O
exercised O
when O
administering O
nabumetone B-drug
with O
warfarin B-drug
since O
interactions O
have O
been O
seen O
with O
other O
NSAIDs B-group
. O

Drugs O
that O
reportedly O
may O
increase O
oral O
anticoagulant B-group
response O
, O
ie O
, O
increased O
prothrombin O
response O
, O
in O
man O
include O
: O
alcohol* B-drug
; O
allopurinol B-drug
; O
aminosalicylic B-drug
acid I-drug
; O
amiodarone B-drug
; O
anabolic B-group
steroids I-group
; O
antibiotics B-group
; O
bromelains B-drug
; O
chloral B-drug
hydrate* O
; O
chlorpropamide B-drug
; O
chymotrypsin B-drug
; O
cimetidine B-drug
; O
cinchophen B-drug
; O
clofibrate B-drug
; O
dextran B-drug
; O
dextrothyroxine B-drug
; O
diazoxide B-drug
; O
dietary O
deficiencies O
; O
diflunisal B-drug
; O
disulfiram B-drug
; O
drugs O
affecting O
blood O
elements O
; O
ethacrynic B-drug
acid I-drug
; O
fenoprofen B-drug
; O
glucagon B-drug
; O
hepatotoxic O
drugs O
; O
ibuprofen B-drug
; O
indomethacin B-drug
; O
influenza B-group
virus I-group
vaccine I-group
; O
inhalation O
anesthetics B-group
; O
mefenamic B-drug
acid I-drug
; O
methyldopa B-drug
; O
methylphenidate B-drug
; O
metronidazole B-drug
; O
miconazole B-drug
; O
monoamine B-group
oxidase I-group
inhibitors I-group
; O
nalidixic B-drug
acid I-drug
; O
naproxen B-drug
; O
oxolinic B-drug
acid I-drug
; O
oxyphenbutazone B-drug
; O
pentoxifylline B-drug
; O
phenylbutazone B-drug
; O
phenyramidol B-drug_n
; O
phenytoin B-drug
; O
prolonged O
hot O
weather O
; O
prolonged B-group
narcotics I-group
; O
pyrazolones B-group
; O
quinidine B-drug
; O
quinine B-drug
; O
ranitidine* B-drug
; O
salicylates B-group
; O
sulfinpyrazone B-drug
; O
sulfonamides B-group
, O
long O
acting O
; O
sulindac B-drug
; O
thyroid B-group
drugs I-group
; O
tolbutamide B-drug
; O
triclofos B-drug
sodium I-drug
; O
trimethoprim/sulfamethoxazole B-drug
; O
unreliable O
prothrombin O
time O
determinations O
; O
warfarin B-drug
sodium I-drug
overdosage O
. O

Nephrotoxicity O
frequently O
limits O
the O
dose O
of O
cisplatin B-drug
to O
less O
than O
120 O
mg/m2 O
per O
injection O
. O

If O
isradipine B-drug
therapy O
is O
initiated O
in O
a O
patient O
currently O
receiving O
cimetidine B-drug
careful O
monitoring O
for O
adverse O
reactions O
is O
advised O
and O
downward O
dose O
adjustment O
may O
be O
required O
. O

Long O
Acting O
Nitrates B-group
: O
Nifedipine B-drug
may O
be O
safely O
co-administered O
with O
nitrates B-group
, O
but O
there O
have O
been O
no O
controlled O
studies O
to O
evaluate O
the O
antianginal O
effectiveness O
of O
this O
combination O
. O

These O
steps O
include O
regular O
reevaluations O
of O
dosages O
and O
plasma O
drug O
concentrations O
, O
recognition O
and O
understanding O
of O
drug O
side O
effects O
, O
and O
avoidance O
of O
certain O
agents O
. O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-group
concomitantly O
with O
ACE B-group
inhibitors I-group
. O

In O
addition O
, O
based O
on O
the O
population O
pharmacokinetics O
analysis O
of O
the O
combined O
data O
from O
grapefruit O
and O
orange O
juices O
studies O
with O
the O
data O
from O
a O
bioequivalence O
study O
, O
the O
bioavailability O
of O
fexofenadine B-drug
was O
reduced O
by O
36 O
% O
. O

Agents O
that O
Induce O
Cytochrome O
P450 O
Isoenzymes O
Carbamazepine B-drug
is O
metabolized O
by O
CYP3A4 O
. O

All O
77 O
strains O
of O
Staphylococcus O
aureus O
, O
Diplococcus O
pneumoniae O
, O
Streptococcus O
pyogenes O
, O
and O
anaerobic O
bacteria O
( O
except O
for O
three O
strains O
of O
Clostridium O
) O
were O
inhibited O
by O
1.6 O
mug O
or O
less O
of O
clindamycin B-drug
per O
ml O
. O

Several O
tricyclic B-group
antidepressants I-group
have O
been O
reported O
to O
block O
the O
pharmacologic O
effects O
of O
guanethidine B-drug
, O
clonidine B-drug
, O
or O
similar O
agents O
, O
and O
such O
an O
effect O
may O
be O
anticipated O
with O
CMI B-drug
because O
of O
its O
structural O
similarity O
to O
other O
tricyclic B-group
antidepressants I-group
. O

The O
consumption O
of O
alcohol B-drug
during O
treatment O
with O
WELLBUTRIN B-brand
should O
be O
minimized O
or O
avoided O
( O
also O
see O
a O
href= O
bupropz_od.htm O
# O
CI O
CONTRAINDICATIONS O
) O

Intravenous O
infusion O
of O
iloprost B-drug
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
digoxin B-drug
. O

Zalcitabine B-drug
also O
has O
no O
significant O
effect O
on O
the O
intracellular O
phosphorylation O
of O
ZDV B-drug
, O
as O
shown O
in O
vitro O
in O
peripheral O
blood O
mononuclear O
cells O
or O
in O
two O
other O
cell O
lines O
( O
U937 O
and O
Molt-4 O
) O
. O

- O
Mercaptopurine B-drug
( O
e.g. O
, O
Purinethol B-brand
) O
or O

Therefore O
, O
patients O
under O
methotrexate B-drug
therapy O
should O
be O
carefully O
monitored O
when O
concomitant O
ciprofloxacin B-drug
therapy O
is O
indicated O
. O

Additionally O
, O
aripiprazole B-drug
and O
dehydroaripiprazole B-drug_n
did O
not O
show O
potential O
for O
altering O
CYP1A2-mediated O
metabolism O
in O
vitro O
. O

75 O
years O
of O
age O
. O

The O
use O
of O
FLUDARA B-brand
FOR O
INJECTION O
in O
combination O
with O
pentostatin B-drug
is O
not O
recommended O
due O
to O
the O
risk O
of O
severe O
pulmonary O
toxicity O
. O

The O
homodimeric O
disintegrin O
contortrostatin B-drug_n
was O
compared O
directly O
to O
the O
monomeric O
disintegrins O
echistatin B-drug_n
and O
flavoridin B-drug_n
for O
the O
ability O
to O
affect O
protein O
tyrosine O
phosphorylation O
in O
tumor O
cells O
. O

Extreme O
caution O
should O
be O
exercised O
when O
administering O
TAXOL B-brand
to O
such O
patients O
, O
with O
dose O
reduction O
as O
recommended O
in O
DOSAGE O
AND O
ADMINISTRATION O
, O
Table O
17 O
. O

The O
carcinogenic O
potential O
of O
ribavirin B-drug
has O
not O
been O
fully O
determined O
. O

Warfarin B-drug
: O
Quinolones B-group
may O
enhance O
the O
effects O
of O
the O
oral O
anticoagulant B-group
, O
warfarin B-drug
, O
or O
its O
derivatives O
. O

however O
, O
it O
is O
considered O
to O
be O
unlikely O
that O
this O
decrease O
of O
phosphorylated O
lamivudine B-drug
concentration O
is O
of O
clinical O
significance O
, O
as O
lamivudine B-drug
is O
a O
more O
efficient O
substrate O
for O
deoxycytidine O
kinase O
than O
zalcitabine B-drug
. O

Therefore O
, O
when O
EDECRIN B-brand
and O
non- B-group
steroidal I-group
anti- I-group
inflammatory I-group
agents I-group
are O
used O
concomitantly O
, O
the O
patient O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
effect O
of O
the O
diuretic B-group
is O
obtained O
. O

Cardiovascular O
disease O
is O
considered O
in O
the O
next O
chapter O
, O
and O
chapter O
7 O
presents O
findings O
on O
endometrial O
, O
ovarian O
, O
cervical O
, O
breast O
, O
and O
other O
cancers O
. O

aeruginosa O
as O
common O
pathogens O
of O
drug O
addicts O
in O
areas O
where O
abuse O
of O
this O
combination O
of O
drugs O
has O
increased O
. O

Antihypertensive B-group
Medications O
and O
Vasodilators B-group
: O
The O
following O
adverse O
events O
were O
experienced O
more O
commonly O
in O
patients O
receiving O
concomitant O
antihypertensive B-group
medications I-group
or O
vasodilators B-group
( O
n O
= O
94 O
) O
compared O
to O
patients O
not O
receiving O
these O
concomitant O
drugs O
( O
n O
= O
456 O
) O
: O
hypotension O
10 O
% O
vs O
4 O
% O
, O
myocardial O
infarction O
3 O
% O
vs O
1 O
% O
, O
serious O
pneumonia O
5 O
% O
vs O
3 O
% O
, O
serious O
falls O
9 O
% O
vs O
3 O
% O
, O
and O
bone O
and O
joint O
injuries O
6 O
% O
vs O
2 O
% O
. O

Antacids B-group
( O
aluminum- B-drug
or O
magnesium-containing B-drug
) O
: O
Concomitant O
administration O
of O
300-mg O
cefdinir B-drug
capsules O
with O
30 O
mL O
Maalox B-brand
TC I-brand
suspension O
reduces O
the O
rate O
( O
Cmax O
) O
and O
extent O
( O
AUC O
) O
of O
absorption O
by O
approximately O
40 O
% O
. O

Acetazolamide B-drug
may O
increase O
or O
decrease O
blood O
glucose O
levels O
. O

Etodolac B-drug
is O
characterised O
by O
a O
high O
oral O
bioavailability O
, O
low O
clearance O
, O
a O
small O
volume O
of O
distribution O
, O
and O
a O
7-hour O
half-life O
. O

Antacids B-group
or O
sucralfate B-drug
substantially O
interfere O
with O
the O
absorption O
of O
some O
quinolones B-group
, O
resulting O
in O
low O
urine O
levels O
. O

amiodarone B-drug
; O

Effects O
of O
GABITRIL B-brand
on O
other O
Antiepilepsy O
Drugs O
( O
AEDs B-group
) O
: O
Phenytoin B-drug
: O
Tiagabine B-drug
had O
no O
effect O
on O
the O
steady-state O
plasma O
concentrations O
of O
phenytoin B-drug
in O
patients O
with O
epilepsy O
. O

It O
is O
not O
known O
whether O
AMEVIVE B-brand
is O
excreted O
in O
human O
milk O
. O

When O
prescribing O
for O
older O
patients O
, O
some O
physicians O
are O
overly O
cautious O
, O
and O
this O
strategy O
can O
result O
in O
a O
less O
than O
optimal O
treatment O
outcome O
. O

Long-term O
studies O
are O
needed O
to O
determine O
whether O
the O
insulin-sensitizing O
effects O
of O
the O
glitazones B-group
can O
prevent O
or O
delay O
premature O
atherosclerotic O
cardiovascular O
disease O
, O
morbidity O
, O
and O
death O
. O

. O

Low O
initial O
dosing O
and O
small O
gradual O
dose O
increases O
should O
be O
employed O
. O

Etodolac B-drug
is O
highly O
protein O
bound O
. O

Caution O
should O
be O
used O
when O
coadministering O
medications O
that O
are O
substrates O
, O
inhibitors O
, O
or O
inducers O
of O
CYP3A4 O
, O
or O
potentially O
toxic O
medications O
that O
are O
metabolized O
by O
CYP3A4 O
. O

Of O
particular O
importance O
, O
sufficient O
time O
must O
elapse O
before O
initiating O
TCAtreatment B-group
in O
a O
patient O
being O
withdrawn O
from O
fluoxetine B-drug
, O
given O
the O
long O
half-life O
of O
the O
parent O
and O
active O
metabolite O
( O
at O
least O
5 O
weeks O
may O
be O
necessary O
) O
. O

In O
some O
cases O
where O
serious O
ventricular O
arrhythmias O
, O
QT O
prolongation O
, O
and O
torsades O
de O
pointes O
have O
occurred O
when O
cisapride B-drug
was O
taken O
in O
conjunction O
with O
one O
of O
the O
cytochrome O
P450 O
3A4 O
inhibitors O
, O
elevated O
blood O
cisapride B-drug
levels O
were O
noted O
at O
the O
time O
of O
the O
QT O
prolongation O
. O

After O
stopping O
Fluvoxamine B-drug
Tablets O
, O
at O
least O
2 O
weeks O
should O
be O
allowed O
before O
starting O
a O
MAOI B-group
. O

cardiovascular O
effects O
can O
be O
potentiated O
. O

When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
tests O
should O
be O
closely O
monitored O
. O

These O
results O
, O
together O
with O
the O
known O
relationships O
between O
estrogen B-group
and O
the O
immune O
response O
, O
suggest O
that O
estrogens B-group
affect O
the O
course O
of O
septic O
shock O
in O
a O
complex O
fashion O
and O
may O
have O
either O
protective O
or O
deleterious O
effect O
. O

Warfarin B-drug
: O
When O
fluvoxamine B-drug
maleate I-drug
( O
50 O
mg O
tid O
) O
was O
administered O
concomitantly O
with O
warfarin B-drug
for O
two O
weeks O
, O
warfarin B-drug
plasma O
concentrations O
increased O
by O
98 O
% O
and O
prothrombin O
times O
were O
prolonged O
. O

Nonketotic O
, O
genetically O
diabetic O
Cinese O
hamsters O
show O
subnormal O
pancreatic O
insulin O
release O
and O
impaired O
suppression O
of O
glucagon O
in O
response O
to O
glucose O
. O

If O
a O
patient O
requires O
TIKOSYN B-brand
and O
anti-ulcer B-group
therapy O
, O
it O
is O
suggested O
that O
omeprazole B-drug
, O
ranitidine B-drug
, O
or B-drug
antacids B-group
( O
aluminum O
and O
magnesium B-drug
hydroxides O
) O
be O
used O
as O
alternatives O
to O
cimetidine B-drug
, O
as O
these O
agents O
have O
no O
effect O
on O
the O
pharmacokinetic O
profile O
of O
TIKOSYN B-brand
. O

Altered O
mental O
status O
in O
an O
adolescent O
presents O
a O
diagnostic O
challenge O
, O
and O
the O
clinician O
depends O
on O
clinical O
evaluation O
and O
laboratory O
studies O
to O
determine O
therapy O
and O
prognosis O
. O

This O
increased O
incidence O
of O
atherosclerotic O
disease O
is O
intricately O
associated O
with O
insulin O
resistance O
, O
which O
is O
a O
major O
pathophysiologic O
abnormality O
in O
type O
2 O
diabetes O
. O

Twenty-four O
h O
exposures O
of O
fully O
formed O
cysts O
had O
no O
effect O
on O
excystment O
in O
vitro O
. O

Co-administration O
of O
atorvastatin B-drug
resulted O
in O
about O
a O
50 O
% O
increase O
in O
aliskiren B-drug
Cmax O
and O
AUC O
after O
multiple O
dosing O
. O

The O
clinical O
relevance O
of O
this O
in O
vitro O
finding O
is O
unknown O
. O

As O
with O
other O
antipsychotic B-group
agents I-group
, O
it O
should O
be O
noted O
that O
HALDOL B-brand
may O
be O
capable O
of O
potentiating O
CNS B-group
depressants I-group
such O
as O
anesthetics B-group
, O
opiates B-group
, O
and O
alcohol B-drug
. O

Clinical O
trials O
of O
such O
combinations O
should O
be O
accompanied O
by O
detailed O
pharmacokinetic O
evaluation O
. O

Beta-adrenergic B-group
blocking I-group
agents I-group
should O
be O
withdrawn O
at O
least O
48 O
hours O
before O
conducting O
an O
arbutamine-mediated B-drug
stress O
test O
. O

Of O
the O
remaining O
cases O
, O
two O
were O
cardiac O
, O
two O
hepatic O
and O
the O
rest O
were O
mixed O
drug O
overdose O
. O

Loop B-group
Diuretics I-group
: O
Furosemide B-drug
administered O
concurrently O
with O
captopril B-drug
does O
not O
alter O
the O
pharmacokinetics O
of O
captopril B-drug
in O
renally O
impaired O
hypertensive O
patients O
. O

Preliminary O
data O
which O
suggest O
that O
dapsone B-drug
may O
inhibit O
the O
anti-inflammatory O
activity O
of O
Lamprene B-brand
have O
not O
been O
confirmed O
. O

Other O
drugs O
which O
may O
enhance O
the O
neuromuscular O
blocking O
action O
of O
nondepolarizing O
agents O
such O
as O
NUROMAX B-brand
include O
certain O
antibiotics B-group
( O
e. O
g. O
, O
aminoglycosides B-group
, O
tetracyclines B-group
, O
bacitracin B-group
, O
polymyxins B-group
, O
lincomycin B-drug
, O
clindamycin B-drug
, O
colistin B-drug
, O
and O
sodium B-drug
colistimethate I-drug
) O
, O
magnesium B-drug
salts O
, O
lithium B-drug
, O
local O
anesthetics B-group
, O
procainamide B-drug
, O
and O
quinidine B-drug
. O

No O
differences O
in O
adverse O
events O
or O
QTc O
interval O
were O
observed O
when O
subjects O
were O
administered O
fexofenadine B-drug
hydrochloride I-drug
alone O
or O
in O
combination O
with O
either O
erythromycin B-drug
or O
ketoconazole B-drug
. O

Ergotamine B-drug

Aminosalicylic B-drug
acid I-drug
may O
also O
decrease O
the O
absorption O
of O
vitamin B-drug
B12 I-drug
, O
which O
can O
lead O
to O
a O
deficiency O
. O

Increasing O
the O
felbamate B-drug
dose O
to O
2400 O
mg/day O
increased O
the O
steadystate O
valproate B-drug
Cmin O
to O
96 O
25 O
micrograms/mL O
. O

St. O
John O
s O
Wort O
should O
be O
avoided O
while O
taking O
this O
medicine O
due O
to O
the O
additive O
effects O
of O
serotonin O
. O

Accordingly O
, O
careful O
patient O
monitoring O
and O
dose O
adjustment O
of O
metformin B-drug
is O
recommended O
in O
patients O
concomitantly O
taking O
cephalexin B-drug
and O
metformin B-drug
. O

Read O
circulars O
for O
lithium B-drug
preparations O
before O
use O
of O
such O
concomitant O
therapy O
. O

In O
two O
controlled O
crossover O
clinical O
pharmacology O
studies O
in O
healthy O
male O
( O
n=12 O
in O
each O
study O
) O
a O
nd O
female O
( O
n=12 O
in O
each O
study O
) O
volunteers O
, O
desloratadine B-drug
7.5 O
mg O
( O
1.5 O
times O
the O
daily O
dose O
) O
once O
daily O
was O
coadministered O
with O
erythromycin B-drug
500 O
mg O
every O
8 O
hours O
or O
ketoconazole B-drug
200 O
mg O
every O
12 O
hours O
for O
10 O
days O
. O

reproductive O
tract O
infections O
; O

If O
iron B-group
supplements I-group
are O
required O
during O
OMNICEF B-brand
therapy O
, O
OMNICEF B-brand
should O
be O
taken O
at O
least O
2 O
hours O
before O
or O
after O
the O
supplement O
. O

Women O
of O
childbearing O
potential O
make O
up O
a O
considerable O
segment O
of O
the O
patient O
population O
affected O
by O
psoriasis O
. O

Generally O
, O
this O
phenomenon O
has O
not O
been O
associated O
with O
other O
clinically O
significant O
events O
. O

. O

Methotrexate B-drug
: O
Concomitant O
administration O
of O
methotrexate B-drug
and O
some O
NSAIDs B-group
has O
been O
reported O
to O
reduce O
the O
clearance O
of O
methotrexate B-drug
, O
enhancing O
the O
toxicity O
of O
methotrexate B-drug
. O

Digitalis B-group
: O
Vitamin B-group
D I-group
dosage O
must O
be O
determined O
with O
care O
in O
patients O
undergoing O
treatment O
with O
digitalis B-group
, O
as O
hypercalcemia O
in O
such O
patients O
may O
precipitate O
cardiac O
arrhythmias O
. O

include O
terfenadine B-drug
, O
astemizole B-drug
, O
cisapride B-drug
, O
midazolam B-drug
, O
and O
triazolam B-drug
. O

Stimulation O
of O
the O
glands O
with O
carbachol B-drug
synergistically O
augmented O
the O
response O
to O
dibutyryl O
cAMP O
. O

There O
were O
no O
clinically O
significant O
drug O
interactions O
for O
any O
of O
these O
drugs O

Caution O
should O
be O
observed O
when O
anileridine B-drug
is O
coadministered O
with O
other O
opioids B-group
, O
sedatives B-group
, O
phenothiazines B-group
, O
or O
anesthetics B-group
, O
as O
these O
agents O
may O
increase O
respiratory O
and O
circulatory O
depression O
. O

However O
, O
no O
adverse O
effects O
on O
fertility O
were O
observed O
in O
male O
Rhesus O
monkeys O
treated O
with O
non-pegylated B-drug
interferon I-drug
alfa-2a I-drug
for O
5 O
months O
at O
doses O
up O
to O
25 O
x O
106 O
IU/kg/day O
. O

The O
most O
potent O
inhibitory O
activity O
was O
observed O
for O
vardenafil O
metabolite O
M1 O
, O
which O
had O
a O
Ki O
of O
1.4 O
uM O
toward O
CYP3A4 O
, O
which O
is O
about O
20 O
times O
higher O
than O
the O
M1 O
Cmax O
values O
after O
an O
80 O
mg O
Vardenafil B-drug
dose O
. O

This O
effect O
did O
not O
depend O
on O
the O
order O
of O
application O
of O
the O
drugs O
. O

Tizoxanide B-drug
is O
highly O
bound O
to O
plasma O
protein O
( O
99.9 O
% O
) O
. O

combination O
therapy O
is O
contemplated O
, O
the O
dosage O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O

There O
was O
no O
significant O
difference O
in O
the O
pharmacodynamic O
effect O
of O
warfarin B-drug
administered O
alone O
and O
warfarin B-drug
administered O
with O
Lodine B-brand
as O
measured O
by O
prothrombin O
time O
. O

Since O
the O
concomitant O
administration O
of O
warfarin B-drug
with O
amiodarone B-drug
increases O
the O
prothrombin O
time O
by O
100 O
% O
after O
3 O
to O
4 O
days O
, O
the O
dose O
of O
the O
anticoagulant B-drug
should O
be O
reduced O
by O
one-third O
to O
one-half O
, O
and O
prothrombin O
times O
should O
be O
monitored O
closely O
. O

The O
clinical O
presentation O
and O
natural O
history O
of O
neoplasia O
are O
also O
affected O
by O
aging O
. O

In O
period O
A O
, O
all O
volunteers O
took O
500 O
mg O
of O
tolbutamide B-drug
orally O
. O

Warfarin B-drug
: O
Concomitant O
administration O
of O
daptomycin B-drug
( O
6 O
mg/kg O
once O
every O
24 O
hours O
for O
5 O
days O
) O
and O
warfarin B-drug
( O
25 O
mg O
single O
oral O
dose O
) O
had O
no O
significant O
effect O
on O
the O
pharmacokinetics O
of O
either O
drug O
, O
and O
the O
INR O
was O
not O
significantly O
altered O
. O

ACE-inhibitors B-group
Reports O
suggest O
that O
NSAIDs B-group
may O
diminish O
the O
antihypertensive O
effect O
of O
ACE-inhibitors B-group
. O

Caution O
is O
recommended O
during O
the O
coadministration O
of O
any O
of O
these O
with O
alprazolam B-drug
. O

Metformin B-drug
: O
When O
Starlix B-brand
120 O
mg O
three O
times O
daily O
before O
meals O
was O
administered O
in O
combination O
with O
metformin B-drug
500 O
mg O
three O
times O
daily O
to O
patients O
with O
Type O
2 O
diabetes O
, O
there O
were O
no O
clinically O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
either O
agent O
. O

. O

Drugs O
Metabolized O
by O
P450 O
2D6 O
: O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
aucasian O
population O
( O
about O
7 O
% O
-10 O
% O
of O
Caucasians O
are O
so-called O
poor O
metabolizers O
) O
; O

The O
clinical O
significance O
of O
these O
findings O
has O
not O
been O
established O
. O

Administration O
of O
1,3-difluoroacetone B-drug_n
( O
100 O
mg O
kg O
( O
-1 O
) O
body O
weight O
) O
to O
rats O
in O
vivo O
resulted O
in O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
synthesis O
in O
the O
kidney O
, O
which O
was O
preceded O
by O
an O
elevation O
in O
fluoride O
levels O
and O
followed O
by O
citrate O
accumulation O
. O

The O
following O
are O
examples O
of O
substances O
that O
may O
reduce O
the O
blood-glucose-lowering O
effect O
: O
corticosteroids B-group
, O
niacin B-drug
, O
danazol B-drug
, O
diuretics B-group
, O
sympathomimetic B-group
agents I-group
( O
e.g. O
, O
epinephrine B-drug
, O
salbutamol B-drug
, O
terbutaline B-drug
) O
, O
isoniazid B-drug
, O
phenothiazine B-group
derivatives I-group
, O
somatropin B-drug
, O
thyroid B-group
hormones I-group
, O
estrogens B-group
, O
progestogens B-group
( O
e.g. O
, O
in O
oral O
contraceptives B-group
) O
. O

In O
EMs O
, O
selective O
inhibitors O
of O
CYP2D6 O
increase O
atomoxetine B-drug
steady-state O
plasma O
concentrations O
to O
exposures O
similar O
to O
those O
observed O
in O
PMs O
. O

If O
these O
preparations O
have O
been O
used O
it O
is O
advisable O
not O
to O
start O
therapy O
with O
DIFFERIN B-brand
Gel O
until O
the O
effects O
of O
such O
preparations O
in O
the O
skin O
have O
subsided O
. O

Based O
on O
clinical O
and O
pharmacokinetic O
results O
from O
the O
ATAC O
trial O
, O
tamoxifen B-drug
should O
not O
be O
administered O
with O
anastrozole B-drug
( O
see O
CLINICAL O
PHARMACOLOGY O
Drug O
Interactions O
and O
CLINICAL O
PHARMACOLOGY O
- O
Clinical O
Studies O
- O
Adjuvant O
Treatment O
of O
Breast O
Cancer O
in O
Postmenopausal O
Women O
subsections O
) O
. O

Naproxen B-drug
may O
interfere O
with O
some O
urinary O
assays O
of O
5-hydroxy O
indoleacetic O
acid O
( O
5HIAA O
) O
. O

Chlorpromazine B-drug
: O
Chlorpromazine B-drug
blocks O
dopamine O
and O
norepinephrine O
receptors O
, O
thus O
inhibiting O
the O
central O
stimulant O
effects O
of O
amphetamines B-group
and O
can O
be O
used O
to O
treat O
amphetamine B-group
poisoning O
. O

The O
pharmacokinetic O
interactions O
listed O
below O
are O
potentially O
clinically O
important O
. O

Quinidine B-drug
: O
Coadministration O
of O
a O
10-mg O
single O
dose O
of O
aripiprazole B-drug
with O
quinidine B-drug
( O
166 O
mg/day O
for O
13 O
days O
) O
, O
a O
potent O
inhibitor O
of O
CYP2D6 O
, O
increased O
the O
AUC O
of O
aripiprazole B-drug
by O
112 O
% O
but O
decreased O
the O
AUC O
of O
its O
active O
metabolite O
, O
dehydroaripiprazole B-drug_n
, O
by O
35 O
% O
. O

The O
effect O
of O
clonazepam B-drug
on O
the O
metabolism O
of O
other O
drugs O
has O
not O
been O
investigated O
. O

Patients O
receiving O
these O
drugs O
who O
are O
given O
Lodine B-brand
, O
or O
any O
other O
NSAID B-group
, O
and O
particularly O
those O
patients O
with O
altered O
renal O
function O
, O
should O
be O
observed O
for O
the O
development O
of O
the O
specific O
toxicities O
of O
these O
drugs O
. O

RESULTS O
: O
The O
geometric O
mean O
( O
90 O
% O
confidence O
interval O
) O
whole O
blood O
sirolimus B-drug
area O
under O
the O
plasma O
concentration O
time-curve O
increased O
60 O
% O
( O
35 O
% O
-90 O
% O
) O
, O
from O
736 O
to O
1178 O
ng O
x O
h/mL O
, O
and O
maximum O
concentration O
increased O
43 O
% O
( O
14 O
% O
-81 O
% O
) O
, O
from O
67 O
to O
96 O
ng/mL O
, O
with O
diltiazem B-drug
coadministration O
, O
whereas O
the O
mean O
elimination O
half-life O
of O
sirolimus B-drug
decreased O
slightly O
, O
from O
79 O
to O
67 O
hours O
. O

This O
might O
be O
explained O
by O
a O
blockade O
by O
probenecid B-drug
of O
the O
elimination O
of O
cloxacillin B-drug
by O
the O
liver O
. O

*CBZ O
epoxide O

Levothyroxine B-drug
Sodium I-drug
Absorption O
: O
The O
following O
agents O
may O
bind O
and O
decrease O
absorption O
of O
levothyroxine B-drug
sodium I-drug
from O
the O
gastrointestinal O
tract O
: O
aluminum B-drug
hydoxide I-drug
, O
cholestyramine B-drug
resin O
, O
colestipol B-drug
hydrochloride I-drug
, O
ferrous B-drug
sulfate I-drug
, O
sodium B-drug
polystyrene I-drug
sulfonate I-drug
, O
soybean O
flour O
( O
e.g. O
, O
infant O
formula O
) O
, O
sucralfate B-drug
. O

Fulvestrant B-drug
was O
associated O
with O
an O
increased O
incidence O
of O
fetal O
variations O
in O
rabbits O
( O
backwards O
displacement O
of O
the O
pelvic O
girdle O
, O
and O
27 O
pre-sacral O
vertebrae O
at O
0.25 O
mg/kg/day O
IM O
; O

Didanosine B-drug
: O
It O
is O
recommended O
that O
didanosine B-drug
be O
administered O
on O
an O
empty O
stomach O
; O

While O
not O
systematically O
studied O
, O
certain O
drugs O
may O
induce O
the O
metabolism O
of O
bupropion B-drug
( O
e.g. O
, O
carbamazepine B-drug
, O
phenobarbital B-drug
, O
phenytoin B-drug
) O
. O

Changes O
in O
the O
testes O
and O
epididymides O
had O
not O
recovered O
20 O
weeks O
after O
cessation O
of O
dosing O
. O

The O
incidence O
of O
ARE O
suddenly O
exceeded O
10 O
% O
of O
the O
patients O
treated O
by O
melarsoprol B-drug
during O
August O
1992 O
and O
September O
1993 O
. O

Monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
prolong O
and O
intensify O
the O
anticholinergic O
effects O
of O
antihistamines B-group
. O

Potential O
for O
Duloxetine B-drug
to O
Affect O
Other O
Drugs O
: O
Drugs O
Metabolized O
by O
CYP1A2 O
: O
In O
vitro O
drug O
interaction O
studies O
demonstrate O
that O
duloxetine B-drug
does O
not O
induce O
CYP1A2 O
activity O
, O
and O
it O
is O
unlikely O
to O
have O
a O
clinically O
significant O
effect O
on O
the O
metabolism O
of O
CYP1A2 O
substrates O
. O

In O
a O
comparison O
of O
digitalis B-group
tolerance O
in O
dogs O
anesthetized O
with O
ketamine B-drug
, O
Innovar B-brand
Vet I-brand
, O
or O
pentobarbital B-drug
, O
the O
dosage O
of O
ouabain B-drug
needed O
to O
cause O
ventricular O
tachycardia O
was O
significantly O
higher O
, O
as O
was O
the O
LD50 O
of O
ouabain B-drug
, O
with O
ketamine B-drug
or O
Innovar B-brand
than O
with O
pentobarbital B-drug
. O

Should O
it O
be O
decided O
to O
discontinue O
therapy O
in O
patients O
receiving O
beta-blockers B-group
and O
clonidine B-drug
concurrently O
, O
the O
beta-blocker B-group
should O
be O
discontinued O
slowly O
over O
several O
days O
before O
the O
gradual O
withdrawal O
of O
clonidine B-drug
. O

Therefore O
, O
prothrombin O
time O
should O
be O
carefully O
monitored O
in O
patients O
receiving O
Itraconazole B-drug
and O
coumarin-like B-group
drugs O
simultaneously O
. O

Few O
data O
exist O
on O
drug O
interactions O
with O
caffeine B-drug
in O
preterm O
neonates O
. O

Ethosuximide B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
ethosuximide B-drug
. O

Selective O
survival O
in O
pentazocine B-drug
and O
tripelennamine B-drug
of O
Pseudomonas O
aeruginosa O
serotype O
O11 O
from O
drug O
addicts O
. O

A O
reduced O
Clozapine B-drug
dose O
should O
be O
considered O
. O

Nevertheless O
, O
caution O
is O
indicated O
in O
the O
coadministration O
of O
TCAs B-group
with O
any O
of O
the O
SSRIs B-group
and O
also O
in O
switching O
from O
one O
class O
to O
the O
other O
. O

Ergot-Containing B-group
Drugs I-group
: O
These O
drugs O
have O
been O
reported O
to O
cause O
prolonged O
vasospastic O
reactions O
. O

Observations O
from O
drug O
interaction O
studies O
with O
FORTOVASE B-brand
may O
not O
be O
predictive O
for O
INVIRASE B-brand
. O

Antihistamines B-drug
: O
astemizole* B-drug
, O
terfenadine* B-drug
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
cardiac O
arrhythmias O
. O

indinavir I-drug
concentration O
ritonavir B-drug
concentration O

No O
data O
on O
the O
level O
of O
circulating O
catecholamines O
after O
apraclonidine B-drug
withdrawal O
are O
available O
. O

Amiodarone B-drug
inhibits O
CYP2D6 B-drug
. O

No O
CNS O
lesions O
have O
been O
observed O
in O
mice O
after O
chronic O
treatment O
for O
up O
to O
2 O
years O
at O
doses O
up O
to O
400 O
mg/kg/day O
or O
in O
rats O
at O
doses O
up O
to O
100 O
mg/kg/day O
. O

Coadministration O
of O
efavirenz B-drug
with O
drugs O
primarily O
metabolized O
by O
these O
isozymes O
may O
result O
in O
altered O
plasma O
concentrations O
of O
the O
coadministered O
drug O
. O

. O

Coadministration O
of O
VIRACEPT B-brand
and O
drugs O
that O
inhibit O
CYP3A O
may O
increase O
nelfinavir B-drug
plasma O
concentrations O
. O

Changes O
in O
hepatic O
function O
induced O
by O
concomitant O
therapies O
may O
affect O
epirubicin B-drug
metabolism O
, O
pharmacokinetics O
, O
therapeutic O
efficacy O
, O
and/or O
toxicity O
. O

Twitch O
gradually O
returned O
to O
pre-gentamycin B-drug
strength O
over O
the O
course O
of O
the O
next O
hour O
. O

